



LUND UNIVERSITY

Acute Pancreatitis. Biomarkers and radiology assessment

Sternby, Hanna

2017

Document Version:

Publisher's PDF, also known as Version of record

[Link to publication](#)

Citation for published version (APA):

Sternby, H. (2017). *Acute Pancreatitis. Biomarkers and radiology assessment*. [Doctoral Thesis (compilation), Department of Clinical Sciences, Malmö]. Lund University, Faculty of Medicine.

Total number of authors:

1

General rights

Unless other specific re-use rights are stated the following general rights apply:

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117
221 00 Lund
+46 46-222 00 00

Acute Pancreatitis

Biomarkers and radiology assessment

Hanna Sternby



LUND
UNIVERSITY

DOCTORAL DISSERTATION

by due permission of the Faculty of Medicine, Lund University, Sweden.
To be defended at Lilla aulan, MFC, Skåne University Hospital Malmö

October 6, 2017, at 1:15 pm.

Faculty opponent

Associate Professor Claes Jönsson

Sahlgrenska University Hospital, Göteborg University

Organization LUND UNIVERSITY	DOCTORAL DISSERTATION	
Department of Surgery Institution of Clinical Sciences Malmö Faculty of Medicine, Lund University	Date of issue Oct 6 th 2017	
Author: Hanna Sternby	Lund University	
Title and subtitle: Acute pancreatitis – biomarkers and radiology assessment		
<p>Abstract</p> <p><i>Background:</i> Acute pancreatitis (AP) is a common and potentially severe disease. Early identification of severity grade is crucial for the outcome of the patient. For study approaches and comparison of inter-institutional data the AP patients need to be uniformly classified.</p> <p>The aims of this thesis were to investigate the early stratification capacity of biomarkers in AP and to assess the morphological criteria of the revised Atlanta classification (RAC).</p> <p><i>Methods:</i> The studies are based on two cohorts. The first cohort encompasses 285 AP patients from six European centers. All patients had at least one CT performed during the first three months after onset of disease. In total 388 CTs were scored by six local radiologists and one central expert radiologist according to the morphological criteria of the RAC. The results were compared using interobserver agreement levels.</p> <p>The second cohort was enrolled at Skåne University Hospital Malmö. Blood samples from 232 AP patients were collected upon admission and daily as long as the pancreatic amylase was elevated. Exact time for onset of pain was requested at inclusion. From the serum samples selected biomarkers were analysed and compared with severity outcome of the patients.</p> <p><i>Results:</i> In general the interobserver agreement between the local radiologists and the central expert radiologist was good regarding clinically important radiological features. Two areas of interpretation inconsistencies were identified: presence of extrapancreatic necrosis and necrotic debris of peripancreatic or pancreatic collections.</p> <p>In biomarker analysis we found that cut-off levels for severe disease established by previous studies did not reach sufficient stratification capacity in our cohort. However, a combination of IL-6 and CRP (with cut-off levels 23.6 pg/ml and 57 mg/L respectively) demonstrated good potential in differentiating mild from non-mild (moderately severe and severe AP according to the RAC) disease. When investigating the temporal development of biomarkers we found that the mean values of IL-6 and IL-1β increased significantly in the severe group between 0-24 and 25-48 hours after onset of disease. Additionally, differences in mean values (i.e. delta-values) varied significantly between the mild and severe group for IL-6, IL-1β and IL-10.</p> <p><i>Conclusions:</i> Our results indicate that radiologists are unfamiliar with some of the new morphological categories of the RAC, potentially resulting in inconsistent reporting of necrotising pancreatitis. Among prognostic biomarkers in AP, in general CRP, IL-6, IL-1β and IL-10 demonstrated superior stratification capacity in our cohort.</p>		
Key words: Acute pancreatitis, severity grade, biomarkers, morphology, classification, radiology assessment		
Classification system and/or index terms (if any)		
Supplementary bibliographical information: Faculty of Medicine, Doctoral Dissertation Series 2017:133	Language English	
ISSN: 1652-8220	ISBN: 978-91-7619-516-1	
Recipient's notes	Number of pages 72	Price
	Security classification	

I, the undersigned, being the copyright owner of the abstract of the above-mentioned dissertation, hereby grant to all reference sources permission to publish and disseminate the abstract of the above-mentioned dissertation.

Signature _____ Date _____

Acute Pancreatitis

Biomarkers and radiology assessment

Hanna Sternby



LUND
UNIVERSITY

© 2017 Hanna Sternby

Coverphoto by Oskar Sternby

Back cover photo by Alfred Sternby

hanna.sternby@med.lu.se

Department of Surgery Skåne University Hospital
Institution of Clinical Sciences Malmö,
Lund University, Sweden

Faculty of Medicine, Doctoral Dissertation Series 2017:133

ISBN 978-91-7619-516-1

ISSN 1652-8220

Printed in Sweden by Media-Tryck, Lund University
Lund 2017



We can't plan life. All we can do is be available for it

Lauryn Hill

Content

List of papers	9
Abbreviations	11
Introduction	13
History	13
Anatomy and physiology	13
Acute pancreatitis	15
Aetiologies	15
Pathogenesis	16
Local inflammation	16
Systemic inflammation	19
Diagnosis	21
Classification	21
Imaging	24
Severity prediction	26
Management of the patient	29
Aims	31
Materials and Methods	33
Paper I	33
Study design and cohort	33
Statistics	34
Paper II-IV	34
Study design and cohort	34
Biomarkers	35
Statistics	36
Results	37
Paper I	37
Patients and CECTs	37
Interobserver agreement	37
Paper II	38
Patients	38
Biomarkers and cut-off levels	39

Paper III	40
Patients	40
Biomarkers	40
Paper IV	41
Patients	41
Biomarkers	41
Discussion	43
Acute pancreatitis	43
Radiological assessment	43
Biomarkers	45
Methodological considerations	47
Conclusions	51
Future perspectives	53
Populärvetenskaplig sammanfattning	55
Acknowledgements	59
References	61

List of papers

This thesis is based on the following original papers, which will be referred to in the text by their Roman numerals

- I. Sternby H, Verdonk RC, Aguilar G, Dimova A, Ignatavicius P, Ilzarbe L, Koiva P, Lantto E, Loigom T, Penttilä A, Regnér S, Rosendahl J, Strahinova V, Zackrisson S, Zviniene K, Bollen T. Significant inter-observer variation in the diagnosis of extrapancreatic necrosis and type of pancreatic collections in acute pancreatitis – An international multicenter evaluation of the revised Atlanta classification. *Pancreatology* 2016 16:5 (791-797)
- II. Sternby H, Hartman H, Johansen D, Thorlacius H, Regnér S. Predictive capacity of biomarkers for severe acute pancreatitis. *Eur Surg Res* 2016 56:3-4 (154-163)
- III. Sternby H, Hartman H, Johansen D, Thorlacius H, Regnér S. IL-6 and CRP are superior in early differentiation between mild and non-mild acute pancreatitis. *Pancreatology* 2017 17:4 (550-554)
- IV. Sternby H, Hartman H, Johansen D, Thorlacius H, Regnér S. The initial development of interleukins differs significantly between mild and severe acute pancreatitis. *Submitted*

Published papers were reproduced with permission from Elsevier (Pancreatology) and Karger (European Surgical Research)

Abbreviations

AC	Atlanta classification of 1992
ANC	acute necrotic collection
AP	acute pancreatitis
APACHE	acute physiology and chronic health evaluation
APFC	acute peripancreatic fluid collection
AUC	area under curve
BUN	blood urea nitrogen
CRP	c-reactive protein
CT	computed tomography
CECT	contrast-enhanced computed tomography
DBC	determinant based classification on acute pancreatitis
ELISA	enzyme-linked immunosorbent assay
ERCP	endoscopic retrograde cholangiopancreatography
EUS	endoscopic ultrasound
HAPS	harmless acute pancreatitis score
Hb	hemoglobin
ICAM	intercellular adhesion molecules
ICU	intensive care unit
IEP	interstitial edematous pancreatitis
IFN- γ	interferon gamma
IL	interleukin
MCP-1	monocyte chemoattractant protein-1

MODS	multiple organ dysfunction syndrome
MRCP	magnetic resonance cholangiopancreatography
MRI	magnetic resonance imaging
NF κ B	nuclear factor- κ B
NP	necrotising pancreatitis
PAF	platelet activating factor
RAC	revised Atlanta classification on acute pancreatitis
ROC	receiver operating characteristic
SD	standard deviation
SIRS	systemic inflammatory reaction syndrome
SOFA	sepsis-related organ failure assessment
TNF- α	tumor necrosis factor alpha
WON	walled-off necrosis

Introduction

The pancreas has discouraged researchers and clinicians for more than a century. With its anatomical inaccessibility, complex physiology and ill-understood pathobiology this organ humbles anyone who dare to confront it.

History

Pan kreas (all flesh) is claimed to be recognised by the Greeks around 300 years BC. Initially regarded as a protective organ either for the stomach or the large adjacent vessels its functions remained unfamiliar for many years. In 1642 Johann Georg Wirsung described the main duct which also holds his name, but it was not until the 19th century that any further understanding of the gland was established. By this time the digestive enzymes were identified, and in 1869 the medical student Paul Langerhans published his revolutionary findings, later named the islands of Langerhans. Major advances during the 20th century were the discovery by Banting and coworkers on how to extract insulin and the description of the exocrine pancreatic cell by George Paladan, for which they both received the Nobel Prize. By the turn of the 20th century acute pancreatitis was recognised as a separate individual disease, and not just a part of general intraabdominal necrosis related to any severe state ^[1].

Anatomy and physiology

The pancreas is situated ventrally to the second lumbar vertebra in the retroperitoneum, thus holding a central position in the upper abdomen. The location implies close proximity to a number of important structures such as large vessels and the duodenum (Figure 1) but also organs like the spleen, the stomach and the transverse colon ^[2]. In acute pancreatitis, the position of the gland plays an important role for possible complications of the disease.

The adult pancreas weights around 100 gram and is divided into head, neck, body and tail, with the head constituting the largest mass. The pancreatic duct (duct of Wirsung) passes from the tail to the head where it unifies with the common bile

duct (Figure 1). Normally they jointly enter the duodenum at the papilla Vateri, however cases with an accessory pancreatic duct also exist (Figure 1) ^[2].




Figure 1

Anatomy of the pancreas and peripancreatic region. Reprinted with courtesy of dr Daniel Ansari ^[3], illustration by Anders Flood ©

Although most famous for its endocrine functions, the distribution of pancreatic cells are approximately 85 % exocrine and 2 % endocrine. The endocrine cells, gathered together in the islets of Langerhans, produce and secrete peptides (mainly insulin and glucagon) into the bloodstream. The exocrine pancreas is composed of ductal cells forming the ductal system and groups of several hundred linked acinar cells which, together with duct endings, form so called acinis. Ductal and acini secretion is regulated by both hormonal input and neural stimulation in response to food. Ductal cells secrete a bicarbonate-rich fluid serving several tasks, including transportation of digestive enzymes from the acinis to the duodenum and neutralization of gastric acid for optimal pH in the duodenum in the context of digestion. About two liters of pancreatic juice is secreted into the intestinal lumen daily ^[2].

The acinar cells are the functional units of the exocrine pancreas where digestive (proteolytic, lipolytic and amylolytic) enzymes are synthesized, stored and secreted. Large amounts of pro-enzymes (trypsinogen, procarboxypeptidase and chymotrypsinogen) are produced by and kept in the endoplasmatic reticulum systems. The endoplasmatic reticulum additionally accommodates calcium, which is a regulator of enzyme release into the ductal system. Due to their aggressive nature, proteases are secreted as inactive pro-enzymes (zymogens), packed within zymogen granules together with secretory trypsin inhibitors. Through exocytosis, the membrane-bound compartments merge with the membrane of the acinar cell and the inactive pro-enzymes are released into the lumen of the pancreatic duct. Isotonic NaCl-rich fluid from the acinus and bicarbonate from the ductal cells inhibit the initiation of autodigestion before the precursors reach the duodenum. As food enters the duodenum the enzyme cholecystokinin is released which in turn initiates the exocytosis. In the duodenum trypsinogen is activated by enterokinase from the duodenal mucosa to trypsin, setting off the activation of other peptidases. The intestinal mucosa itself is protected from the proteases by protease inhibitors [2, 4].

Acute pancreatitis

Acute pancreatitis (AP) is an inflammatory disorder of the pancreas. Depending on demographic variations the annual incidence ranges between 13-73 per 100 000 inhabitants, and numbers are reported to be increasing worldwide [5, 6]. In 2012, Peery et al reported AP to be the third most common disease for hospital admission among gastroenterology disorders in the United States. Additionally it was demonstrated to be the fifth highest cause of in-hospital mortalities, in second place regarding total hospital stay and the largest contributor to increasing hospital costs [7].

Aetiologies

The dominating aetiologies of AP within western populations are gallstones and alcohol, together accounting for 70-80% of the cases in most studies [5, 8]. Biliary disease is more common in women and elderly whereas alcohol misuse appears more often among men [5]. In 10-30 % of the cases the aetiology remains unknown. Less common causes are pancreatic duct obstruction (tumours and other strictures of the common bile duct) endoscopic retrograde cholangiopancreatography (ERCP), other iatrogenic causes, hypercalcemia, hyperlipidemia, drugs (thiazides, azathioprine, tetracyclin), pancreatic trauma,

infections and parasites, autoimmune diseases, cystic fibrosis etc ^[2, 9]. In Malmö, Sweden, around 55 % of the patients suffer from acute biliary pancreatitis, whereas alcohol misuse causes 15 % of the cases with AP.

Pathogenesis

Despite decades of research the complex pathophysiological pathways of AP are still poorly understood. Both precise initial events and subsequent reactions are still subjects of debate ^[8].

It is generally recognized that dysfunction in basalmembranes of acinar cells and subsequent defects in pancreatic secretion is, regardless of aetiology, the catalyst of the disease ^[10]. Subsequent events are likely a combination of multiple pathways. Secretion blockage leads to an abnormal increase in intracellular calcium level which prevents the regular zymogen exocytosis ^[11]. As the regular inhibitory system thus becomes reduced the precursor containing zymogens converge with lysosomes holding cathepsin B which has the capacity to convert premature trypsinogen to trypsin. The result is an inappropriate intraacinar activation of trypsin, which has been considered a key event in AP ^[12, 13]. Until recently the trypsin-mediated course has been the dominating theory on the pathogenesis behind AP ^[14]. However, another early event in AP is the activation of intraacinar nuclear factor- κ B (NF κ B). Increasing evidence suggest that NF κ B is not only a crucial pathway in AP but also trypsin-independent with sufficient capacity to induce the inflammatory response autonomously ^[15, 16, 17]. An additional event that might be of importance is the increased intraacinar calcium levels which themselves lead to acinar apoptosis.

Regardless of the different theories, trypsin converts other digestive pro-enzymes leading to the process of autodigestion of the acinus ^[18, 19]. Destruction of cell membranes and tissue by the activated proteases (trypsin, chymotrypsin and elastase) results in pancreatic damage with oedema and necrosis.

Local inflammation

In immediate response to pancreatic cell injury, a local inflammatory reaction is initiated including vasodilatation, increased permeability of vessels and infiltration of leukocytes (primarily neutrophils and monocytes) into the pancreatic tissue. The complex process of leukocyte recruitment is since long considered central for the determination of disease severity ^[20]. Local pancreatic tissue damage results in the unleashing of cytokines and free radicals directly from the destructed gland, yielding changes in the microvascular system as well as leukocyte activation and

enrolment. The aggregation of leukocytes in the pancreas conduce further release of various promoters of inflammation. Subsequently a cycle of gradually enhanced production of inflammatory mediators is accomplished ^[21, 22, 23].

Pro-inflammatory cytokines

Cytokines are low molecular weight proteins able to interact with various target cells. Such events result in both extraction and release of other cytokines as well as the self-amplification of their own production. Although the inflammatory pathways of AP are unclarified multiple pro- and anti-inflammatory mediators, playing important roles for both local as systemic reactions, have been identified ^[19]. From a temporal perspective both the acinar cell injury and the accumulation of leukocytes stimulate the release of interleukin-1 β (IL-1 β) and tumor necrosis factor- α (TNF- α) followed by production and leakage of interleukin-6 (IL-6) and interleukin-8 (IL-8) ^[24, 25]. As they correlate with degree of inflammation these biomarkers have been repeatedly investigated as markers for sepsis and systemic complications ^[26].

TNF- α is mainly secreted by macrophages and measurable as early an hour after onset of AP, with a reported distinct rise over the next six hours ^[23]. In the context of AP increased levels of *TNF- α* has been found to correlate with severity grade, probably by increasing vascular permeability and upgrading of the inflammatory cytokine and chemokine response ^[23, 27, 28]. However, *TNF- α* has also proven to be an unsteady marker of severe disease since it is promptly purged from the blood by the liver and thus difficult to detect in the clinical setting ^[27].

Like *TNF- α* , inteleukin-1 (IL-1) is derived from macrophages. IL-1 exists in two forms *IL-1 β* and interleukin-1 α (IL-1 α). Being a potent inflammatory mediator, *IL-1 β* has the capacity to induce severe disease in animal models and possesses a central role in the systemic inflammatory reaction. *IL-1 β* works synergistically with *TNF- α* and additionally stimulates the production of cytokines like IL-6 and IL-8 ^[27, 29, 30].

As a response to *TNF- α* and IL-1 β stimulation, *IL-6* is derived from various cell types ^[19]. Being the principal mediator of the acute phase response, *IL-6* rises six hours after onset of AP and peaks 24-48 hours before CRP ^[21, 31]. *IL-6* additionally affects both the immune (B- and T-cells) and coagulation system. Multiple studies have demonstrated its discriminative properties in AP where increased levels have been associated with both organ failure and systemic complications ^[32, 33, 34].

Chemokines

Chemokines, a subfamily of the cytokines, are key components in the immune system possessing strong capacity for recruitment, migration and activation of leukocytes ^[23, 35]. Both *IL-8* and monocyte chemoattractant protein-1 (*MCP-1*) belong to the chemokine family. Upon stimulation by $\text{TNF-}\alpha$, *IL-8* is synthesized by a large variety of cells and has a strong neutrophil attractant capacity causing release of, among others, the tissue dilapidator elastase. It is associated with severe AP, in particular the presence of respiratory complications, and can be detected from 24 hours after onset of disease ^[21, 36, 37]. The chemokine *MCP-1* both recruits and activates monocytes in the pancreatic tissue. Upregulated *MCP-1* expression has been found in both experimental models and human tissue implicating a role of this marker in the course of AP ^[38]. Additionally, levels of *MCP-1* have been correlated with disease severity ^[39, 40].

Anti-inflammatory cytokines

As pro-inflammatory mediators are released a compensatory anti-inflammatory reaction is initiated. Among identified anti-inflammatory interleukins *IL-1* receptor antagonist (*IL-1ra*), interleukin-4 (*IL-4*) and interleukin-10 (*IL-10*) are the most investigated. Levels of *IL-1ra* have demonstrated to be significantly more increased in patients with severe AP as it moderates the effects of *IL-1*. It has also been found to decrease severity in experimental AP ^[31, 41]. *IL-4* inhibits the production of cytokines in general ^[42]. Interferon- γ (*IFN-}\gamma*) is released by *IL-1*, however levels of *IFN-}\gamma* have been found to be suppressed in severe AP, indicating that *IFN-}\gamma* has anti-inflammatory characteristics ^[42, 43, 44].

The most well-known anti-inflammatory cytokine is *IL-10* which reduces levels and functions of proinflammatory mediators like $\text{IL-1}\beta$, $\text{TNF-}\alpha$, *IL-6* and *IL-8* and also correlates with grade of severity ^[45, 46, 47]. The levels of *IL-10* elevate within 24 hours after onset of disease and, in the patients with severe AP, remain increased during the first week ^[36, 48].

Numerous additional cytokines with possibly interesting roles in AP have been investigated, however they will not be further discussed in this thesis.

Additional inflammatory mediators

Apart from cytokines other inflammatory mediators play important roles in the pathogenic course of AP.

IL-1 stimulates the release of platelet activating factor (*PAF*) ^[42]. *PAF* is a proinflammatory phospholipid originating from the vascular endothelium. As well

as being a potent vasodilator capable to increase capillary permeability, it also has the potential to activate and recruit neutrophils and amplify the production of IL-1 β , IL-6 and TNF- α . Increased levels of *PAF* have been measured in AP [49, 50]. It has thus been suggested that specific *PAF*-antagonists could reduce the inflammatory response [51, 52]. However in a large multicentre phase III study the antagonist (lexipafant) did not demonstrate improved outcomes in patients with severe disease [53].

IL-1, IL-8 and TNF- α induce the expression and up-regulation of intercellular adhesion molecules (*ICAMs*) on the surface of endothelial cells. The process facilitates the adhesion of leukocytes making *ICAMs* play an important role in the process of leukocyte migration in AP [54, 55].

Pancreatic necrosis

Impaired microcirculation with hypotension, tissue hypoxia and cellular damage subsequently results in necrosis of the pancreas [56, 57]. In the mild disease cell destruction generally occurs through controlled apoptosis whereas in severe AP the tissue damage and necrosis develops unrestrainedly [58]. Repeated bursts of cytokine release not only result in capillary leakage but also mucosal damage and increased intestinal permeability. The causal factor of infected necrosis is suggested to be translocation of bacteria due to ischemia of the bowel and impaired gut barrier function [59]. It normally takes about one week into the course of the disease before infectious complications emerge. Evolution of infected tissue creates a second burst of cytokine and chemokine release, leading to clinical deterioration of the patient and increased risk of organ failure and mortality [60, 61, 62].

Systemic inflammation

Apart from acting locally, cytokines and inflammatory mediators propagate via the vena portae into the systemic circulation. The result is a general distortion of normal physiology and initiation of a systemic inflammatory response syndrome (SIRS). By up-regulation and systemic propagation of cytokines the vascular endothelium is activated leading to capillary leakage and migration of leukocytes into all tissues. Additionally oxygen radicals and proteases are released which bring on parenchymal and endothelial cell damage causing deterioration in microcirculation and subsequent tissue oxygen deficiency [26]. Enhanced vascular leakage, peripheral leukopenia and secondary oedema increase the risk of organ degradation and failure. The state of coagulopathy and fibrinolysis with elevated levels of d-dimer are reported as important features of the systemic inflammatory

process in AP [50, 63, 64]. Furthermore, study reports have demonstrated cytokine-induced lung complications to occur early in the course of the disease, followed by kidney deterioration [37, 65, 66]. Iterating cascade-like bursts of cytokine overproduction eventually lead to multiple organ dysfunction syndrome (MODS) [67].

Organ failure may occur within the first 24 hours after onset of disease or develop during or after several days. It is generally accepted that early organ failure is caused by sterile inflammation whereas organ failure developing later (>1 week) into the disease course rather is correlated to septic complications, often in association with infected pancreatic necrosis. Accordingly, two peaks in mortality have been commonly reported. Multiple studies demonstrate most important determinants of disease severity, and consequently also mortality, to be persistent organ failure (>48 h) and the development of infected necrosis. In single organ failure the mortality is less than 10 % whereas in multi-organ failure it increases to 35-50% [68, 69, 70, 71].




Figure 2

Schematic overview of the inflammatory cascade and development of systemic complications in AP

Diagnosis

For the diagnosis of AP it is generally accepted that the patient should present at least two of the following symptoms: 1) Sudden onset of upper abdominal pain, 2) elevated pancreatic amylase (or lipase) at least three times the upper level of normal and 3) signs of pancreatitis on computed tomography (CT) scan [72, 73].

Classification

Several attempts have emerged with the aim of reaching global consensus on terms and descriptions of AP. The Marseille and Cambridge classifications were predecessors, but it was not until the international symposium in Atlanta 1992 that a worldwide adopted system was established [74, 75, 76]. The Atlanta classification (AC) was a clinically based framework proposed by 40 internationally recognized experts containing descriptive terms of local and systemic complications as well as a binary stratification into mild and severe disease. However, after 20 years of assessment, studies have demonstrated considerable inconsistencies regarding the application of nomenclature and interpretation of terminology of the AC. [77, 78, 79, 80, 81, 82]. Additionally, substantial progress has been made in the understanding of pathophysiological pathways, disease-related complications and morbidity as well as imaging and surgical interventions. Thus, in 2012 two new classifications were introduced for assessment of AP severity: the revised Atlanta classification of 2012 (RAC) and the determinant-based classification (DBC) [73, 83]. Main characteristics of the AC, the RAC and the DBC are outlined in table 1.

Table 1

Definitions of the categories of severity according to the Atlanta classification, the revised Atlanta classification and the determinant-based classification on acute pancreatitis.

	Mild	Moderate/moderately severe	Severe	Critical
<i>Atlanta Classification</i>	No OF and no local complications	N/A	OF and/or local complications	N/A
<i>Revised Atlanta Classification</i>	No organ failure No local or systemic complications	Transient OF and/or local or systemic complications	Persistent OF	N/A
<i>Determinant Based Classification</i>	No (peri)pancreatic necrosis and no OF	Sterile (peri)pancreatic necrosis and/or transient OF	Infected (peri)pancreatic necrosis or persistent OF	Infected (peri)pancreatic necrosis and persistent OF

OF organ failure, N/A not applicable

Local complications: necrosis, abscesses and/or pseudocysts

Transient OF – resolves within 48 hours, Persistent organ failure – organ failure more than 48 hours

Since their publication, all three classifications have been validated in various settings [84, 85, 86, 87, 88, 89, 90]. Main findings of these studies are the AC being inferior in severity prediction compared to the RAC and the DBC, whereas both the latter were comparable regarding investigated outcomes.

As the Atlanta classification is now considered outdated no further review on this classification will be performed here.

The revised Atlanta classification

The RAC was developed through an international iterative web consultative process led by a working group [73]. In this classification a number of definitions are stated; diagnosis of AP, detailed morphological features and contrast-enhanced computed tomography (CECT) criteria of local complications (see Box 1), early and late phase of the disease as well as a trisected assessment of severity. Apart from the groups outlined in Box 1 additional local complications stated are colonic necrosis, gastric outlet dysfunction as well as splenic and portal vein thrombosis. The RAC defines systemic complications as deterioration of co-morbidities and organ failure according to the modified Marshall scoring system (table 2) [73, 91].

BOX 1

Morphological features and CECT criteria in AP according to the RAC

Morphology groups	CECT criteria	Time
Interstitial oedematous pancreatitis (IEP)	Homogenous enhancement of the pancreatic parenchyma, normal or minor inflammatory changes of the peripancreatic tissue (see below - APFC or pancreatic pseudocyst)	-
Necrotising pancreatitis	Heterogeneous enhancement of the pancreatic parenchyma and/or peripancreatic tissue necrosis (see below – ANC or WON)	-
Acute peripancreatic fluid collection (APFC)	Homogeneous fluid density. No complete wall. No necrosis. Associated with IEP. Solely extrapancreatic location.	≤ 4 weeks
Pancreatic pseudocyst	Homogeneous fluid density. Fully encapsulated. No necrosis. Associated with IEP. Solely extrapancreatic location.	> 4 weeks
Acute necrotic collection (ANC)	Heterogeneous and non-liquid density. No complete wall. Associated with necrotising pancreatitis. Intra- or extrapancreatic location	≤ 4 weeks
Walled-off necrosis (WON)	Heterogeneous and non-liquid density. Fully encapsulated. Associated with necrotising pancreatitis. Intra- or extrapancreatic location	> 4 weeks

CECT contrast enhanced computed tomography

Table 2

Modified Marshall scoring system for organ failure - A score of 2 or more equals organ failure

Organ system	No organ failure		Organ failure		
	0	1	2	3	4
<i>Respiratory</i> (PaO ₂ /FiO ₂)	> 400	301-400	201-300	101-200	> 101
<i>Renal</i>					
(serum creatinine µmol/l)	≤ 134	134-169	170-310	311-439	> 439
(serum creatinine mg/dl)	< 1.4	1.4-1.8	1.9-3.6	3.7-4.9	> 4.9
<i>Cardiovascular</i> *					
(systolic blood pressure, mm Hg)	> 90	< 90 RF	< 90 Not RF	< 90 <pH 7.3	< 90 <pH 7.2

* Without inotropic support

RF responsive to fluids, Not RF not responsive to fluids

The determinant-based classification

Whilst the RAC is built on clinical descriptions the DBC uses determinants of severity in AP ^[83]. The DBC was processed through three stages; a meta-analysis of published studies, a global web-based survey and an international consensus symposium. In the DBC, AP is classified into four categories of severity based on the main determinants organ failure and infected pancreatic necrosis. For the definition of OF, the DBC uses the Sepsis-related Organ Failure Assessment score (SOFA-score) ^[92].

Correlation between severity grades and outcome

The grades of severity are clinically crucial as they differ significantly in prognosis and outcome. The overall mortality in AP is approximately 5 % ^[93]. Mild disease is self-limiting with almost negligible mortality and long-term morbidity. The vast majority of the AP patients, 70-80%, pertain to this group ^[94]. As has been demonstrated in multiple validation studies both mortality and morbidity increases significantly with each degree of severity. In the moderately severe (RAC) and moderate (DBC) groups morbidity rises with more frequent admission to the intensive care unit (ICU), prolonged hospital stay, need for interventions and nutritional support, whereas mortality remains low (0-6%). For the groups with severe and critical AP the level of morbidity is 100 % accompanied by very high numbers in mortality, in particular for the critical group (22-80%) ^[88, 89, 95, 96].

Imaging

Computed tomography (CT) is the gold standard imaging modality when assessing both diagnostic uncertainty and suspected complications in AP ^[97]. However, despite major technical advancement during the last decades, a CT obtained during the first days after onset of disease cannot evaluate the severity of the disease and is thus not recommended to be performed routinely ^[72, 98, 99]. As AP is a dynamic disease the assessment of radiological changes are highly time-dependent. In mild AP characteristic morphological findings are peripancreatic fat stranding (increased attenuation) and diffuse enlargement, however with homogeneous enhancement, of the gland ^[99, 100]. In moderately severe and severe disease the process of collections and necrosis takes days to evolve. Necrosis is defined as focal or diffuse non-enhancing pancreatic parenchyma and/or heterogeneous density of collections. Peripancreatic necrosis is more difficult to identify as fat perfusion is not detectable on CT and diagnosis has to be based on secondary signs ^[99].




Figure 3

Peripancreatic necrosis

The pancreas enhances heterogeneously (asterisks) but no apparent necrosis can be identified. Peripancreatic necrotic collections are present in the retroperitoneal pancreatic compartment and transverse mesocolon (arrowheads pointing at the borders)

CT has good capacity for defining collections as incompletely or fully encapsulated which is essential for decisions on interventions and classification. Whether the collections contain fluid or necrotic debris is of importance for correct AP classification, see Box 1. Presence of infection is seen as gas bubbles in necrotic areas on CT, in general 2-4 weeks after onset of AP [60, 101].

Abdominal ultrasound is indicated during the initial phase for the detection of gallstones in all patients with AP [98]. Magnetic resonance cholangiopancreatography (MRCP) is, with the identical purpose, a commonly utilized complementary instrument in suspected biliary disease [102]. Magnetic Resonance Imaging (MRI) has equal sensitivity to CT regarding severity evaluation and diagnosis of AP. For the assessment of collections (fluid and/or necrosis) MRI is superior to CT [103]. Endoscopic ultrasound (EUS) offers the possibility of both diagnosis and intervention in the same séance. As it is superior compared to MRCP in the exclusion of small (<5 mm) gallstones EUS is a complimentary method likely to become more developed and utilized in the future [72, 104].

Correlation between CT findings and disease severity

Like the clinical degrees of severity, the morphologic types (Box 1) of AP also differ considerably in clinical outcome, treatment strategies and prognosis. Several radiological scoring systems have been developed for the prediction of severity grades [105, 106, 107, 108]. However, none reach sufficient stratification accuracy and thereby a CT upon admission is not a general recommendation for the AP patients [109].

Mortality in interstitial disease is reported to be 0-3% with strong correlation to comorbidity [94, 110, 111, 112]. Although morphological and clinical severity are not necessarily consistent, the level of morbidity in interstitial AP is low as clinical symptoms most frequently resolve within a week [94]. Corresponding figures in necrotising pancreatitis have been a matter of debate. Necrotising AP afflicts 20-30% of the AP patients and it is of general conclusion that presence of necrosis is related to high morbidity, however influenced by anatomical location and extent of morphological changes [80, 93, 110, 113]. Necrosis has additionally been associated with high mortality, in some studies up to 40% [113, 114]. Other studies claim death in necrotising pancreatitis to be solely associated with organ failure and not necrosis [77, 93, 115, 116]. As both pancreatic necrosis and organ failure are established determinants of severe AP, the relationship between these entities has been repeatedly investigated. Several studies present significantly increased organ failure in patients with necrotising pancreatitis, particularly with exceeding extent of necrosis [117, 118, 119]. However, other works show no correlation making general

conclusions difficult ^[115, 116, 120, 121]. The relationship is thus considered not fully understood. It is likely that the pathophysiological processes of necrosis propel the development of organ failure when simultaneously reduced perfusion due to organ failure contributes to the evolution of necrosis ^[122].

Among the patients with necrotising pancreatitis 33 % have infected necrosis ^[93]. Mortality in this group has been reported to be very high, thereof the introduction of the critical category of the DBC, which was mainly based on a large review by Petrov et al. ^[61].

Severity prediction

Early identification of patients in risk of developing severe disease is important as it is recognised that these patients benefit from prompt management in the ICU. Despite large efforts and multiple studies no method exists to, upon admission, determine the severity of AP with sufficiently high sensitivity and specificity ^[9, 123]. Age, aetiology, obesity and comorbidity are established risk factors for severe disease ^[124, 125, 126, 127]. A number of scoring systems and predictive markers have been proposed, however none have demonstrated adequate prognostic capacity ^[72, 128, 129]. SIRS (table 3), in particular persistent SIRS at 48 hours, has proven to be the best predictor of severe disease with strong correlation to increased morbidity and mortality ^[70, 130, 131, 132]. According to recent guidelines the superior approach for severity prediction is thus to combine the information on 1) risk factors, 2) SIRS and 3) response to initial therapy ^[72].

Table 3
Systemic Inflammatory Response Syndrome (SIRS) ^[130]

SIRS = Presence of two or more of the following criteria	
Temperature	< 36° or > 38°
Heart rate	> 90 / min
Respiratory rate	> 20 / min
White blood cells	< 4 x10 ⁹ / L or > 12 x 10 ⁹ / L

The Harmless Acute Pancreatitis Score (HAPS, Box 2) is developed for the identification of patients with mild AP upon admission. Although simple and validated this scoring system is not yet applied in general clinical practice^[133, 134].

BOX 2

The Harmless Acute Pancreatitis Score (HAPS)^[133]

Parameters of severity to be estimated upon admission:

- Signs of peritonitis (rebound tenderness or guarding in abdominal examination)
- Serum creatinine > 2 mg/dL
- Hematocrit level > 43% for men and >39.6% for women

If the patient is negative in all parameters the clinical course is categorised as *harmless*

If the patient is positive in any of the parameters the clinical course is categorised as *non-harmless*

Predictive biomarkers

The ideal prognostic biomarker in AP holds several features. It is clinically available, inexpensive, insensitive to inter-individual differences and accurately predicts severe cases upon admission. The search for such a biomarker ranges over decades and numerous promising candidates have been proposed. However, still no marker has repeatedly, with a generally defined and accepted cut-off level, been able to predict complicated disease with sufficient precision.

C-reactive protein (*CRP*) is the most commonly used marker due to its clinical availability and low analysis cost. Being produced by the hepatocytes, through initiation of IL-1 and IL-6, CRP peaks as late as 72 hours after onset of disease. There is no established cut-off level for severe disease, at 150 mg/dL (within 24 hours from admission) 100% sensitivity and 81.4 % specificity was found for necrotising pancreatitis^[4, 135].

As the interleukins are established mediators of the inflammatory reaction vast investigations have been made within this groups of cytokines. *IL-6* peaks 24-36 hours before CRP and, in the absence of a complicated course, decreases rapidly^[31]. According to two meta-analysis elevated levels are associated with severe disease^[136, 137]. Zhang et al reported (for admission samples) a pooled sensitivity of 91 % and pooled specificity of 79 % whereas corresponding figures from Aoun et al were 83.6 % and 75.6 %. The chronological profile of *IL-8* resemble the one of IL-6 with an early rise, making it a theoretically interesting marker. However, meta-analysis have demonstrated widespread sensitivities and specificities for complicated disease making general conclusions difficult. As being a powerful

inflammatory mediator, *IL-1 β* has repeatedly been associated with complicated AP manifesting increased levels in severe disease [31, 47, 138]. However, further studies are needed to understand the significance of this marker. The cardinally investigated anti-inflammatory marker is *IL-10*. *IL-10* is related to both organ failure and other complications but general cut-off levels have been difficult to set [23, 31, 45, 47, 48].

Numerous other interleukins (*IL-11*, *IL-12*, *IL-15*, *IL-17*, *IL-18* etc) have been investigated in the search for prognostic markers in AP [128]. However, since previous studies are generally small and results not sufficiently promising these biomarkers will not be further discussed in this thesis.

With regard to being the first cytokine to be released during the course of AP *TNF- α* has been repeatedly studied. Increased levels have been associated with a complicated course in AP but the opposite has also been demonstrated [23, 139, 140]. The inconsistent results might be explained by *TNF- α* having a short plasma half-life making it an unstable marker when measured in blood [27]. Additionally, positive results are in general inferior to findings for *IL-6* and *IL-8*.

The acute phase reactant *procalcitonin* is a widely used marker for sepsis. According to a meta-analysis by Mofidi et al superior capacity was primarily demonstrated for the identification of infected pancreatic necrosis. For this complication the pooled sensitivity and specificity was 0.80 and 0.91 respectively [141]. Moreover, results for *procalcitonin* in predicting severe AP have been inconsistent [140].

As coagulopathy is a contributing factor to the disease course in AP haemostasis parameters related to disseminated coagulation have been investigated as possible predictive markers. *D-dimer* has been studied in multiple settings demonstrating promising results with a sensitivity of 81-90% and specificity of 67-89% for complicated disease [63, 64, 142]. However, referred studies present a wide range of cut-offs making general conclusions and clinical applicability difficult.

With an odds ratio of 40.8 (95% CI 8.5-195) *MCP-1* has been correlated with severe disease already 24 hours into the course of the disease [39, 40].

In a large post-hoc analysis by Koutroumpakis et al the prognostic performances of *hematocrit* and *blood urea nitrogen* (BUN) in AP were analyzed [143]. Compared with the acute physiology and chronic health evaluation II (APACHE II) and creatinine at 24 hours increased BUN and a hematocrit level >44% better predicted pancreatic necrosis and organ failure.

Management of the patient

As no causal medical treatment exists for AP, management is empirical and unspecific with the primary aim to support vital functions and prevent complications. Early identification of organ deterioration and non-delayed admission to an intermediate care unit or the ICU is crucial ^[131, 144, 145].

The initial caretaking focuses on hemodynamic stabilisation, principally through volume resuscitation and monitoring of fluid losses. To maintain adequate perfusion, and thus oxygen supply of vital organs, aggressive (250-500 ml/h) infusion of fluids (crystalloids) needs to start already in the emergency department. Early resuscitation is associated with reduced rates of SIRS, organ failure, MODS and mortality ^[146, 147, 148]. Clinical response to fluid resuscitation is considered obtained if the following parameters are maintained: heartbeat <120/min, mean arterial pressure >65 mm Hg and a urinary output of >0.5 ml/kg/hour ^[72]. The requirements of fluids should be repeatedly evaluated to confirm adequate response but also to avoid over-resuscitation and oedema ^[149].

Effective pain management is a deficiently studied field in AP and there is no consensus on preferred analgesic or administration method. Pain reduction should nevertheless be of priority immediately upon admission ^[150].

The impact of enteral nutrition on SIRS and organ failure is yet to be clarified. However, it has been demonstrated that early enteral nutrition decreases infectious complications, organ failure and mortality ^[151, 152]. Additionally, in mild AP early oral feeding is considered safe ^[153].

Meta-analysis and reviews have not found any benefits for systemic antibiotics in the prevention of infections in AP ^[154]. Prophylactic antibiotics are thus not recommended as routine treatment, neither for mild, moderately severe nor severe AP. Future studies will need to expose whether antibiotic treatment should be supported in certain subgroups.

The aetiology of AP needs to be established upon admission by reason of severity prediction and patient treatment. Laboratory test and upper abdominal ultrasound should be performed for complete investigation. If the aetiology cannot be determined during the first attack of AP further examinations (CT, MRCP, EUS, genetic counseling) should be performed ^[9, 72, 155]. Elimination of the causative factor is important to reduce the risk of recurrent AP. In biliary pancreatitis same-admission cholecystectomy have demonstrated a 72 % reduced risk for complications related to gallstones ^[156].

During the last twenty years, in accordance with international consensus, there has been a shift towards a more conservative approach and less surgical interventions

in AP ^[157]. For infected necrosis open necrosectomy has been the standard of care for decades. However, recent studies have demonstrated a reduction in both mortality and numbers of serious complications when a minimally invasive approach is applied ^[62, 158, 159].

ERCP is indicated when there are signs of cholangitis. There is no consensus or clear evidence for ERCP in patients with ongoing AP and persistent cholestasis without cholangitis ^[160].

Aims

The general aim of this thesis was to investigate stratification assessment of defined severity categories in AP using clinical features and biomarkers.

Specific aims were

Paper I

To, in a routine clinical setting, evaluate and validate the morphological CT-criteria defined by the revised Atlanta classification on AP.

Paper II

To select prognostic biomarkers in AP from the literature and study these using preset cut-off levels based on the results from previous studies.

Paper III

To investigate the capacity of biomarkers to differentiate mild from non-mild (moderately severe plus severe) AP during the initial phase of the disease.

Paper IV

To analyse the temporal development of biomarkers in AP with regard to the severity categories of the revised Atlanta classification.

Materials and Methods

Paper I

Study design and cohort

Paper I is based on a multicentre study originated from a research project during the Pancreas 2000 course – an international course in pancreatology. Adult patients with AP were retrospectively enrolled at 6 European centres (Skåne University Hospital, Malmö, Sweden; Hospital del Mar, Barcelona, Spain; University Hospital of Emergency Medicine “Pigorov”, Sofia, Bulgaria; Lithuanian University of Health Sciences, Kaunas, Lithuania; East Tallinn Central Hospital, Tallinn, Estonia and Helsinki University Hospital, Helsinki, Finland) going backwards from January 2013 to January 2012. All included patients had at least one CECT performed during the course of the disease, and all CECTs up until 3 months after date of admission were included. Thereby CTs from the whole spectra of the disease were obtained. Patients who had had an invasive intervention (except from ERCP) were not included, neither were patients with a history of chronic pancreatitis. All CECTs were performed in the pancreatic and/or the portal venous phase.

At each centre one local radiologist, specialised in gastroenterological radiology, reviewed the CECTs using a protocol based on the morphological criteria stated by the revised Atlanta classification (see Box 1 in the Introduction) ^[73]. All local radiologists received an instruction sheet as interpretation support before scoring the CECTs. All CECTs were additionally reviewed according to the same protocol by a central radiologist (Thomas L Bollen), who is an expert in pancreatic radiology. The local and central radiologists had information on time elapsed from onset of disease until CECT performance but were blinded to other clinical data.

The following information was obtained from the medical records; SIRS upon admission, highest level of CRP during hospitalisation, need for invasive intervention, organ failure (according to the RAC) and in-hospital mortality. All patients were retrospectively classified according to the RAC ^[73].

Statistics

Continuous data were presented as median (range) and in analysis Mann-Whitney U test was performed. Paired samples were analysed using Wilcoxon rank test. $P < 0.05$ was considered statistically significant. In sample size calculation 360 CECTs were estimated to give sufficient statistical power based on the aspect that the RAC has several categories divided into 2, 3 or 4 parts. 50 patients were enrolled at each centre, with the assumption that numerous patients would have had more than one CECT performed during the course of the disease. From scoring results, the interobserver agreement between the local and central radiologists was calculated using Cohens kappa test. For defined kappa values and corresponding levels of agreement see table 4. All analysis was performed using IBM SPSS Statistics for Windows version 21 and 22, Armonk, NY:IBM Corp.

Table 4
Kappa values and defined levels of agreement

0.00-0.20	Slight
0.21-0.40	Fair
0.41-0.60	Moderate
0.61-0.80	Substantial
0.81-1.00	Good

Paper II-IV

Study design and cohort

Papers II-IV are based on a mutual cohort, originating from a study named the AMY-study. Patients > 18 years old with AP were prospectively and consecutively enrolled at Skåne University Hospital, Malmö, from January 2010 until September 2013. Patients where more than 72 hours had passed since onset of disease were excluded. The grade of severity was either classified according to the Atlanta classification of 1993 or the revised Atlanta classification of 2013 ^[73, 76]. Clinical data including exact time for onset of disease (i.e. onset of pain) and validated questions on comorbidities were collected upon inclusion and through medical notes.

Biomarkers

Serum samples were taken upon arrival to the emergency room and daily as long as the pancreatic amylase was increased. Samples for analysis of IFN- γ , IL-1 β , IL-6, interleukin-6 receptor (IL-6R), IL-8, IL-10, interleukin-12 (IL-12), TNF- α , MCP-1, procalcitonin and d-dimer were collected in plasma separator tubes, centrifuged (2000 rounds, 25°C, 10 minutes) and stored at -80°C until analysed. IFN- γ , IL-1 β , IL-6, IL-8, IL-10, IL-12 and TNF- α were analysed with a human proinflammatory 7-plex ultrasensitive kit and IL-6R with 1-plex human IL-6R ultrasensitive kit (K15008C, K151ALC, Meso Scale Diagnostics LLC, Rockville, MD, USA). MCP-1 was assessed through human CCL2 (MCP-1) Elisa Ready-set-go kit (88-7399-88, aBioscience, San Diego, CA, USA) and d-dimer with human D-Dimer Elisa kit (D2D, 20870, Bmassay, Beijing, China). All analyses were assessed according to the manufacturer's instructions. Procalcitonin was determined with an accredited Elisa method based on monoclonal anti-procalcitonin antibodies in accordance with routine methods at the department of Clinical Chemistry, Skåne University Hospital Malmö.

BOX 3

Biomarker units

Biomarker	Unit
IL-1 β , IL-6, IL-6R, IL-8, IL-10, IL-12, IFN- γ , TNF- α	pg/ml
MCP-1, d-dimer, procalcitonin	ng/ml
Albumin, hemoglobin	g/L
CRP	mg/L
Calcium, glucose, lactate	mmol/L
Thrombocytes, white blood cells	$\times 10^9/L$

Albumin, calcium, CRP, glucose, hematocrit, haemoglobin, lactate, thrombocytes and white blood cells were analysed in accordance with certified standard analysis at the department of Clinical Chemistry, Skåne University Hospital Malmö (ISO 15189:2012, accreditation number 1309).

In Paper II the cut-off levels for analysed biomarkers were set through literature review. Solely admission samples were utilised in calculations.

In Paper III samples taken between 13-36 hours after onset of disease were used for analysis. The Harmless Acute Pancreatitis Score (HAPS) was set for all patients^[133].

In Paper IV samples taken at 0-24 hours and 25-48 hours after onset of pain were compared.

Statistics

Data is presented as median (with range and interquartile range), numbers (and percentages) or as mean with standard deviation (SD). All statistic analysis were performed using nonparametric tests. For comparison between two groups the Mann-Whitney *U* test was used and $p < 0.05$ was considered statistically significant. Kruskal Wallis test was performed for comparison between three groups with an adjusted level of significance; $p < 0.017$. Differences in biomarker levels between paired samples were analysed through Wilcoxon's test.

Optimal cut-off levels for individual biomarkers were acquired from Receiver Operating Characteristic curves (ROC-curves). Through selected cut-off levels sensitivity, specificity, negative and positive likelihood ratios as well as negative and positive predictive values were calculated. For evaluation of biomarker performances areas under the curves (AUCs) were obtained from the ROC-curves.

All analysis were performed using IBM SPSS Statistics for Windows, version 22 and 23, Armonk, NY:IBM corp.

Results

Paper I

Patients and CECTs

In total 301 patients with 405 CECTs were included at the six centres. Due to insufficient CECT quality 16 patients were excluded leaving 388 CECTs from 285 patients for analysis. Several of the patient characteristics like gender, age and aetiology of AP differed substantially between the centres. As all patients had had a CECT performed the grades of severity were slightly higher compared to an unselected AP cohort. Median time, for all centres, from onset of disease to CECT was seven days (range 0-90).

Interobserver agreement

As seen in table 5 the centre dependent kappa values varied distinctly between the centres. In seven categories the level of agreement was substantial (0.61-0.80); Necrosis-neck, Necrosis-body, Necrosis-tail, Presence of collections, Location of collections, Presence of wall and Presence of intraluminal gas/fluid level. Moderate agreement (0.41-0.60) was found for Parenchymal necrosis as well as Necrosis-head. Finally fair agreement (0.21-0.40) was reached on the categories Type of pancreatitis, Extrapancreatic necrosis, Characteristics of collection and Collection – most appropriate term.

Further investigation of the categories with fair level of agreement demonstrated large discrepancies in the identification of extrapancreatic necrosis and necrotic contents of collections. The central expert identified significantly more cases with necrosis compared to the local radiologists. The clinical outcome of the patients had superior correspondence with morphological findings according to the central expert.

Table 5

Centre independent (All) and dependent (Centre B-G) kappa values for all categories scored

	All	B	C	D	E	F	G
Type of pancreatitis	0.370	0.317	0.342	0.309	0.098†	0.838*	0.360
Parenchymal Necrosis	0.539	0.380	0.319†	0.609	0.731*	0.663	0.465
Necrosis - Head	0.516	0.669	0.345	0.323†	1.00 *	0.660	0.646
Necrosis - Neck	0.618	0.922*	0.577	0.822	0.660	0.364	0.236†
Necrosis – Body	0.628	0.766	0.611	0.687	0.873	0.392†	0.570
Necrosis – Tail	0.617	0.451	0.626	0.687	0.409†	0.806*	0.532
Extrapaneatritic Necrosis	0.326	0.321	0.504	0.293	0.120	0.877*	0.024†
Collections	0.756	0.780	0.750	0.624†	0.864*	0.827	0.625
Location of Collections	0.633	0.728	0.761*	0.508	0.694	0.604	0.439†
Characteristics of Collections	0.408	0.397	0.485	0.293	0.305	0.744*	0.251†
Wall	0.675	0.638	0.638	0.588†	0.777*	0.726	0.632
Intraluminal gas/fluid level	0.764	0.774	0.671†	0.764	0.887*	0.837	0.675
Collection – most appropriate term	0.356	0.385	0.480	0.136†	0.218	0.673*	0.261

* Highest kappa value for center B to G for each category

† Lowest kappa value for center B to G for each category

Paper II

Patients

To enable comparison with previous studies the patients were retrospectively classified as having mild or severe disease according to the Atlanta classification of 1993 ^[76]. Among the 232 patients enrolled 193 (83.2%) had mild and 39 (16.8%) severe AP. The only significant difference in baseline characteristics found between the groups was level of CRP within the first 72 h which was higher in the severe group ($p < 0.0001$).

Biomarkers and cut-off levels

The cut-off levels presented in Box 4 were assessed from literature review

BOX 4

Biomarker	Preset cut-off level	Biomarker	Preset cut-off level
IL-1 β	1 pg/ml	TNF- α	10 pg/ml
IL-6	100 pg/ml	MCP-1	500 ng/ml
IL-8	40 pg/ml	Procalcitonin	0.5 ng/ml
IL-10	7.5 pg/ml	d-dimer	0.5 ng/ml

IL-1 β (p=0.008), IL-6 (p=0.013) and IL-10 (p=0.009) differed significantly between the patients with mild and severe disease upon admission.

Application of the preset cut-off levels on our cohort did not result in any acceptable sensitivity, specificity and positive or negative predictive value. A considerable number of the patients with severe AP were found below cut-off levels.

To acquire optimal cut-off levels for our cohort ROC curves were performed with results as presented in table 6.

Table 6

Areas under curves and optimal cut-off levels for the individual biomarkers

Biomarker	Optimal cut-off	AUC	Biomarker	Optimal cut-off	AUC
IL-1 β	0.9 pg/ml	0.640	TNF- α	n.a	0.459
IL-6	72 pg/ml	0.623	MCP-1	399 ng/ml	0.604
IL-8	49 pg/ml	0.601	Procalcitonin	0.35 ng/ml	0.552
IL-10	12 pg/ml	0.638	d-dimer	n.a	0.516

n.a, not applicable

The biomarkers were additionally analysed using the revised Atlanta classification without reaching superior results.

Paper III

Patients

In the established cohort (Paper II) 175 patients had their admission sample taken between 13-36 hours after onset of pain. The patients were divided into mild (70.9%) and non-mild (moderately severe + severe) (29.1%) AP in accordance with the revised Atlanta classification ^[73].

Biomarkers

Routine (Albumin, calcium, CRP, glucose, hematocrit, haemoglobin, lactate, thrombocytes, white blood cells) and non-routine biomarkers (IFN- γ , IL-1 β , IL-6, IL-6R, IL-8, IL-10, IL-12, TNF- α , MCP-1, procalcitonin and d-dimer) were analysed. Significant difference ($p < 0.05$) between the mild and the non-mild group was found for IL-1 β , IL-6, IL-6R, IL-10, MCP-1, calcium and CRP. In ROC curve analysis, CRP and IL-6 presented superior ability to differentiate the non-mild patients with AUCs of 0.808 and 0.742 respectively. With the high morbidity and mortality of the disease taken into consideration optimal cut-off levels for CRP (57 mg/L) and IL-6 (pg/ml) were selected, resulting in predictive capacities for non-mild AP as presented in table 7. Additionally, the result of combining CRP and IL-6 is demonstrated.

Table 7

Predictive capacity of CRP, IL-6 and the combination of both together.

	Cut-off	Sensitivity	Specificity	LR+	LR-	PPV	NPV
CRP	57	0.88	0.5	1.76	0.24	0.42	0.87
IL-6	23.6	0.89	0.54	1.87	0.20	0.39	0.93
CRP + IL-6	57 + 23.6	0.98	0.53	2.1	0.06	0.49	0.98

LR+ positive likelihood ratio, LR negative likelihood ratio, PPV positive predictive value, NPV negative predictive value
CRP in mg/L, IL-6 in pg/ml

Application of the HAPS and the combination of CRP and IL-6 with regard to mild AP are presented in table 8. One patient classified as harmless according to the HAPS developed moderately severe AP with transient multiorgan failure. The patient with non-mild disease and CRP and IL-6 values found below assessed cut-off levels had a deterioration of comorbidity (short period of atrial fibrillation).

Table 8
HAPS score and CRP + IL-6 for the prediction of mild disease

	Outcome		Sens	Spec	LR+	LR-	PPV	NPV
	Mild	Non-mild						
HAPS								
Harmless	10	1	0.08	0.98	4	0.94	0.91	0.30
Not harmless	114	50						
CRP+IL-6								
Mild	71	1	0.53	0.98	26.5	0.48	0.99	0.48
Non-mild	53	50						

HAPS harmless acute pancreatitis score, Non-mild moderately severe plus severe AP, Sens sensitivity, Spec specificity, LR+ positive likelihood ratio; LR- negative likelihood ratio, PPV positive predictive value, NPV negative predictive value

Paper IV

Patients

Among the 232 patients enrolled in the AMY-study, 115 had samples taken at both 0-24 hours and 25-48 hours after onset of pain. This smaller cohort of 115 patients was used for paired comparisons.

In the whole cohort 70.3% developed mild, 22.8% moderately severe and 6.9% severe AP ^[73]. The group with paired samples (n=115) did not differ significantly from the entire cohort regarding basal characteristics. There were more severe cases in the paired group (9.6% vs 6.9%), admission to the ICU was slightly lower (72.2% vs 81.35%), however mortality in the severe group was higher with 45.5% compared to 31.3% in the large original cohort.

Biomarkers

Using the human proinflammatory 7-plex ultrasensitive kit IFN- γ , IL-1 β , IL-6, IL-8, IL-10, IL-12, TNF- α were measured. In the whole cohort significant differences between severity grades were found for IL-1 β , IL-6, IL-8 and IL-10, thus these biomarkers were further investigated. Among admission samples (of the large group) the variations were most expressed for IL-1 β , IL-6 and IL-10.

Paired samples (n=115) of IL-1 β , IL-6, IL-8 and IL-10 were analysed separately. The mean value of each severity group was calculated for the individual biomarkers at 0-24 and 25-48 hours after onset of disease. Significant changes in

mean values were found for IL-8 and IL-10 in the mild group and for IL-1 β and IL-6 in the moderately severe and severe groups, see table 9.

Table 9

Mean values of paired samples of biomarkers at 0-24 h and 25-48 h in the different severity groups

	MAP (n= 71)			MSAP (n= 33)			SAP (n= 11)		
	0 - 24 h	25 - 48 h	<i>p-value</i>	0 - 24 h	25 - 48 h	<i>p-value</i>	0 - 24 h	25 - 48h	<i>p-value</i>
IL-1β	2 ± 0.6	2 ± 0.3	<i>ns</i>	2.4 ± 0.7	5.9 ± 1.5	0.0001	3.5 ± 1	11 ± 6	0.049
IL-6	194 ± 84	178 ± 88	<i>ns</i>	394 ± 254	221 ± 44	0.009	288. 240	717 ± 37 1	0.008
IL-8	188 ± 69	76 21	0.0001	188 ± 64	102. ± 15	<i>ns</i>	229 ± 87	503 ± 35 6	<i>ns</i>
IL-10	108 ± 64	40 ± 14	0.0001	202 ± 118	27 ± 6	<i>ns</i>	101 ± 49	427 ± 39 4	<i>ns</i>

MAP mild AP, MSAP moderately severe AP, SAP severe AP, *ns* not significant, *h* hours

Values are in mean (\pm SD)

All interleukins are in pg/ml

Differences in mean values (of 0-24 and 25-48 hours) of the biomarkers were named delta-values. We investigated whether the delta-values for the individual markers differed between severity groups, see table 10. Although all values appeared to differ significantly, statistical significance was only found for IL-1 β , IL-6 and IL-10 when comparing the mild and severe groups.

Table 10

Delta-values and differences between severity groups

	Delta-values			p-values		
	MAP n=71	MSAP n=33	SAP n=11	MAP – MSAP	MSAP - SAP	SAP - MAP
IL-1β	0.24 ± 4.4	3.5 ± 8	7.9 ± 17	0.0001	<i>ns</i>	0.011
IL-6	16 ± 679	173 ± 1326	429 ± 436	0.001	0.012	0.0001
IL-8	1112 ± 411	85 ± 331	275 ± 838	<i>ns</i>	<i>ns</i>	<i>ns</i>
IL-10	68 ± 399	175 ± 626	326 ± 1063	<i>ns</i>	<i>ns</i>	0.039

MAP mild AP, MSAP moderately severe AP, SAP severe AP, *ns* not significant

Values are in mean (\pm SD)

All interleukins are in pg/ml

Discussion

Acute pancreatitis

Clinical expressions of acute pancreatitis varies from the mildly ill patient with pain in the upper abdomen alone to extremely severe cases with multiorgan failure who dies in the ICU after weeks, or sometimes just hours, of struggling against the disorder. How the disease profile and critical pathophysiological processes differ between these patients is still unclear. In the present thesis these problems are addressed from a routine clinical perspective.

Radiological assessment

The elaboration of the revised Atlanta classification started in 2007 through a web-based consultation. A wide range of pancreatology experts from national and international associations were invited to join the project. The initial draft was revised in response to comments, and the statements of the final version were based on published evidence ^[73]. Regardless, the content of the classification was established through experts opinions. This severity stratification system has been multiply validated with good results ^[86, 87, 88, 95]. However, the clinical applicability of morphological features and radiological assessment of the classification have been questioned ^[161, 162].

*Paper I Significant inter-observer variation in the diagnosis of
extrapancreatic necrosis and type of pancreatic collections in acute
pancreatitis – An international multicenter evaluation of the revised
Atlanta classification*

The revised Atlanta classification acknowledge both peripancreatic necrosis and necrotic debris of collections to be difficult to identify in the initial course of the disease ^[73]. The process of enhancement impairment normally evolves over days

making early CECTs difficult to interpret and thus unreliable for morphologic categorisation.

With this in mind we specifically addressed this particular problem in the instruction sheet provided to all local radiologists prior to CECT interpretation. Additionally, for all parameters in the scoring sheet the category "indeterminate" was available. In cases of doubt regarding the existence of necrosis the local radiologists were encouraged to select "indeterminate".

When analysing the kappa values we found in general sufficient agreement between the central expert and the local radiologists concerning morphological assessment of AP. For clinically important findings such as presence of parenchymal necrosis, signs of infection and presence of collections the level of agreement was good (kappa values 0.54, 0.76 and 0.76).

However, large differences were seen in the interpretation of four categories; Type of pancreatitis, Extrapancreatic necrosis, Characteristics of collections and Collections - most appropriate term. The central expert diagnosed peripancreatic necrosis, acute necrotic collections and consequently necrotising AP to a much larger extent. He also selected the term indeterminate more often, in particular concerning presence of extrapancreatic necrosis (12% vs 4%). We suggested that the local radiologists were unfamiliar with the new morphology, in particular when interpreting CECTs from the early phase of the disease. Additionally, specific interest in pancreatic radiology as well as yearly number of cases investigated are likewise important. The radiologist from centre F has since previously a special focus on pancreatic radiology, mirrored by the excellent interobserver agreement with the central expert (table 5). Centre F also has (among the participating centres) annually the largest amount of patients with AP admitted including a substantial number of severe cases.

Correct classification is important for several reasons. The clinical outcome differs between the morphological types of AP and although radiological findings not always changes the management strategies it is still an essential part for the understanding of the clinical picture of patient and the disease. In our study the scoring by the central expert to a larger extent correlated with the clinical outcome of the patients.

For research purposes, development of medical therapies and comparison of inter-institutional data the interpretation of findings need to be identical. One of the aims with the revised Atlanta classification was to clarify the definitions on AP. Nevertheless our study indicates that the morphological assessment pertaining to the identification of extrapancreatic necrosis and necrotic debris remains inadequate with a risk of misclassifying the AP patients.

Biomarkers

Countless numbers of attempts have been made to perceive predictive biomarkers in AP. Despite promising results the conduction into clinical applicability has been scarce. Whether additional studies are of value is thereby a legitimate question. Considering the large amount of efforts and the minimal impact on routine management we need to address the primary issues of the disease. Is the pathogenesis in AP too complex or the inter-individual variation overly significative for the possibility to make general conclusions? Or is it rather about shortcomings in study methodologies?

Although there have been advances, knowledge on the decisive steps of the pathophysiological process and profound insight into the role of inflammatory markers are still lacking. Additionally, when studying biomarkers in AP an evident fact is that all severity categories contain both high and low responders, making the range for each marker widely scattered also within severity groups. The results from the AMY-study analogically demonstrated explicitly heterogenetic circumstances. For all biomarkers we found what seemed to be a distinct continuous rise in mean value when comparing mild against moderately severe and severe AP. However, for several of the biomarkers statistical analysis could not demonstrate any significant differences, giving the impression that the individual disparities override the discrepancies of severity groups.

Paper II Predictive capacity of biomarkers for severe acute pancreatitis

The setup of this study was to compile cut-off levels from previous studies on biomarkers in AP and apply them on our unselected cohort which also has a normal distribution of severity grades. By this approach we aimed to resemble the routine clinical situation.

The predetermination of cut-off levels was more complicated than expected as we found earlier works to be expressely disparate in setups and outcomes making comparisons difficult. Finally only 14 studies met our inclusion criteria, still the cut-off levels of these studies were substantially diversified and approximations had to be made in value assessment. When applied on our cohort the preset cut-off levels demonstrated suboptimal capacity for severity prediction with low AUCs and insufficient sensitivity and specificity. In recalculation, using ROC curves, optimal cut-offs for selected biomarkers were within acceptable range from those presented by previous works. The prognostic ability, estimated in AUCs, as well as sensitivities and specificities, were however still on a low level.

The reasons for biomarkers demonstrating various results pertaining to predictive capacity are likely multiple. Numbers of patients with severe AP as well as age, gender and aetiology are factors that are likely to have impact. The temporal development of the disease and the aspect of time concerning sample collection might additionally influence. In our study no difference was found between the mild and severe group regarding these basic characteristics. These findings strengthen the assumption that the AMY-cohort consists of unselected AP patients.

Paper III IL-6 and CRP are superior in early differentiation between mild and non-mild acute pancreatitis

With the aim of investigating the initial phase of AP samples from the AMY-study taken between 13-36 hours into the course of the disease were used. The time frame was set based on the results from a large review by Staubli et al where initial results were presented ^[140]. As the group with mild AP is large but fairly uninvestigated and concurrently identification of the non-mild (moderately severe and severe) patients is prioritised we aimed to explore early differences between these two groups. To the best of our knowledge such a study had not been previously executed. The 175 patients included were thus separated into mild and non-mild AP. Biomarkers demonstrating positive performance in earlier studies in AP were analysed ^[40, 45, 137, 138, 141]. We found that a combination of IL-6 and CRP identified the non-mild group with high AUC, good sensitivity and acceptable specificity (table 7). Due to the high morbidity and possible mortality of AP cut-off levels for IL-6 and CRP were chosen to obtain high sensitivity.

Comparison was additionally made with the HAPS which is the only score compiled for mild AP ^[133]. By applying IL-6 plus CRP (using defined cut-off levels) the specificity was equal to what was found for the HAPS. However in all other analysis the combination of IL-6 and CRP was superior in the identification of mild cases (table 8). The HAPS has previously been validated with good results ^[134]. Nevertheless this scoring system has not reached clinical practice. In our study the HAPS certainly demonstrated high specificity for the mild cases but the sensitivity of 0.08 is far too low to be clinical usable.

Since there is a lack of predictive scoring systems the vast majority of the AP patients are currently hospitalised with supportive care and various interventions ^[163]. As the incidence of AP is increasing future identification of both mild and non-mild cases will be utterly essential, both due to the high morbidity of the disease but also for health care costs ^[6]. As CRP and IL-6 are fairly inexpensive and generally clinically available we find the results of this study valuable and worth further investigation, preferably in an international multicenter study.

The temporal dynamics of biomarkers in AP has not been extensively investigated in clinical studies. In general, exact amount of hours from onset of pain to collection of blood sample is rarely reported and all admission samples up until 72 hours after onset of disease are analysed together. However, in a disease with such rapid alterations a difference in hours between sample collections is likely to matter. By obtaining information on exact time lapse from disease onset to sample we aimed to give a detailed description of biomarker development in the initial phase of AP.

In this study we compared mean values of serum samples taken at 0-24 hours and 25-48 hours after onset of disease to examine the development of inflammatory reactions between but also within severity grades.

According to discrepancies in mean values all biomarkers seemed to differ significantly from 0-24 to 25-48 hours into the disease. However, in statistical analysis this was not the case due to the widespread individual variation in biomarker levels (table 9). We found a significant raise in mean level between day one and two for IL-1 β and IL-6 regarding the moderately severe and severe AP patients and likewise a significant decrease for IL-8 and IL-10 in the mild group. In comparison of severity groups, the differences in mean values (named delta-values) of IL-1 β , IL-6 and IL-10 varied significantly between the mild and the severe group (table 10).

Herein we have elucidated the development and temporal changes of interleukins during the initial phase of AP. Our results indicate that interleukins, in particular IL-1 β and IL-6, could be valuable tools in the early prediction of AP. However, further investigations, preferably large international multicenter studies, are needed to clinically establish this statement.

Methodological considerations

Paper I

This study contained retrospectively enrolled patients, whereas the CECTs were scored prospectively. All CECTs were performed between January 2012 and 2013, thus imaging techniques and patient management remained unchanged during the short inclusion period. Likewise collection of clinical data was uncomplicated. Due to the retrospective design, correlation between observed inconsistencies and

actual clinical decision-making was not investigated. An overall prospective setting would have been preferable but most likely not executable with regard to the time frame set for the project.

It is recognised that necrotic material, in particular within collections, is often disregarded on CT ^[73]. Both ultrasound and MRI are superior diagnostic methods for the depiction of necrotic material ^[98, 103]. Still, CT is globally the dominant imaging modality emphasising the importance of knowledge regarding possible areas of indeterminate or ambiguous interpretation.

As described previously in this thesis, the process of the revised Atlanta classification started as an iterative web process. The base of the classification is built on experts opinions and not validated data, although all statements were derived from accepted publications. It is generally considered to be a clear and simple classification, developed with the clinician in mind. However, the moderately severe category has been criticised for being diffuse as it contains a wide spectra of disease severity - from patients with deterioration of a comorbidity to those with multiorgan failure.

In this study only one central expert radiologist scored the CECTs potentially introducing bias. However high level of agreement was obtained with the local radiologist from centre F, who has a similar level of expertise. Additionally the central expert had an important role in the development of the RAC and his interpretation demonstrated superior correlation with clinical outcome.

Paper II-IV

The AMY-study was a prospective cohort study with consecutively enrolled, and thus unselected, AP patients included from January 2010 to September 2013. By this approach we aimed to assemble a cohort representative of the disease regarding aetiologies, gender, age and number of severe cases. The information on exact time for onset of pain was specifically requested upon inclusion.

All serum samples were analysed within a short time frame by one single laboratory engineer (Anne-Marie Rohrstock) using established commercial methods, thereby diminishing the amount of variability sources.

To assess the predictive capacity of biomarkers several analytical approaches exist. In our works we have used ROC-curves, AUCs, sensitivity, specificity, positive and negative predictive values and positive and negative likelihood ratios to describe the individual performances of the biomarkers. By applying various methods we aimed to present the results from different angles for extended understanding.

The setting for *Paper II* was designed in 2009, at a time when the framing of the RAC was yet in its infancy and the valid classification was still the AC. Thus *Paper II* was designed as a validation study of cut-off levels from previous studies on biomarkers in AP. All earlier works classified the patients according to the 1993 Atlanta classification and for this reason our patients were separated accordingly, although the AC was out of date at the time for our final analysis.

All studies based on the AMY-study are of an exploratory and descriptive nature, implying some limitations. In *Paper III* the capacity of biomarkers was investigated and cut-off levels for the separation of mild versus non-mild disease was suggested. However the aim of the study was not to generate a prognostic score, then a validation set would have been required. Additionally, the most interesting group of patients, from a clinical perspective, are those who develop severe AP. Nevertheless, this is also the smallest group consequently increasing the risk for type II errors with false negative results due to low numbers of patients. In general our findings, in particular those of *Paper III and IV*, thus need to be confirmed in larger studies.

In *paper IV* only a subgroup (n=115) and not the whole cohort had samples taken at both 0-24 and 25-48 hours after onset of disease. However this subgroup did not differ significantly in any basic characteristic compared to the large group. In this study the group with severe AP (in both the whole cohort and the subgroup) was significantly older compared to those with mild and moderately severe disease. As age is an established risk factor for severe disease supplementary multivariate analysis have been performed, demonstrating no association in our material between age and grade of severity.

Conclusions

Paper I

There are areas of controversy regarding the morphologic CT-criteria established by the revised Atlanta classification, especially pertaining to the identification of extrapancreatic necrosis and necrotic debris of collections.

Paper II

The variations in approaches and outcomes of earlier studies on predictive biomarkers in AP are substantial making comparisons complicated. In a cohort with consecutively enrolled patients application of previously defined cut-off levels demonstrates in general insufficient prognostic capacity of biomarkers.

Paper III

In the differentiation of mild and non-mild (moderately severe plus severe) AP CRP and IL-6 demonstrate good predictive capacity during the initial course of the disease.

Paper IV

During the first 48 hours of AP mean levels of IL-1 β and IL-6 increase significantly in patients with moderately severe and severe disease. Differences in mean values between day one and two were explicit for IL-1 β , IL-6 and IL-10 when comparing severity groups.

Future perspectives

The incidence of AP is increasing globally, accompanied by patient suffering and rising costs ^[6]. Thus there is a substantial need for urgent development in severity stratification methods and therapy approaches. A recent review of the quality of medical and surgical care of AP patients in the United Kingdom stated four areas of improvement; disease prevention, management of antibiotics, utilisation of existing prognostic scores and finally development of national networks and treatment strategies ^[164].

Prevention

The rise in number of AP patients can be explained by a wider accessibility of assessment tools, i.e sampling and imaging. Another important cause is likely the global epidemic in obesity. Obesity (body mass index ≥ 30) has been correlated to an increased risk ratio of 2.5 for gallstones but also an independently augmented risk ratio for AP (2.2) ^[165]. Additionally, obesity has demonstrated to correlate with level of disease severity ^[125, 166]. Preventive interventions to reduce the numbers of overweight and obese humans would likely have an impact on AP incidence. Additionally it has been stated that patients with gallstones clearly benefit from same-admission cholecystectomy, however these recommendations are to a large extent not complied with ^[72, 156, 164].

Pathophysiology and biomarkers

Although considerable advances have been reached much is still left regarding our understanding of the pathogenesis in AP. Profound knowledge on molecular events is important not only for early severity stratification but also for the development of targeted therapies. Currently numerous experimental efforts are being made to proceed in this direction, however to reach clinical impact results need to be confirmed in large prospective clinical multicenter studies. For the future, shortening of the distance between the laboratory and patients, i.e implementation of basic science into clinical practice, is crucial ^[167]. Additionally, new biomarkers have to be explored. Recently the interest in free fatty acids have

increased due to their cytotoxicity and capacity to up-regulate pro-inflammatory mediators. Also, the distribution of visceral fat has gained attention ^[168, 169, 170].

Genetic mechanisms in pancreatic disease have mainly been investigated regarding chronic pancreatitis and pancreatic adenocarcinoma. However, in recent years the interest in genetic alterations have increased also for AP, a development which might expand our understanding of the disease ^[167, 171].

Management

An essential challenge for the future is the improvement of clinical management of the AP patients. Currently all patients are hospitalised and treated identically. Overall, interventions are symptom-related as there is no specific therapy towards the disease itself.

In a recent Cochrane review of pharmacological therapy in AP the conclusion was that none of the investigated randomised controlled trials could demonstrate any benefits in the interventions groups regarding mortality ^[172]. Additionally, due to substantial variations in study approaches comparisons of morbidity outcomes were inapplicable. In general the quality of evidence was low and numerous systematic errors and biases were found.

Development of targeted therapies together with well-planned and strict clinical studies are necessary to reach success regarding novel treatments. Patients need to be correctly classified and the results of experimental studies should be confirmed clinically ^[167].

Populärvetenskaplig sammanfattning

Äkt pankreatit, inflammation i bukspottskörteln, är en relativt vanlig sjukdom som ökar världen över. Sjukdomen orsakas i de flesta fall av gallsten eller alkoholöverkonsumtion. Symtomen är hastigt insättande smärta i övre delen av buken. Diagnos sätts med hjälp av blodprov, där man ser förhöjt bukspottskörtelenzym, i kombination med att patienten har ont i magen. Majoriteten av patienterna drabbas av en mild, själveliminerande form av sjukdomen. Cirka 30 % får dock en medelsvår eller svår akut pankreatit vilket leder till en lång sjukhusvistelse med organsvikt och ofta vård på intensivvårdsavdelning. Mellan 20-40% av patienterna i den svåra gruppen avlider i sjukdomen. Vid den medelsvåra och svåra formen är risken också stor att drabbas av livslånga besvär, såsom diabetes och kroniska buksmärtor.

Ännu idag vet man inte varför endast vissa patienter blir svårt sjuka. Trots mycket forskning har man inte heller funnit någon metod (t.ex blodprov eller undersökning) som tidigt i förloppet kan avslöja vilken svårighetsgrad patienten kommer att utveckla. Därför behandlas alla som kommer till sjukhus med akut pankreatit som att de skulle kunna bli svårt sjuka vilket för en stor del av patienterna innebär överbehandling. Det finns inte heller någon specifik medicin mot sjukdomen utan enbart understödande behandling när olika organ sviktar. Tidigare genomgick många patienter stora kirurgiska ingrepp, t.ex för att ta bort död vävnad runt bukspottskörteln, medan man nuförtiden försöker hålla en mer konservativ linje. Hos de patienter där den akuta pankreatiten orsakats av gallsten rekommenderas dock att man tar bort gallblåsan i anslutning till aktuellt sjukdomstillfälle.

Det specifika sjukdomsförloppet i bukspottskörteln är till stora delar fortfarande oklart. Bukspottskörteln producerar bukspott vilket innehåller enzymer. Eftersom dessa har en nedbrytande funktion transporteras vissa av dem i ett inaktiverat tillstånd från bukspottskörteln till tolvfingertarmen. Väl i tarmen aktiveras de och kan då spjälka proteiner, kolhydrater och fetter. Vid akut pankreatit aktiveras enzymer av oklar anledning redan inne i själva körteln vilket leder till att de börjar angripa vävnaden där. Den skada som uppstår sätter igång ett flertal lokala och systemiska inflammatoriska processer, det sk inflammatoriska svaret. Hur stor påverkan detta får på den drabbade patientens organ avgör vilken svårighetsgrad av akut pankreatit patienten utvecklar. Många steg i denna sjukdomsprocess är

dock fortfarande okända vilket medför att man inte heller har kunnat utveckla målinriktade mediciner och andra behandlingar.

Patienterna delas oftast in i svårighetsgraderna mild, medelsvår och svår akut pankreatit enligt en klassifikation (den reviderade Atlanta klassifikationen) som publicerades 2013. Denna klassifikation är en reviderad variant av en tidigare version (Atlanta 1993) som ansetts utdaterad. När man inom forskning och studier vill jämföra olika patientgrupper och deras resultat är det av yttersta vikt att patienterna klassificeras likadant oavsett vilket forskningscentra man befinner sig vid.

Syftet med denna avhandling var dels att validera några av de nya röntgenbaserade kriterier som införts i den reviderade Atlanta klassifikationen. Vi ville också undersöka olika biomarkörer vid akut pankreatit och på olika sätt kunna visa på deras förmåga att avgöra vilka patienter som kommer att få mild, medelsvår eller svår sjukdom.

I delarbete I evaluerade sex stycken röntgenläkare (lokala radiologer) vid olika europeiskt universitetssjukhus 388 skiktröntgenbilder från patienter med olika stadier och olika svårighetsgrad av akut pankreatit. Bilderna bedömdes utifrån de morfologiska kriterier som anges i den reviderade Atlanta klassifikationen. Samma röntgenbilder utvärderades sedan på samma sätt av en röntgenläkare (expertradiologen) som är speciellt inriktad på just bukspottskörteln. Hur väl de lokala radiologernas och expertradiologens bedömningar stämde överens beräknades statistiskt. Vi kunde se att man var eniga gällande flera viktiga fynd, t.ex tecken på infektion och vävnadsdöd i körteln. De lokala radiologerna hade emellertid svårt att identifiera död vävnad i det fett som omger bukspottskörteln samt i de vätskeansamlingar som bildas vid medelsvår och svår sjukdom. Kännedom om dessa skillnader i tolkning av röntgenbilder är viktigt eftersom variation i bedömning gör att patienterna klassificeras olika. Samma patient kan alltså värderas som mer eller mindre sjuk beroende på vem som granskar hans röntgenbilder. Att bilderna tolkas likadant är av stor vikt för korrekt medicinsk behandling men även för jämförelse av patientgrupper med samma svårighetsgrad av sjukdomen.

Delarbete II-IV bygger alla på en gemensam databas av 232 patienter med akut pankreatit. Blodprover togs när patienterna sökte akutmottagningen samt upprepat till dess att patienternas bukspottskörtelenzym hade normaliserats. I proverna mätte vi sedan nivåer av ett flertal biomarkörer. Resultaten användes i de olika delarbetena för att, på ett tidigt stadium, försöka avgöra vilka patienter som kommer drabbas av mild, medelsvår eller svår sjukdom.

I delarbete II är patienterna uppdelade i mild eller svår sjukdom enligt Atlanta klassifikationen från 1993. Vi valde detta upplägg för att kunna jämföra våra resultat med tidigare studier. Föregående arbeten om biomarkörer och akut pankreatit har redovisat så kallade cut-off:er, dvs de nivåer hos biomarkörerna som bäst skiljer på mild och svår sjukdom. I delarbete II validerade vi dessa cut-off:er genom att applicera dem på våra egna patienter. Vi kom fram till att tidigare studier var svåra att jämföra beroende på mycket varierande studieupplägg samt att de utvalda cut-off:erna inte gav något bra resultat i vår patientgrupp.

I delarbete III delades patienterna upp i mild och icke-mild (medelsvår plus svår) sjukdom enligt den reviderade Atlanta klassifikationen. Vi tittade sedan på om nivåerna hos biomarkörerna skilde sig mellan dessa två grupper och fann att genom att använda två vanliga markörer, CRP och IL-6, kunde patienter med mild och icke-mild sjukdom identifieras tidigt i sjukdomsförloppet.

I delarbete IV analyserade vi olika biomarkörers utveckling mellan första och andra dygnet vid akut pankreatit. Vi tittade också på om nivåerna hos biomarkörerna skilde sig mellan mild, medelsvår och svår sjukdom. Resultaten visade att medelvärdena hos markörerna IL-1 β och IL-6 ökade tydligt från dag ett till dag två i den medelsvåra och svåra gruppen. Vi fann även att skillnaderna i medelvärde (så kallade deltavärden) hos IL-1 β , IL-6 och IL-10 var statistiskt olika i den milda jämfört den svåra gruppen. Våra resultat tyder på att dessa biomarkörer kan vara intressanta att undersöka vidare för att tidigt kunna skilja ut de patienter som riskerar att bli svårt sjuka i sin akuta pankreatit.

Acknowledgements

Sara Regnér – my super supervisor. Clever, wise, cool, patient and always positive. I hope we have many years of collaboration ahead of us!

Henrik Thorlacius - my co-supervisor, thanks for your intellectual support and for reminding me that there are a lot of unenlightened reviewers out there...

Lucas Ilzarbe, Robert C Verdonk, Anne Penttilä, Povilas Ignatavicius, Alexandra Dimova, Peeter Koiva and Jonas Rosendahl - my co-authors, my brothers and sisters from my second family, the best Pancreas 2000 group ever! Thank you for your everlasting positive thinking, friendship and never-ending nights of fun. May we enjoy many future years together, love you!

The Pancreas 2000 squad - Bengt Holmberg, Matthias Löhr and Thomas Gasslander. Thank you so much for giving me the opportunity to join this course that have changed my life in so many perspectives!

All the mentors at the Pancreas 2000 course 6 - thanks for all your wise comments and good friendship. A special thank you to Marco del Chiaro for your honesty and wisdom, for pushing me out into world, making me face my fears and for so generously sharing your enormous global network.

Hannes Hartman - my coauthor and friend – thank you for your intellectual contributions, encouragement and good laughs!

Dorthe Johansen, Anne-Marie Rohrstock and Ingrid Palmquist – coauthor, data collectors, laboratory maestros and ladies of diligence and control. Without you nothing in this book would have been possible. Thank you!

Sophia Zackrisson, Eila Lantto, Guadalupe Aguilar, Tonis Loigom, Vanya Strahinova, Kristina Zviniene and especially Thomas L Bollen – radiologists and coauthors from all over Europe. Thank you for offering and sharing your wide knowledge and expertise in the Atlanta project.

Current and past colleagues in Malmö and Lund – thank you all for so liberally sharing your surgical competence daily.

My friends – thanks for all the energy, the wise words and the fun!

Berit, Jan and all the other relatives from the Sternby/Eilard/Jönsson/Lundsgård clan - thanks for valuable discussions and your never-ending positive thinking.

Cicki, Lennart, Per o Mats – my nearest and dearest, thank you for your continuous support.

Viktor, Oskar and Alfred – my kings, my happiness, my earth and my breath. You will always be stars - never cut down on your fantasy, your energy and your sunshine.

Jakob – you are the true definition of patience, love and support. Thank you.

References

- 1 Busnardo AC, DiDio LJ, Tidrick RT, Thomford NR. History of the pancreas. *Am J Surg* 1983;146:539-50.
- 2 Lankisch PG, Banks PA, SpringerLink (Online service). Pancreatitis. Berlin ; New York: Springer,, 1998:1 online resource (xvii, 377 pages).
- 3 Ansari D. Pancreatic Cancer - Early detection, prognostic factors, and treatment. *Doctoral dissertation*. Lund University 2014.
- 4 Beger HG. The pancreas an integrated textbook of basic science, medicine, and surgery. Malden, Mass. ; Oxford: Blackwell Pub.,, 2008:1 online resource (xv, 1006 p.).
- 5 Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. *Gastroenterology* 2013;144:1252-61.
- 6 Peery AF, Crockett SD, Barritt AS, Dellon ES, Eluri S, Gangarosa LM, *et al*. Burden of Gastrointestinal, Liver, and Pancreatic Diseases in the United States. *Gastroenterology* 2015;149:1731-41 e3.
- 7 Peery AF, Dellon ES, Lund J, Crockett SD, McGowan CE, Bulsiewicz WJ, *et al*. Burden of gastrointestinal disease in the United States: 2012 update. *Gastroenterology* 2012;143:1179-87 e1-3.
- 8 Weiss FU, Halangk W, Lerch MM. New advances in pancreatic cell physiology and pathophysiology. *Best Pract Res Clin Gastroenterol* 2008;22:3-15.
- 9 Tenner S, Baillie J, DeWitt J, Vege SS, American College of G. American College of Gastroenterology guideline: management of acute pancreatitis. *Am J Gastroenterol* 2013;108:1400-15; 16.
- 10 Saluja AK, Lerch MM, Phillips PA, Dudeja V. Why does pancreatic overstimulation cause pancreatitis? *Annu Rev Physiol* 2007;69:249-69.
- 11 Sutton R, Criddle D, Raraty MG, Tepikin A, Neoptolemos JP, Petersen OH. Signal transduction, calcium and acute pancreatitis. *Pancreatology* 2003;3:497-505.
- 12 Laukkarinen JM, Van Acker GJ, Weiss ER, Steer ML, Perides G. A mouse model of acute biliary pancreatitis induced by retrograde pancreatic duct infusion of Na-taurocholate. *Gut* 2007;56:1590-8.
- 13 Halangk W, Lerch MM. Early events in acute pancreatitis. *Clin Lab Med* 2005;25:1-15.
- 14 Hedstrom J, Sainio V, Kemppainen E, Haapiainen R, Kivilaakso E, Schroder T, *et al*. Serum complex of trypsin 2 and alpha 1 antitrypsin as diagnostic and prognostic marker of acute pancreatitis: clinical study in consecutive patients. *BMJ* 1996;313:333-7.

- 15 Hietaranta AJ, Saluja AK, Bhagat L, Singh VP, Song AM, Steer ML. Relationship between NF-kappaB and trypsinogen activation in rat pancreas after supramaximal caerulein stimulation. *Biochem Biophys Res Commun* 2001;280:388-95.
- 16 Altavilla D, Famulari C, Passaniti M, Galeano M, Macri A, Seminara P, *et al.* Attenuated cerulein-induced pancreatitis in nuclear factor-kappaB-deficient mice. *Lab Invest* 2003;83:1723-32.
- 17 Dawra R, Sah RP, Dudeja V, Rishi L, Talukdar R, Garg P, *et al.* Intra-acinar trypsinogen activation mediates early stages of pancreatic injury but not inflammation in mice with acute pancreatitis. *Gastroenterology* 2011;141:2210-17 e2.
- 18 Gaiser S, Daniluk J, Liu Y, Tsou L, Chu J, Lee W, *et al.* Intracellular activation of trypsinogen in transgenic mice induces acute but not chronic pancreatitis. *Gut* 2011;60:1379-88.
- 19 Bhatia M, Brady M, Shokuhi S, Christmas S, Neoptolemos JP, Slavin J. Inflammatory mediators in acute pancreatitis. *J Pathol* 2000;190:117-25.
- 20 Rinderknecht H. Fatal pancreatitis, a consequence of excessive leukocyte stimulation? *Int J Pancreatol* 1988;3:105-12.
- 21 Norman J. The role of cytokines in the pathogenesis of acute pancreatitis. *Am J Surg* 1998;175:76-83.
- 22 Pooran N, Indaram A, Singh P, Bank S. Cytokines (IL-6, IL-8, TNF): early and reliable predictors of severe acute pancreatitis. *J Clin Gastroenterol* 2003;37:263-6.
- 23 Makhija R, Kingsnorth AN. Cytokine storm in acute pancreatitis. *J Hepatobiliary Pancreat Surg* 2002;9:401-10.
- 24 Kusske AM, Rongione AJ, Reber HA. Cytokines and acute pancreatitis. *Gastroenterology* 1996;110:639-42.
- 25 Gukovskaya AS, Gukovsky I, Zaninovic V, Song M, Sandoval D, Gukovsky S, *et al.* Pancreatic acinar cells produce, release, and respond to tumor necrosis factor-alpha. Role in regulating cell death and pancreatitis. *J Clin Invest* 1997;100:1853-62.
- 26 Osman MO, Jensen SL. Acute pancreatitis: the pathophysiological role of cytokines and integrins. New trends for treatment? *Dig Surg* 1999;16:347-62.
- 27 de Beaux AC, Goldie AS, Ross JA, Carter DC, Fearon KC. Serum concentrations of inflammatory mediators related to organ failure in patients with acute pancreatitis. *Br J Surg* 1996;83:349-53.
- 28 Gamble JR, Harlan JM, Klebanoff SJ, Vadas MA. Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. *Proc Natl Acad Sci U S A* 1985;82:8667-71.
- 29 Okusawa S, Gelfand JA, Ikejima T, Connolly RJ, Dinarello CA. Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. *J Clin Invest* 1988;81:1162-72.
- 30 Dinarello CA. Biologic basis for interleukin-1 in disease. *Blood* 1996;87:2095-147.
- 31 Mayer J, Rau B, Gansauge F, Beger HG. Inflammatory mediators in human acute pancreatitis: clinical and pathophysiological implications. *Gut* 2000;47:546-52.

- 32 Dambrauskas Z, Giese N, Gulbinas A, Giese T, Berberat PO, Pundzius J, *et al.* Different profiles of cytokine expression during mild and severe acute pancreatitis. *World J Gastroenterol* 2010;16:1845-53.
- 33 Sathyanarayan G, Garg PK, Prasad H, Tandon RK. Elevated level of interleukin-6 predicts organ failure and severe disease in patients with acute pancreatitis. *J Gastroenterol Hepatol* 2007;22:550-4.
- 34 Tran DD. Interleukin-6 in the early assessment of acute pancreatitis. *Gut* 1993;34:1467.
- 35 Baggiolini M. Chemokines in pathology and medicine. *J Intern Med* 2001;250:91-104.
- 36 Berney T, Gasche Y, Robert J, Jenny A, Mensi N, Grau G, *et al.* Serum profiles of interleukin-6, interleukin-8, and interleukin-10 in patients with severe and mild acute pancreatitis. *Pancreas* 1999;18:371-7.
- 37 Donnelly SC, Strieter RM, Kunkel SL, Walz A, Robertson CR, Carter DC, *et al.* Interleukin-8 and development of adult respiratory distress syndrome in at-risk patient groups. *Lancet* 1993;341:643-7.
- 38 Marra F. Renaming cytokines: MCP-1, major chemokine in pancreatitis. *Gut* 2005;54:1679-81.
- 39 Papachristou GI, Sass DA, Avula H, Lamb J, Lokshin A, Barmada MM, *et al.* Is the monocyte chemoattractant protein-1 -2518 G allele a risk factor for severe acute pancreatitis? *Clin Gastroenterol Hepatol* 2005;3:475-81.
- 40 Regner S, Appelros S, Hjalmarsson C, Manjer J, Sadic J, Borgstrom A. Monocyte chemoattractant protein 1, active carboxypeptidase B and CAPAP at hospital admission are predictive markers for severe acute pancreatitis. *Pancreatology* 2008;8:42-9.
- 41 Norman J, Franz M, Messina J, Riker A, Fabri PJ, Rosemurgy AS, *et al.* Interleukin-1 receptor antagonist decreases severity of experimental acute pancreatitis. *Surgery* 1995;117:648-55.
- 42 Thomson AW, Lotze MT, ebrary Inc. The cytokine handbook. Amsterdam ; Boston: Academic Press,, 2003:2 v. in 1.
- 43 Hayashi T, Ishida Y, Kimura A, Iwakura Y, Mukaida N, Kondo T. IFN-gamma protects cerulein-induced acute pancreatitis by repressing NF-kappa B activation. *J Immunol* 2007;178:7385-94.
- 44 Kylanpaa ML, Mentula P, Kempainen E, Puolakkainen P, Aittomaki S, Silvennoinen O, *et al.* Monocyte anergy is present in patients with severe acute pancreatitis and is significantly alleviated by granulocyte-macrophage colony-stimulating factor and interferon-gamma in vitro. *Pancreas* 2005;31:23-7.
- 45 Chen CC, Wang SS, Lu RH, Chang FY, Lee SD. Serum interleukin 10 and interleukin 11 in patients with acute pancreatitis. *Gut* 1999;45:895-9.
- 46 Rongione AJ, Kusske AM, Kwan K, Ashley SW, Reber HA, McFadden DW. Interleukin 10 reduces the severity of acute pancreatitis in rats. *Gastroenterology* 1997;112:960-7.

- 47 Mentula P, Kylanpaa ML, Kemppainen E, Jansson SE, Sarna S, Puolakkainen P, *et al.* Early prediction of organ failure by combined markers in patients with acute pancreatitis. *Br J Surg* 2005;92:68-75.
- 48 Pezzilli R, Billi P, Miniero R, Barakat B. Serum interleukin-10 in human acute pancreatitis. *Dig Dis Sci* 1997;42:1469-72.
- 49 Sandoval D, Gukovskaya A, Reavey P, Gukovsky S, Sisk A, Braquet P, *et al.* The role of neutrophils and platelet-activating factor in mediating experimental pancreatitis. *Gastroenterology* 1996;111:1081-91.
- 50 Kakafika A, Papadopoulos V, Mimidis K, Mikhailidis DP. Coagulation, platelets, and acute pancreatitis. *Pancreas* 2007;34:15-20.
- 51 Kingsnorth AN, Galloway SW, Formela LJ. Randomized, double-blind phase II trial of Lexipafant, a platelet-activating factor antagonist, in human acute pancreatitis. *Br J Surg* 1995;82:1414-20.
- 52 McKay CJ, Curran F, Sharples C, Baxter JN, Imrie CW. Prospective placebo-controlled randomized trial of lexipafant in predicted severe acute pancreatitis. *Br J Surg* 1997;84:1239-43.
- 53 Johnson CD, Kingsnorth AN, Imrie CW, McMahon MJ, Neoptolemos JP, McKay C, *et al.* Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis. *Gut* 2001;48:62-9.
- 54 Lowry SF. Cytokine mediators of immunity and inflammation. *Arch Surg* 1993;128:1235-41.
- 55 Frossard JL, Saluja A, Bhagat L, Lee HS, Bhatia M, Hofbauer B, *et al.* The role of intercellular adhesion molecule 1 and neutrophils in acute pancreatitis and pancreatitis-associated lung injury. *Gastroenterology* 1999;116:694-701.
- 56 Kinnala PJ, Kuttala KT, Gronroos JM, Havia TV, Nevalainen TJ, Niinikoski JH. Pancreatic tissue perfusion in experimental acute pancreatitis. *Eur J Surg* 2001;167:689-94.
- 57 Zhou ZG, Chen YD, Sun W, Chen Z. Pancreatic microcirculatory impairment in experimental acute pancreatitis in rats. *World J Gastroenterol* 2002;8:933-6.
- 58 Wang G, Han B, Zhou H, Wu L, Wang Y, Jia G, *et al.* Inhibition of hydrogen sulfide synthesis provides protection for severe acute pancreatitis rats via apoptosis pathway. *Apoptosis* 2013;18:28-42.
- 59 Wu LM, Sankaran SJ, Plank LD, Windsor JA, Petrov MS. Meta-analysis of gut barrier dysfunction in patients with acute pancreatitis. *Br J Surg* 2014;101:1644-56.
- 60 Besselink MG, van Santvoort HC, Boermeester MA, Nieuwenhuijs VB, van Goor H, Dejong CH, *et al.* Timing and impact of infections in acute pancreatitis. *Br J Surg* 2009;96:267-73.
- 61 Petrov MS, Shanbhag S, Chakraborty M, Phillips AR, Windsor JA. Organ failure and infection of pancreatic necrosis as determinants of mortality in patients with acute pancreatitis. *Gastroenterology* 2010;139:813-20.

- 62 van Santvoort HC, Besselink MG, Bakker OJ, Hofker HS, Boermeester MA, Dejong CH, *et al.* A step-up approach or open necrosectomy for necrotizing pancreatitis. *N Engl J Med* 2010;362:1491-502.
- 63 Salomone T, Tosi P, Palareti G, Tomassetti P, Migliori M, Guariento A, *et al.* Coagulative disorders in human acute pancreatitis: role for the D-dimer. *Pancreas* 2003;26:111-6.
- 64 Radenkovic D, Bajec D, Ivancevic N, Milic N, Bumbasirevic V, Jeremic V, *et al.* D-dimer in acute pancreatitis: a new approach for an early assessment of organ failure. *Pancreas* 2009;38:655-60.
- 65 Darville T, Giroir B, Jacobs R. The systemic inflammatory response syndrome (SIRS): immunology and potential immunotherapy. *Infection* 1993;21:279-90.
- 66 Awla D, Zetterqvist AV, Abdulla A, Camello C, Berglund LM, Spegel P, *et al.* NFATc3 regulates trypsinogen activation, neutrophil recruitment, and tissue damage in acute pancreatitis in mice. *Gastroenterology* 2012;143:1352-60 e1-7.
- 67 Halonen KI, Pettila V, Leppaniemi AK, Kemppainen EA, Puolakkainen PA, Haapiainen RK. Multiple organ dysfunction associated with severe acute pancreatitis. *Crit Care Med* 2002;30:1274-9.
- 68 Renner IG, Savage WT, 3rd, Pantoja JL, Renner VJ. Death due to acute pancreatitis. A retrospective analysis of 405 autopsy cases. *Dig Dis Sci* 1985;30:1005-18.
- 69 Blum T, Maisonneuve P, Lowenfels AB, Lankisch PG. Fatal outcome in acute pancreatitis: its occurrence and early prediction. *Pancreatology* 2001;1:237-41.
- 70 Mofidi R, Duff MD, Wigmore SJ, Madhavan KK, Garden OJ, Parks RW. Association between early systemic inflammatory response, severity of multiorgan dysfunction and death in acute pancreatitis. *Br J Surg* 2006;93:738-44.
- 71 Pandol SJ, Saluja AK, Imrie CW, Banks PA. Acute pancreatitis: bench to the bedside. *Gastroenterology* 2007;132:1127-51.
- 72 Working Group IAPAPAAPG. IAP/APA evidence-based guidelines for the management of acute pancreatitis. *Pancreatology* 2013;13:e1-15.
- 73 Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, *et al.* Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. *Gut* 2013;62:102-11.
- 74 Sarles H. Revised classification of pancreatitis--Marseille 1984. *Dig Dis Sci* 1985;30:573-4.
- 75 Sarner M, Cotton PB. Classification of pancreatitis. *Gut* 1984;25:756-9.
- 76 Bradley EL, 3rd. A clinically based classification system for acute pancreatitis. Summary of the International Symposium on Acute Pancreatitis, Atlanta, Ga, September 11 through 13, 1992. *Arch Surg* 1993;128:586-90.
- 77 Vege SS, Chari ST. Organ failure as an indicator of severity of acute pancreatitis: time to revisit the Atlanta classification. *Gastroenterology* 2005;128:1133-5.
- 78 Bollen TL, Besselink MG, van Santvoort HC, Gooszen HG, van Leeuwen MS. Toward an update of the atlanta classification on acute pancreatitis: review of new and abandoned terms. *Pancreas* 2007;35:107-13.

- 79 van Santvoort HC, Bollen TL, Besselink MG, Banks PA, Boermeester MA, van Eijck CH, *et al.* Describing peripancreatic collections in severe acute pancreatitis using morphologic terms: an international interobserver agreement study. *Pancreatology* 2008;8:593-9.
- 80 Vege SS, Gardner TB, Chari ST, Munukuti P, Pearson RK, Clain JE, *et al.* Low mortality and high morbidity in severe acute pancreatitis without organ failure: a case for revising the Atlanta classification to include "moderately severe acute pancreatitis". *Am J Gastroenterol* 2009;104:710-5.
- 81 Petrov MS. Revising the Atlanta classification of acute pancreatitis: festina lente. *J Gastrointest Surg* 2010;14:1474-5.
- 82 de-Madaria E, Soler-Sala G, Lopez-Font I, Zapater P, Martinez J, Gomez-Escolar L, *et al.* Update of the Atlanta Classification of severity of acute pancreatitis: should a moderate category be included? *Pancreatology* 2010;10:613-9.
- 83 Dellinger EP, Forsmark CE, Layer P, Levy P, Maravi-Poma E, Petrov MS, *et al.* Determinant-based classification of acute pancreatitis severity: an international multidisciplinary consultation. *Ann Surg* 2012;256:875-80.
- 84 Thandassery RB, Yadav TD, Dutta U, Appasani S, Singh K, Kochhar R. Prospective validation of 4-category classification of acute pancreatitis severity. *Pancreas* 2013;42:392-6.
- 85 Talukdar R, Bhattacharaya A, Rao B, Sharma M, Nageshwar Reddy D. Clinical utility of the revised Atlanta classification of acute pancreatitis in a prospective cohort: have all loose ends been tied? *Pancreatology* 2014;14:257-62.
- 86 Acevedo-Piedra NG, Moya-Hoyo N, Rey-Riveiro M, Gil S, Sempere L, Martinez J, *et al.* Validation of the determinant-based classification and revision of the Atlanta classification systems for acute pancreatitis. *Clin Gastroenterol Hepatol* 2014;12:311-6.
- 87 Choi JH, Kim MH, Oh D, Paik WH, Park DH, Lee SS, *et al.* Clinical relevance of the revised Atlanta classification focusing on severity stratification system. *Pancreatology* 2014;14:324-9.
- 88 Chen Y, Ke L, Tong Z, Li W, Li J. Association between severity and the determinant-based classification, Atlanta 2012 and Atlanta 1992, in acute pancreatitis: a clinical retrospective study. *Medicine (Baltimore)* 2015;94:e638.
- 89 Kadiyala V, Suleiman SL, McNabb-Baltar J, Wu BU, Banks PA, Singh VK. The Atlanta Classification, Revised Atlanta Classification, and Determinant-Based Classification of Acute Pancreatitis: Which Is Best at Stratifying Outcomes? *Pancreas* 2016;45:510-5.
- 90 Zubia-Olaskoaga F, Maravi-Poma E, Urreta-Barallobre I, Ramirez-Puerta MR, Mourelo-Farina M, Marcos-Neira MP, *et al.* Comparison Between Revised Atlanta Classification and Determinant-Based Classification for Acute Pancreatitis in Intensive Care Medicine. Why Do Not Use a Modified Determinant-Based Classification? *Crit Care Med* 2016;44:910-7.
- 91 Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. *Crit Care Med* 1995;23:1638-52.

- 92 Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, *et al.* The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. *Intensive Care Med* 1996;22:707-10.
- 93 Banks PA, Freeman ML, Practice Parameters Committee of the American College of G. Practice guidelines in acute pancreatitis. *Am J Gastroenterol* 2006;101:2379-400.
- 94 Singh VK, Bollen TL, Wu BU, Repas K, Maurer R, Yu S, *et al.* An assessment of the severity of interstitial pancreatitis. *Clin Gastroenterol Hepatol* 2011;9:1098-103.
- 95 Bansal SS, Hodson J, Sutcliffe RS, Marudanayagam R, Muiesan P, Mirza DF, *et al.* Performance of the revised Atlanta and determinant-based classifications for severity in acute pancreatitis. *Br J Surg* 2016;103:427-33.
- 96 Guo Q, Li M, Chen Y, Hu W. Determinant-based classification and revision of the Atlanta classification, which one should we choose to categorize acute pancreatitis? *Pancreatology* 2015;15:331-6.
- 97 Lankisch PG, Apte M, Banks PA. Acute pancreatitis. *Lancet* 2015;386:85-96.
- 98 Balthazar EJ. Acute pancreatitis: assessment of severity with clinical and CT evaluation. *Radiology* 2002;223:603-13.
- 99 Bollen TL. Imaging of acute pancreatitis: update of the revised Atlanta classification. *Radiol Clin North Am* 2012;50:429-45.
- 100 Balthazar EJ, Freeny PC, vanSonnenberg E. Imaging and intervention in acute pancreatitis. *Radiology* 1994;193:297-306.
- 101 Bollen TL. Acute pancreatitis: international classification and nomenclature. *Clin Radiol* 2016;71:121-33.
- 102 Mofidi R, Lee AC, Madhavan KK, Garden OJ, Parks RW. The selective use of magnetic resonance cholangiopancreatography in the imaging of the axial biliary tree in patients with acute gallstone pancreatitis. *Pancreatology* 2008;8:55-60.
- 103 Morgan DE, Baron TH, Smith JK, Robbin ML, Kenney PJ. Pancreatic fluid collections prior to intervention: evaluation with MR imaging compared with CT and US. *Radiology* 1997;203:773-8.
- 104 Kondo S, Isayama H, Akahane M, Toda N, Sasahira N, Nakai Y, *et al.* Detection of common bile duct stones: comparison between endoscopic ultrasonography, magnetic resonance cholangiography, and helical-computed-tomographic cholangiography. *Eur J Radiol* 2005;54:271-5.
- 105 Balthazar EJ, Ranson JH, Naidich DP, Megibow AJ, Caccavale R, Cooper MM. Acute pancreatitis: prognostic value of CT. *Radiology* 1985;156:767-72.
- 106 London NJ, Neoptolemos JP, Lavelle J, Bailey I, James D. Contrast-enhanced abdominal computed tomography scanning and prediction of severity of acute pancreatitis: a prospective study. *Br J Surg* 1989;76:268-72.
- 107 Balthazar EJ, Robinson DL, Megibow AJ, Ranson JH. Acute pancreatitis: value of CT in establishing prognosis. *Radiology* 1990;174:331-6.


- 108 Morteale KJ, Wiesner W, Intriere L, Shankar S, Zou KH, Kalantari BN, *et al.* A modified CT severity index for evaluating acute pancreatitis: improved correlation with patient outcome. *AJR Am J Roentgenol* 2004;183:1261-5.
- 109 Bollen TL, Singh VK, Maurer R, Repas K, van Es HW, Banks PA, *et al.* A comparative evaluation of radiologic and clinical scoring systems in the early prediction of severity in acute pancreatitis. *Am J Gastroenterol* 2012;107:612-9.
- 110 Bakker OJ, van Santvoort H, Besselink MG, Boermeester MA, van Eijck C, Dejong K, *et al.* Extrapaneatic necrosis without pancreatic parenchymal necrosis: a separate entity in necrotising pancreatitis? *Gut* 2013;62:1475-80.
- 111 Rana SS, Sharma V, Sharma RK, Chhabra P, Gupta R, Bhasin DK. Clinical significance of presence and extent of extrapancreatic necrosis in acute pancreatitis. *J Gastroenterol Hepatol* 2015;30:794-8.
- 112 Wang M, Wei A, Guo Q, Zhang Z, Lu H, Li A, *et al.* Clinical outcomes of combined necrotizing pancreatitis versus extrapancreatic necrosis alone. *Pancreatolgy* 2015.
- 113 Beger HG, Rau B, Isenmann R. Natural history of necrotizing pancreatitis. *Pancreatolgy* 2003;3:93-101.
- 114 Baron TH, Morgan DE. Acute necrotizing pancreatitis. *N Engl J Med* 1999;340:1412-7.
- 115 Tenner S, Sica G, Hughes M, Noordhoek E, Feng S, Zinner M, *et al.* Relationship of necrosis to organ failure in severe acute pancreatitis. *Gastroenterology* 1997;113:899-903.
- 116 Perez A, Whang EE, Brooks DC, Moore FD, Jr., Hughes MD, Sica GT, *et al.* Is severity of necrotizing pancreatitis increased in extended necrosis and infected necrosis? *Pancreas* 2002;25:229-33.
- 117 Isenmann R, Rau B, Beger HG. Bacterial infection and extent of necrosis are determinants of organ failure in patients with acute necrotizing pancreatitis. *Br J Surg* 1999;86:1020-4.
- 118 Garg PK, Madan K, Pande GK, Khanna S, Sathyanarayan G, Bohidar NP, *et al.* Association of extent and infection of pancreatic necrosis with organ failure and death in acute necrotizing pancreatitis. *Clin Gastroenterol Hepatol* 2005;3:159-66.
- 119 Gotzinger P, Sautner T, Kriwanek S, Beckerhinn P, Barlan M, Armbruster C, *et al.* Surgical treatment for severe acute pancreatitis: extent and surgical control of necrosis determine outcome. *World J Surg* 2002;26:474-8.
- 120 Lankisch PG, Pflithofer D, Lehnick D. No strict correlation between necrosis and organ failure in acute pancreatitis. *Pancreas* 2000;20:319-22.
- 121 Talukdar R, Clemens M, Vege SS. Moderately severe acute pancreatitis: prospective validation of this new subgroup of acute pancreatitis. *Pancreas* 2012;41:306-9.
- 122 Mole DJ, McClymont KL, Lau S, Mills R, Stamp-Vincent C, Garden OJ, *et al.* Discrepancy between the extent of pancreatic necrosis and multiple organ failure score in severe acute pancreatitis. *World J Surg* 2009;33:2427-32.
- 123 Mounzer R, Langmead CJ, Wu BU, Evans AC, Bishehsari F, Muddana V, *et al.* Comparison of existing clinical scoring systems to predict persistent organ failure in patients with acute pancreatitis. *Gastroenterology* 2012;142:1476-82; quiz e15-6.

- 124 de Beaux AC, Palmer KR, Carter DC. Factors influencing morbidity and mortality in acute pancreatitis; an analysis of 279 cases. *Gut* 1995;37:121-6.
- 125 Wang SQ, Li SJ, Feng QX, Feng XY, Xu L, Zhao QC. Overweight is an additional prognostic factor in acute pancreatitis: a meta-analysis. *Pancreatology* 2011;11:92-8.
- 126 Frey C, Zhou H, Harvey D, White RH. Co-morbidity is a strong predictor of early death and multi-organ system failure among patients with acute pancreatitis. *J Gastrointest Surg* 2007;11:733-42.
- 127 Frey CF, Zhou H, Harvey DJ, White RH. The incidence and case-fatality rates of acute biliary, alcoholic, and idiopathic pancreatitis in California, 1994-2001. *Pancreas* 2006;33:336-44.
- 128 Sigounas DE, Tatsioni A, Christodoulou DK, Tsianos EV, Ioannidis JP. New prognostic markers for outcome of acute pancreatitis: overview of reporting in 184 studies. *Pancreas* 2011;40:522-32.
- 129 Papachristou GI, Muddana V, Yadav D, O'Connell M, Sanders MK, Slivka A, *et al.* Comparison of BISAP, Ranson's, APACHE-II, and CTSI scores in predicting organ failure, complications, and mortality in acute pancreatitis. *Am J Gastroenterol* 2010;105:435-41; quiz 42.
- 130 American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. *Crit Care Med* 1992;20:864-74.
- 131 Johnson CD, Abu-Hilal M. Persistent organ failure during the first week as a marker of fatal outcome in acute pancreatitis. *Gut* 2004;53:1340-4.
- 132 Singh VK, Wu BU, Bollen TL, Repas K, Maurer R, Morteale KJ, *et al.* Early systemic inflammatory response syndrome is associated with severe acute pancreatitis. *Clin Gastroenterol Hepatol* 2009;7:1247-51.
- 133 Lankisch PG, Weber-Dany B, Hebel K, Maisonneuve P, Lowenfels AB. The harmless acute pancreatitis score: a clinical algorithm for rapid initial stratification of nonsevere disease. *Clin Gastroenterol Hepatol* 2009;7:702-5; quiz 607.
- 134 Oskarsson V, Mehrabi M, Orsini N, Hammarqvist F, Segersvard R, Andren-Sandberg A, *et al.* Validation of the harmless acute pancreatitis score in predicting nonsevere course of acute pancreatitis. *Pancreatology* 2011;11:464-8.
- 135 Khanna AK, Meher S, Prakash S, Tiwary SK, Singh U, Srivastava A, *et al.* Comparison of Ranson, Glasgow, MOSS, SIRS, BISAP, APACHE-II, CTSI Scores, IL-6, CRP, and Procalcitonin in Predicting Severity, Organ Failure, Pancreatic Necrosis, and Mortality in Acute Pancreatitis. *HPB Surg* 2013;2013:367581.
- 136 Zhang J, Niu J, Yang J. Interleukin-6, interleukin-8 and interleukin-10 in estimating the severity of acute pancreatitis: an updated meta-analysis. *Hepatogastroenterology* 2014;61:215-20.
- 137 Aoun E, Chen J, Reighard D, Gleeson FC, Whitcomb DC, Papachristou GI. Diagnostic accuracy of interleukin-6 and interleukin-8 in predicting severe acute pancreatitis: a meta-analysis. *Pancreatology* 2009;9:777-85.
- 138 Chen CC, Wang SS, Lee FY, Chang FY, Lee SD. Proinflammatory cytokines in early assessment of the prognosis of acute pancreatitis. *Am J Gastroenterol* 1999;94:213-8.

- 139 Shen Y, Cui N, Miao B, Zhao E. Immune dysregulation in patients with severe acute pancreatitis. *Inflammation* 2011;34:36-42.
- 140 Staubli SM, Oertli D, Nebiker CA. Laboratory markers predicting severity of acute pancreatitis. *Crit Rev Clin Lab Sci* 2015;52:273-83.
- 141 Mofidi R, Suttie SA, Patil PV, Ogston S, Parks RW. The value of procalcitonin at predicting the severity of acute pancreatitis and development of infected pancreatic necrosis: systematic review. *Surgery* 2009;146:72-81.
- 142 Maeda K, Hirota M, Ichihara A, Ohmuraya M, Hashimoto D, Sugita H, *et al.* Applicability of disseminated intravascular coagulation parameters in the assessment of the severity of acute pancreatitis. *Pancreas* 2006;32:87-92.
- 143 Koutroumpakis E, Wu BU, Bakker OJ, Dudekula A, Singh VK, Besselink MG, *et al.* Admission Hematocrit and Rise in Blood Urea Nitrogen at 24 h Outperform other Laboratory Markers in Predicting Persistent Organ Failure and Pancreatic Necrosis in Acute Pancreatitis: A Post Hoc Analysis of Three Large Prospective Databases. *Am J Gastroenterol* 2015;110:1707-16.
- 144 Brivet FG, Emilie D, Galanaud P. Pro- and anti-inflammatory cytokines during acute severe pancreatitis: an early and sustained response, although unpredictable of death. Parisian Study Group on Acute Pancreatitis. *Crit Care Med* 1999;27:749-55.
- 145 Lytras D, Manes K, Triantopoulou C, Paraskeva C, Delis S, Avgerinos C, *et al.* Persistent early organ failure: defining the high-risk group of patients with severe acute pancreatitis? *Pancreas* 2008;36:249-54.
- 146 Warndorf MG, Kurtzman JT, Bartel MJ, Cox M, Mackenzie T, Robinson S, *et al.* Early fluid resuscitation reduces morbidity among patients with acute pancreatitis. *Clin Gastroenterol Hepatol* 2011;9:705-9.
- 147 Gardner TB, Vege SS, Chari ST, Petersen BT, Topazian MD, Clain JE, *et al.* Faster rate of initial fluid resuscitation in severe acute pancreatitis diminishes in-hospital mortality. *Pancreatology* 2009;9:770-6.
- 148 Singh VK, Gardner TB, Papachristou GI, Rey-Riveiro M, Faghieh M, Koutroumpakis E, *et al.* An international multicenter study of early intravenous fluid administration and outcome in acute pancreatitis. *United European Gastroenterol J* 2017;5:491-98.
- 149 de-Madaria E, Soler-Sala G, Sanchez-Paya J, Lopez-Font I, Martinez J, Gomez-Escolar L, *et al.* Influence of fluid therapy on the prognosis of acute pancreatitis: a prospective cohort study. *Am J Gastroenterol* 2011;106:1843-50.
- 150 Stigliano S, Sternby H, de Madaria E, Capurso G, Petrov MS. Early management of acute pancreatitis: A review of the best evidence. *Dig Liver Dis* 2017;49:585-94.
- 151 Petrov MS, van Santvoort HC, Besselink MG, van der Heijden GJ, Windsor JA, Gooszen HG. Enteral nutrition and the risk of mortality and infectious complications in patients with severe acute pancreatitis: a meta-analysis of randomized trials. *Arch Surg* 2008;143:1111-7.
- 152 Bakker OJ, van Brunschot S, Farre A, Johnson CD, Kalfarentzos F, Louie BE, *et al.* Timing of enteral nutrition in acute pancreatitis: meta-analysis of individuals using a single-arm of randomised trials. *Pancreatology* 2014;14:340-6.

- 153 Eckerwall GE, Tingstedt BB, Bergenzaun PE, Andersson RG. Immediate oral feeding in patients with mild acute pancreatitis is safe and may accelerate recovery--a randomized clinical study. *Clin Nutr* 2007;26:758-63.
- 154 Jiang K, Huang W, Yang XN, Xia Q. Present and future of prophylactic antibiotics for severe acute pancreatitis. *World J Gastroenterol* 2012;18:279-84.
- 155 Tandon M, Topazian M. Endoscopic ultrasound in idiopathic acute pancreatitis. *Am J Gastroenterol* 2001;96:705-9.
- 156 da Costa DW, Bouwense SA, Schepers NJ, Besselink MG, van Santvoort HC, van Brunschot S, *et al.* Same-admission versus interval cholecystectomy for mild gallstone pancreatitis (PONCHO): a multicentre randomised controlled trial. *Lancet* 2015;386:1261-8.
- 157 Freeman ML, Werner J, van Santvoort HC, Baron TH, Besselink MG, Windsor JA, *et al.* Interventions for necrotizing pancreatitis: summary of a multidisciplinary consensus conference. *Pancreas* 2012;41:1176-94.
- 158 Raraty MG, Halloran CM, Dodd S, Ghaneh P, Connor S, Evans J, *et al.* Minimal access retroperitoneal pancreatic necrosectomy: improvement in morbidity and mortality with a less invasive approach. *Ann Surg* 2010;251:787-93.
- 159 Gardner TB, Coelho-Prabhu N, Gordon SR, Gelrud A, Maple JT, Papachristou GI, *et al.* Direct endoscopic necrosectomy for the treatment of walled-off pancreatic necrosis: results from a multicenter U.S. series. *Gastrointest Endosc* 2011;73:718-26.
- 160 Tse F, Yuan Y. Early routine endoscopic retrograde cholangiopancreatography strategy versus early conservative management strategy in acute gallstone pancreatitis. *Cochrane Database Syst Rev* 2012:CD009779.
- 161 Windsor JA, Petrov MS. Acute pancreatitis reclassified. *Gut* 2013;62:4-5.
- 162 Lerch MM. Classifying an unpredictable disease: the revised Atlanta classification of acute pancreatitis. *Gut* 2013;62:2-3.
- 163 Chauhan S, Forsmark CE. The difficulty in predicting outcome in acute pancreatitis. *Am J Gastroenterol* 2010;105:443-5.
- 164 O'Reilly DA, McPherson SJ, Sinclair MT, Smith N. Lessons from a national audit of acute pancreatitis: A summary of the NCEPOD report 'Treat the Cause'. *Pancreatol* 2017;17:329-33.
- 165 Camilleri M, Malhi H, Acosta A. Gastrointestinal Complications of Obesity. *Gastroenterology* 2017;152:1656-70.
- 166 Premkumar R, Phillips AR, Petrov MS, Windsor JA. The clinical relevance of obesity in acute pancreatitis: targeted systematic reviews. *Pancreatol* 2015;15:25-33.
- 167 Pasca di Magliano M, Forsmark C, Freedman S, Hebrok M, Pasricha PJ, Saluja A, *et al.* Advances in acute and chronic pancreatitis: from development to inflammation and repair. *Gastroenterology* 2013;144:e1-4.
- 168 Acharya C, Navina S, Singh VP. Role of pancreatic fat in the outcomes of pancreatitis. *Pancreatol* 2014;14:403-8.
- 169 Noel P, Patel K, Durgampudi C, Trivedi RN, de Oliveira C, Crowell MD, *et al.* Peripancreatic fat necrosis worsens acute pancreatitis independent of pancreatic

- necrosis via unsaturated fatty acids increased in human pancreatic necrosis collections. *Gut* 2016;65:100-11.
- 170 Patel K, Durgampudi C, Noel P, Trivedi RN, de Oliveira C, Singh VP. Fatty Acid Ethyl Esters Are Less Toxic Than Their Parent Fatty Acids Generated during Acute Pancreatitis. *Am J Pathol* 2016;186:874-84.
- 171 Zator Z, Whitcomb DC. Insights into the genetic risk factors for the development of pancreatic disease. *Therap Adv Gastroenterol* 2017;10:323-36.
- 172 Moggia E, Koti R, Belgaumkar AP, Fazio F, Pereira SP, Davidson BR, *et al*. Pharmacological interventions for acute pancreatitis. *Cochrane Database Syst Rev* 2017;4:CD011384.



Original Article

Significant inter-observer variation in the diagnosis of extrapancreatic necrosis and type of pancreatic collections in acute pancreatitis – An international multicenter evaluation of the revised Atlanta classification



Hanna Sternby ^{a,*}, Robert C. Verdonk ^b, Guadalupe Aguilar ^c, Alexandra Dimova ^d, Povilas Ignatavicius ^e, Lucas Ilzarbe ^f, Peeter Koiva ^g, Eila Lantto ^h, Tonis Loigom ⁱ, Anne Penttilä ^j, Sara Regnér ^a, Jonas Rosendahl ^k, Vanya Strahinova ^l, Sophia Zackrisson ^m, Kristina Zviniene ⁿ, Thomas L. Bollen ^o

^a Department of Surgery, Institution of Clinical Sciences Malmö, Lund University, Malmö, Sweden

^b Department of Gastroenterology, St. Antonius Hospital, Nieuwegein, The Netherlands

^c Department of Radiology, Hospital del Mar, Barcelona, Spain

^d Department of Surgery, University Hospital for Emergency Medicine "Pirogov", Sofia, Bulgaria

^e Department of Surgery, Lithuanian University of Health Sciences, Kaunas, Lithuania

^f Department of Gastroenterology, Hospital del Mar, Barcelona, Spain

^g Department of Gastroenterology, East Tallinn Central Hospital, Tallinn, Estonia

^h Department of Radiology, Helsinki University Central Hospital, Helsinki, Finland

ⁱ Department of Radiology, East Tallinn Central Hospital, Tallinn, Estonia

^j Department of Surgery, Helsinki University Central Hospital, Helsinki, Finland

^k Department of Internal Medicine, Neurology and Dermatology, Division of Gastroenterology and Rheumatology, Leipzig, Germany

^l Department of Emergency Radiology, University Hospital for Emergency Medicine "Pigorov", Sofia, Bulgaria

^m Department of Radiology, Institution of Clinical Sciences Malmö, Lund University, Malmö, Sweden

ⁿ Department of Radiology, Lithuanian University of Health Sciences, Kaunas, Lithuania

^o Department of Radiology, St. Antonius Hospital, Nieuwegein, The Netherlands

ARTICLE INFO

Article history:

Received 10 February 2016

Received in revised form

14 June 2016

Accepted 11 August 2016

Available online 13 August 2016

Keywords:

Acute pancreatitis

Classification

Computed tomography

Extrapancreatic necrosis

Necrotising pancreatitis

ABSTRACT

Background: For consistent reporting and better comparison of data in research the revised Atlanta classification (RAC) proposes new computed tomography (CT) criteria to describe the morphology of acute pancreatitis (AP). The aim of this study was to analyse the interobserver agreement among radiologists in evaluating CT morphology by using the new RAC criteria in patients with AP.

Methods: Patients with a first episode of AP who obtained a CT were identified and consecutively enrolled at six European centres backwards from January 2013 to January 2012. A local radiologist at each center and a central expert radiologist scored the CTs separately using the RAC criteria. Center dependent and independent interobserver agreement was determined using Kappa statistics.

Results: In total, 285 patients with 388 CTs were included. For most CT criteria, interobserver agreement was moderate to substantial. In four categories, the center independent kappa values were fair: extrapancreatic necrosis (EXPN) (0.326), type of pancreatitis (0.370), characteristics of collections (0.408), and appropriate term of collections (0.356). The fair kappa values relate to discrepancies in the identification of extrapancreatic necrotic material. The local radiologists diagnosed EXPN (33% versus 59%, $P < 0.0001$) and non-homogeneous collections (35% versus 66%, $P < 0.0001$) significantly less frequent than the central expert. Cases read by the central expert showed superior correlation with clinical outcome.

Abbreviations: AP, acute pancreatitis; CECT, contrast-enhanced computed tomography; Central exp, Central expert; CRP, C-reactive protein; CT, computed tomography; EXPN, extrapancreatic necrosis; IEP, Interstitial Oedematous Pancreatitis; IQR, interquartile range; Local rad, local radiologists; No, number; RAC, the revised Atlanta classification; SIRS, systemic inflammatory response syndrome.

* Corresponding author. Department of Surgery, Skåne University Hospital, Lund University, Jan Waldenströms gata 44, 205 02 Malmö, Sweden. Tel.: +46 736 297981.

E-mail address: Hanna.Sternby@med.lu.se (H. Sternby).

Conclusion: Diagnosis of EXPN and recognition of non-homogeneous collections show only fair agreement potentially resulting in inconsistent reporting of morphologic findings.

© 2016 IAP and EPC. Published by Elsevier B.V. All rights reserved.

1. Introduction

Acute pancreatitis (AP) is a complex disease with potentially severe and fatal outcome [1,2]. Simple but clear definitions of the disease are crucial in interdisciplinary consultation, communication, and in reporting of clinical research. Such were the incentives to update the 1992 Atlanta Classification on AP [1]. Besides redefining the disease into three levels of clinical severity, the 2012 revised Atlanta Classification (RAC) has put substantial efforts into clarifying the terminology on the morphologic subtypes of AP and associated peripancreatic collections based on computed tomography (CT)-based criteria [1]. Two morphologic types of AP are discriminated: acute interstitial oedematous pancreatitis and acute necrotising pancreatitis. Acute necrotising pancreatitis is subdivided into three forms: pancreatic parenchymal necrosis, extrapancreatic necrosis (EXPN), and combined necrosis. Peripancreatic collections are classified into four types depending on content and maturation. Acute peripancreatic fluid collections and pancreatic pseudocysts are composed of fluid only and occur in interstitial oedematous pancreatitis. On CT, these collections show a homogeneous fluid density with no or incomplete well-defined wall (acute peripancreatic fluid collection) or a complete wall (pseudocyst). Acute necrotic collections and walled-off necrosis are associated with acute necrotising pancreatitis and contain varying amounts of fluid and necrotic material. On CT, these collections have various densities (fat, fluid, solid material) with no or incomplete well-defined wall (acute necrotic collection) or a complete wall (walled-off necrosis) [1,3–5]. The RAC provides approximate time frames for these pancreatic collections. Acute peripancreatic fluid collection and acute necrotic collection pertain to the first four weeks of disease after which they usually turn into a completely encapsulated pseudocyst and walled-off necrosis, respectively.

It is well established that the morphologic types of AP differ in outcomes, therapies, and prognosis. For prognostication, stratification, and comparing of interinstitutional data, accurate assessment of AP morphology in the different stages of disease is imperative [1]. The extent of variation in interpretation of the new CT criteria is, however, unknown [6–8]. The aim of this study was to assess the interobserver agreement among radiologists in the evaluation of CT morphology using the RAC criteria.

2. Methods

2.1. Patients and study design

Patients >18 years with a first episode of AP were consecutively identified at six European study centres, going backwards from January 2013 to January 2012. Each center included 50 patients in whom at least one contrast-enhanced CT (CECT) was performed. The cases were anonymously enrolled and each patient obtained a code blinded for all investigators except for the referring center. CECTs performed within 3 months from date of admission were recorded and subsequently reviewed and scored by a local radiologist at each center. The time frame of 3 months was chosen because most CTs are performed within this period and controversies in nomenclature and management of pancreatic collections

are most evident during this phase. Exclusion criteria were insufficient quality of the CECT, signs of chronic pancreatitis (i.e. pancreatic calcifications) or patients with prior pancreatitis-related invasive intervention, except from endoscopic retrograde cholangiography. Each CECT was performed in the pancreatic and/or in the portal venous phase (see [Supplementary file 1](#) for CT specifications). Severity and CT morphology of AP were defined according to the RAC (see [Box 1](#) for definitions) [1].

The following clinical data was collected from review of medical notes: systemic inflammatory response syndrome (SIRS) upon admission, highest level of C-reactive protein (CRP) during hospitalisation, need for invasive intervention, organ failure (persistent and transient, in line with the RAC), and in-hospital mortality. The six participating local radiologists had expertise in the field of abdominal radiology, each with more than five years' experience. A short instruction sheet was provided to local radiologists to assist in interpretation ([Supplementary file 2](#)). All individual CECTs were scored according to a protocol based on the parameters stated in the RAC ([Supplementary file 3](#)). Subsequently, all CECTs were reviewed and scored (using the same scoring sheet) by a central expert radiologist (T.L.B.) using open source DICOM viewer software (32-bit OsiriX version 3.3, Geneva, Switzerland). Local and central reviewers were blinded to any clinical data except for the timing (number of days after onset of symptoms) of each CECT. Formal approval of the local medical ethical committee was requested and obtained at each study center.

Box 1

Morphological features and CECT criteria in AP according to the RAC.

Morphology groups	CECT criteria	Time
Interstitial oedematous pancreatitis (IEP)	Homogenous enhancement of the pancreatic parenchyma, normal or minor inflammatory changes of the peripancreatic tissue (see below – APFC or pancreatic pseudocyst)	–
Necrotising pancreatitis	Heterogeneous enhancement of the pancreatic parenchyma and/or peripancreatic tissue necrosis (see below – ANC or WON)	–
Acute peripancreatic fluid collection (APFC)	Homogeneous fluid density. No complete wall. No necrosis. Associated with IEP. Solely extrapancreatic location.	≤4 weeks
Pancreatic pseudocyst	Homogeneous fluid density. Fully encapsulated. No necrosis Associated with IEP. Solely extrapancreatic location.	>4 weeks
Acute necrotic collection (ANC)	Heterogeneous and non-liquid density. No complete wall. Associated with necrotising pancreatitis. Intra- or extrapancreatic location	≤4 weeks
Walled-off necrosis (WON)	Heterogeneous and non-liquid density. Fully encapsulated. Associated with necrotising pancreatitis. Intra- or extrapancreatic location	>4 weeks

CECT = contrast enhanced computed tomography.

2.2. Statistical analysis

Sample size calculations for variables with 2, 3, and 4 categories were performed because most of the variables of the revised Atlanta criteria are based on 2, 3, or 4 categories. Kappa values of >0.40 and > 0.60 were used since they represent at least moderate and substantial agreement [9]. Based on such a calculation, in a test for agreement between two raters, a sample size of 360 CECTs would provide a 95% confidence interval for the κ statistic with a width not greater than 0.20. Assuming that several patients would have more than one CECT performed, a total of 50 patients were included per center. Interobserver agreement was calculated between the local and the central radiologist, using Cohen's kappa test, for each of the categories scored on the radiology sheet. Agreement levels were defined as: κ level 0.00–0.20 slight; 0.21–0.40 fair; 0.41–0.60 moderate; 0.61–0.80 substantial; and 0.81–1.00 almost perfect. Continuous data analysis was conducted using Mann-Whitney *U* test. Wilcoxon Signed Rank test was used for paired sample analysis. $P < 0.05$ was considered statistically significant. All analysis was performed using IBM SPSS Statistics for Windows, version 21 and 22, Armonk, NY:IBM corp.

3. Results

3.1. Patients

In total, 301 patients were included at six European centres of whom 159 (56%) were male with a median age of 58 years (range 18–92). Sixteen patients were excluded due to reasons stated in the CECT section below. Baseline characteristics of the remaining 285 patients are summarised in Table 1. Etiology of AP differed substantially between the centres. According to the RAC, 37.5% of the patients had mild AP, 51.5% moderately severe AP and 11.0% severe AP [1]. Overall fourteen patients died (4.9%, range 0–14%), whereas mortality within the severe group was 32.3% (range 0–78%). Each center admits 175–250 patients with AP annually, except for center F where the figure is approximately 470.

3.2. Contrast-enhanced computed tomography

A total of 405 CECTs derived from 301 patients were collected. Seventeen CECT studies were excluded due to insufficient quality of the CECT or signs of chronic pancreatitis, leaving a study cohort of 285 patients with 388 CECTs. Data on CECTs for the separate centres

are presented in Table 2. Median time from onset of disease to CECT for all centres was 7 days (range 0–90, interquartile range 3–13).

3.3. Interobserver agreement

For specific information concerning all categories evaluated we refer to Supplementary file 2. The kappa values representing the interobserver agreement are shown in Table 3. There was substantial agreement in seven categories: “Necrosis – Neck” (0.618); “Necrosis – Body” (0.628); “Necrosis – Tail” (0.617); presence of “Collections” (0.756); “Location of Collections” (0.633); presence of “Wall” (0.675); and presence of “Intraluminal Gas and/or Fluid level” (0.764). Moderate agreement was reached on “Parenchymal Necrosis” (0.539) and “Necrosis – Head” (0.516). Finally, there was fair agreement on the categories “Type of Pancreatitis” (0.370), “Extrapaneatic Necrosis” (0.326), “Characteristics of Collection” (0.408), and “Collection – most appropriate term” (0.356). The center dependent kappa values differed considerably between centres.

Discrepancies in the identification of EXPN are shown in Table 4. For image samples see Fig. 1a,b and 2a–c. The expert radiologist diagnosed EXPN significantly more often than the local radiologists (59% vs. 33%, $P < 0.0001$). Table 4 shows that this difference in total number of EXPN stems from the subgroup of isolated EXPN. Since the RAC acknowledges that EXPN might be difficult to diagnose within the first week, interobserver agreement was recalculated for the categories with low kappa values excluding CECTs performed within 72 h, seven days and two weeks after onset of disease (see Supplementary file 4). In this subanalysis, kappa values did improve only for CECTs performed after two weeks.

Morphological findings scored by the central and local radiologists were correlated with clinical outcome parameters (see Table 5). Cases read as interstitial oedematous pancreatitis and isolated EXPN by the central expert correlate significantly better with clinical outcome than scoring by local radiologists. Given the good interobserver agreement for pancreatic parenchymal necrosis, results did not differ significantly between central and local radiologists for this subgroup (Supplementary file 5).

4. Discussion

The RAC proposed a new set of morphologic CT-based criteria to account for alleged shortcomings of the 1992 Atlanta classification [1,2]. One of the major aims of the RAC was to ease and ensure

Table 1
Baseline characteristics of patients in each center and all centres combined.

	All patients n = 285	Center B n = 42	Center C n = 48	Center D n = 50	Center E n = 48	Center F n = 47	Center G n = 50
Male sex	159 (56%)	28 (67%)	24 (50%)	29 (58%)	18 (37%)	32 (68%)	28 (68%)
Age (years)	58 (18–92) IQR (45–71)	46 (22–83) IQR 34–61	65 (18–88) IQR 52–76	62 (21–92) IQR 41–76	60 (22–88) IQR 42–73	52 (35–85) IQR 45–68	62 (23–87) IQR 52–73
Etiology (%)							
Biliary	36.6	24.4	56.3	18.0	54.1	19.2	46.0
Alcohol	35.9	43.9	14.5	26.0	41.7	63.8	28.0
Other	27.5	31.7	29.2	56.0	4.2	17.0	26.0
Highest CRP (mg/l)	261 (0–553)	259 (44–493)	208 (3–480)	281 (0–477)	258 (2–444)	278 (9–519)	277 (41–553)
Classification n (%)							
Mild	107 (37.5)	17 (40.5)	26 (54.2)	10 (20.0)	11 (22.9)	19 (40.4)	24 (48.0)
Moderately severe	147 (51.5)	24 (57.1)	18 (37.5)	31 (62.0)	35 (72.9)	20 (42.6)	19 (38.0)
Severe	31 (11.0)	1 (2.4)	4 (8.3)	9 (18.0)	2 (4.2)	8 (17.0)	7 (14.0)
Mortality (%)	4.9	2.0	0.0	14.0	0.0	8.5	4.0

Continuous variables are median. Range and IQR are displayed if applicable.

n = number of patients.

IQR=Inter quartile range.

CRP=C-reactive protein.

Table 2

Characteristics of CECTs of each center and all centres combined.

	All CECTs	Center B	Center C	Center D	Center E	Center F	Center G
No of CECTs	388	49	74	59	73	63	69
No of CECTs performed per patient	1.4 (1–5)	1.2 (1–3)	1.5 (1–5)	1.2 (1–3)	1.5 (1–4)	1.3 (1–4)	1.4 (1–4)
Time to CECT	7 (0–90)	6 (0–26)	6.5 (0–90)	9 (1–31)	6 (0–87)	12 (1–67)	4 (1–88)
	IQR 3–13	IQR 3–8	IQR 3–16	IQR 4–13	IQR 3–11	IQR 3–41	IQR 2–11
Type of pancreatitis and time to CECT							
Oedematous pancreatitis	3 (0–73)	4 (0–19)	5.5 (0–73)	5 (1–9)	2 (0–57)	4 (1–65)	3 (1–50)
	IQR 2–7	IQR 1–7	IQR 3–9	IQR 2–8	IQR 1–6	IQR 3–7	IQR 2–4
Necrotising pancreatitis	10 (1–90)	8 (0–26)	13 (0–90)	9 (1–32)	8 (0–87)	23 (1–67)	9 (2–89)
	IQR 5–21	IQR 6–12	IQR 6–33	IQR 5–14	IQR 4–15	IQR 11–46	IQR 5–27
Indeterminate pancreatitis	3 (0–14)	2 (0–8)	4 (1–5)	4 (1–14)	4 (1–7)	2 (2–11)	2 (1–5)
	IQR 2–5	IQR 1–8	IQR 2–4	IQR 2–5	IQR 1–6	IQR 2–10	IQR 1–4

No=Number.

IQR=Inter quartile range.

Continuous variables are median. Range and IQR are displayed if applicable.

Time to CECT=Time from symptom onset to CECT in days.

Type of pancreatitis and time to CECT = Time from symptom onset to CECT in days divided by type of pancreatitis.

Table 3

Center independent and dependent kappa values for all categories scored.

Category	All centres	Center B	Center C	Center D	Center E	Center F	Center G
Type of pancreatitis	0.370	0.317	0.342	0.309	0.098 ^b	0.838 ^a	0.360
Parenchymal Necrosis	0.539	0.380	0.319 ^b	0.609	0.731 ^a	0.663	0.465
Necrosis – Head	0.516	0.669	0.345	0.323 ^b	1.00 ^a	0.660	0.646
Necrosis – Neck	0.618	0.922 ^a	0.577	0.822	0.660	0.364	0.236 ^b
Necrosis – Body	0.628	0.766	0.611	0.687	0.873	0.392 ^b	0.570
Necrosis – Tail	0.617	0.451	0.626	0.687	0.409 ^b	0.806 ^a	0.532
Extrapaneatic Necrosis	0.326	0.321	0.504	0.293	0.120	0.877 ^a	0.024 ^b
Collections	0.756	0.780	0.750	0.624 ^b	0.864 ^a	0.827	0.625
Location of Collections	0.633	0.728	0.761 ^a	0.508	0.694	0.604	0.439 ^b
Characteristics of collections	0.408	0.397	0.485	0.293	0.305	0.744 ^a	0.251 ^b
Wall	0.675	0.638	0.638	0.588 ^b	0.777 ^a	0.726	0.632
Intraluminal gas/fluid level	0.764	0.774	0.671 ^b	0.764	0.887 ^a	0.837	0.675
Collection – most appropriate term	0.356	0.385	0.480	0.136 ^b	0.218	0.673 ^a	0.261

^a Highest kappa value for center B to G for each category.^b Lowest kappa value for center B to G for each category.**Table 4**

Number of extrapancreatic necrosis (EXPN) scored by the local radiologists and central expert.

	Total number of EXPN		Combined necrosis		Isolated EXPN	
	Local rad	Central exp	Local rad	Central exp	Local rad	Central exp
Yes	126 (33%)	230 (59%)	85 (22%)	92 (24%)	41 (11%)	138 (36%)
No	245 (63%)	110 (28%)	303 (78%)	296 (76%)	347 (89%)	250 (64%)
Indet	17 (4%)	48 (12%)				

Total number of EXPN = diagnosis of EXPN (yes/no) and indeterminate by local radiologists and central expert, respectively.

Combined necrosis = Extrapaneatic necrosis with Parenchymal necrosis in cases where presence of EXPN (yes/no) was determined.

Isolated EXPN = Extrapaneatic necrosis without Parenchymal Necrosis in cases where presence of EXPN (yes/no) was determined.

Local rad = Local radiologists.

Central exp = Central expert radiologist.

Indet = Indeterminate (radiologist was not able to determine the presence of EXPN, yes/no).

consistency in the investigation and reporting of data in clinical research [1]. However, the degree of interobserver agreement in the interpretation of CT findings using these new RAC criteria has been questioned [6–8].

Main findings of our study are twofold: on the one hand, the morphologic assessment of the RAC generates overall moderate to good interobserver agreement (range 0.516–0.764) among European radiologists in 9 out of 13 items evaluated. Importantly, agreement among raters was good in evaluating clinically important CT findings in patients with AP, such as the presence of parenchymal necrosis and gas bubbles. On the other hand, only fair agreement (range 0.326–0.408) was obtained for items pertaining to necrosis of extrapancreatic tissues. The central expert diagnosed

EXPN significantly more frequent than the local radiologists (59% versus 33%, $P < 0.0001$) with better correlation with patient outcome. Our findings suggest that radiologists are largely unfamiliar with the newly defined entity of EXPN.

Several explanations exist for the fair agreement in diagnosing EXPN and for characterisation of pancreatic collections on CT. The RAC regards CT as the first-line imaging modality in AP, albeit acknowledging the fact that necrotic material within pancreatic collections is often overlooked [1]. It is well-established that ultrasound and magnetic resonance imaging are better capable of delineating the exact composition of pancreatic collections, especially for depicting necrotic material [10,11]. Furthermore, the CT diagnosis of EXPN and associated necrotic collections relies

Table 5

Correlation of morphologic findings with clinical outcome by central and local radiologists.

	Total (N)	IEP			Isolated EXPN		
		Local	Central	P-value	Local	Central	P-value
All cases	(388)	199	107	0.0001	41	138	0.0001
Organ Failure							
Persistent	(50)	20 (10.0%)	5 (4.7%)	0.0001	4 (9.7%)	24 (17.4%)	0.0001
Transient	(51)	15 (7.5%)	5 (4.7%)	0.002	4 (9.7%)	20 (14.5%)	0.0001
Mortality	(20)	9 (4.5%)	4 (3.7%)	0.025	1 (2.4%)	7 (5.1%)	0.025
Intervention	(79)	11 (5.5%)	6 (5.6%)	ns	12 (29.3%)	26 (18.8%)	0.001
CRP (mg/l)		271	165	0.0001	298	318	ns
SIRS	(104)	41 (20.6%)	12 (11.2%)	0.0001	9 (22.0%)	38 (27.5%)	0.0001

Cases scored as 'indeterminate' are not accounted for.

IEP = Interstitial Edematous Pancreatitis.

Isolated EXPN = Extrapancreatic Necrosis without Parenchymal Necrosis.

Local = Local radiologists.

Central = Central Expert.

CRP = C-reactive protein, highest value.

SIRS = Systemic Inflammatory Response Syndrome.

primarily on subjective secondary findings, such as 'heterogeneity' or the detection of various densities (liquid and non-liquid) within collections, rather than using the more objective and reproducible criteria of perfusion characteristics, which is used for detecting pancreatic parenchymal necrosis. Perfusion characteristics, however, cannot be used to diagnose EXPN because normal extrapancreatic fat does not enhance. In addition, the RAC acknowledges that EXPN is difficult to diagnose initially but becomes easier when the disease process evolves over time [1]. This is in line with our results with improved kappa values for EXPN diagnosis two weeks after symptom onset. Finally, reader expertise and familiarity seem equally important for diagnosing EXPN exemplified by the excellent interobserver agreement between the central expert and the local radiologist affiliated with center F that admits the highest number of patients with AP annually.

In a previous study on CT assessment of morphologic features of AP, good to excellent interobserver agreement was found in 55 cases of AP [12]. However, this study used selected cases biased towards severe disease (likely associated with more established peripancreatic collections) reviewed by tertiary experts. Although imaging is rarely required for mild AP, most patients who undergo CT for evaluation of AP turn out to have interstitial pancreatitis. Our study more closely resembles clinical practice in different European countries by enrolling patients with AP consecutively and evaluating unselected CECTs encompassing the full spectrum of morphologic abnormalities in AP, including mild and equivocal cases.

Previous studies show considerable differences in clinical outcome, treatment strategies, and prognoses between the various morphological types of AP [13–17]. Clinical outcome of EXPN is worse compared with acute interstitial pancreatitis, but better than pancreatic necrosis [13,15,17]. Patients with EXPN stay in hospital considerable longer, develop more often organ failure, and undergo interventional therapy significantly more frequent than those with interstitial pancreatitis. Moreover, when infection ensues of necrotic collections in EXPN patients, outcome, therapy, and prognosis are similar to those with infected pancreatic necrosis [15]. In our study, the interpretation by the central expert more closely corroborated with actual clinical outcome. As such, accurate differentiation between the types of AP is important both from a clinical perspective as for consistent reporting of research and reliable comparison of inter-institutional data.

This study has some limitations. First, a single central expert radiologist served as standard of reference, potentially introducing bias. We considered this a limited risk because of his extensive experience in pancreatic imaging, his involvement in the

development of the RAC, the superior correlation with patient outcome, and the excellent agreement with a local radiologist with



Fig. 1. 70-year-old male with acute pancreatitis (a, b). The pancreas enhances heterogeneously (asterisks) but no apparent necrosis was observed by both reviewers. Peripancreatic collections are present in the retroperitoneal pancreatic compartment and transverse mesocolon (arrowheads pointing at the borders). The local reviewer scored this as interstitial pancreatitis with acute peripancreatic fluid collections; the central reviewer as necrotising pancreatitis, subtype EXPN, with acute necrotic collections.




Fig. 2. 55-year-old female with acute pancreatitis (a–c). Normal enhancement of pancreatic parenchyma was noted by both reviewers (asterisks). Extensive peripancreatic collections are present in the retroperitoneum bilaterally and transverse mesocolon (arrowheads pointing at the borders). These represented ‘acute peripancreatic fluid collections’ and ‘acute necrotic collections’ according to the local and central reviewer, respectively. Coronal reformatted image (c) depicts the magnitude of collections.

similar expertise. Second, given the retrospective design of this study, we did not investigate to what extent the inconsistencies observed eventually affected clinical decision-making. Future studies should focus on this interesting topic. Finally, we merely studied the interobserver agreement of morphological abnormalities in AP and did not correlate imaging findings with histopathology.

Results of this study have revealed areas of controversy when using the RAC criteria for CT assessment, especially pertaining to distinguishing interstitial pancreatitis from EXPN only. There are several options for improving consistent reporting in AP. Both radiologists and clinicians need to become better familiar with imaging features of EXPN (i.e. by education or training). Second, the definition of EXPN should preferably be redefined such that stronger interrater agreement will be achieved, even among readers with varying expertise. For example, by adding a time interval of 2 weeks before its diagnosis or by using an alternative imaging (MRI or US) modality as these are better capable of detecting necrotic material within collections [10]. Third, a greater role should be attributed to MRI for overall evaluation of AP. Finally, as has been alluded to in previous reports, a three-degree morphologic classification system (‘interstitial pancreatitis’ refers to normal enhancing parenchyma without collections, ‘EXPN’ refers to normal perfused pancreatic parenchyma with pancreatic collections, and ‘necrotising pancreatitis’ refers to parenchymal necrosis with or without associated collections) could potentially lead to less interobserver variability as the differentiation between the various types of pancreatic collections becomes less of an issue [18,19]. Additionally, Such a system would likely be more in concordance with clinical grades of severity [13–17,20].

In conclusion, this study found only moderate interrater agreement for identification of EXPN. For correctly identifying EXPN and necrotic collections on CT, a diligent search for heterogeneity within pancreatic collections is crucial for accurate and consistent reporting of imaging findings (see Figs. 1 and 2).

Disclosure

The authors declare no conflict of interests.

Funding resources

No funding was involved in any part of the study or manuscript.

Acknowledgements

The authors thank Luigi Santoro, Division of Epidemiology and Biostatistics, European Institute of Oncology, for assistance with statistical analysis. The group was part of Pancreas 2000 – a research program for future pancreatologists, who in part also supported this study (www.pancreas2000.org).

Appendix A. Supplementary data

Supplementary data related to this article can be found at <http://dx.doi.org/10.1016/j.pan.2016.08.007>.

References

- [1] Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, et al. Classification of acute pancreatitis–2012: revision of the atlanta classification and definitions by international consensus. *Gut* 2013;62:102–11.
- [2] Bradley 3rd EL. A clinically based classification system for acute pancreatitis. Summary of the international symposium on acute pancreatitis, atlanta, ga, september 11 through 13, 1992. *Arch Surg* 1993;128:586–90.
- [3] Bollen TL. Imaging of acute pancreatitis: update of the revised atlanta

- classification. *Radiol Clin North Am* 2012;50:429–45.
- [4] Thoeni RF. The revised Atlanta classification of acute pancreatitis: its importance for the radiologist and its effect on treatment. *Radiology* 2012;262:751–64.
 - [5] Shyu JY, Sainani NI, Sahni VA, Chick JF, Chauhan NR, Conwell DL, et al. Necrotizing pancreatitis: diagnosis, imaging and intervention. *Radiographics* 2014;34:1218–39.
 - [6] Windsor JA, Petrov MS. Acute pancreatitis reclassified. *Gut* 2013;62:4–5.
 - [7] Revision of the atlanta classification of acute pancreatitis: the editorial perspective Gress TM, El-Omar EM, editors. *Gut* 2013;62:1.
 - [8] Lerch MM. Classifying an unpredictable disease: the revised atlanta classification of acute pancreatitis. *Gut* 2013;62:2–3.
 - [9] Landis JR, Koch GG. The measurement of observer agreement for categorical data. *Biometrics* 1977;33:159–74.
 - [10] Morgan DE, Baron TH, Smith JK, Robbin ML, Kenney PJ. Pancreatic fluid collections prior to intervention: evaluation with mr imaging compared with ct and us. *Radiology* 1997;203:773–8.
 - [11] Balthazar EJ. Acute pancreatitis: assessment of severity with clinical and ct evaluation. *Radiology* 2002;223:603–13.
 - [12] van Santvoort HC, Bollen TL, Besselink MG, Banks PA, Boermeester MA, van Eijck CH, et al. Describing peripancreatic collections in severe acute pancreatitis using morphologic terms: an international interobserver agreement study. *Pancreatology* 2008;8:593–9.
 - [13] Singh VK, Bollen TL, Wu BU, Repas K, Maurer R, Yu S, et al. An assessment of the severity of interstitial pancreatitis. *Clin Gastroenterol Hepatol* 2011;9:1098–103.
 - [14] Sakorafas GH, Tsiotos GG, Sarr MG. Extrapaneatic necrotizing pancreatitis with viable pancreas: a previously under-appreciated entity. *J Am Coll Surg* 1999;188:643–8.
 - [15] Bakker OJ, van Santvoort H, Besselink MG, Boermeester MA, van Eijck C, Dejong K, et al. Extrapaneatic necrosis without pancreatic parenchymal necrosis: a separate entity in necrotising pancreatitis? *Gut* 2013;62:1475–80.
 - [16] Rana SS, Sharma V, Sharma RK, Chhabra P, Gupta R, Bhasin DK. Clinical significance of presence and extent of extrapancreatic necrosis in acute pancreatitis. *J Gastroenterol Hepatol* 2015;30:794–8.
 - [17] Wang M, Wei A, Guo Q, Zhang Z, Lu H, Li A, et al. Clinical outcomes of combined necrotizing pancreatitis versus extrapancreatic necrosis alone. *Pancreatol* 2016;16:57–65.
 - [18] Bollen TL, Besselink MG, van Santvoort HC, Gooszen HG, van Leeuwen MS. Toward an update of the atlanta classification on acute pancreatitis: review of new and abandoned terms. *Pancreas* 2007;35:107–13.
 - [19] Bollen TL, van Santvoort HC, Besselink MG, van Leeuwen MS, Horvath KD, Freeny PC, et al. The atlanta classification of acute pancreatitis revisited. *Br J Surg* 2008;95:6–21.
 - [20] Lankisch PG, Struckmann K, Lehnick D. Presence and extent of extrapancreatic fluid collections are indicators of severe acute pancreatitis. *Int J Pancreatol* 1999;26:131–6.

Original Paper

Predictive Capacity of Biomarkers for Severe Acute Pancreatitis

Hanna Sternby^a Hannes Hartman^b Dorte Johansen^a
Henrik Thorlacius^a Sara Regnér^a

Departments of ^aSurgery and ^bGastroenterology, Institution of Clinical Sciences Malmö,
Lund University, Malmö, Sweden

Key Words

Acute pancreatitis · Biomarkers · Cut-off · Prediction

Abstract

Background: Early prediction of severe acute pancreatitis (SAP) substantially improves treatment of patients. A large amount of biomarkers have been studied with this objective. The aim of this work was to study predictive biomarkers using preset cut-off levels in an unselected population of patients with acute pancreatitis (AP). **Methods:** 232 patients (52.2% males, median age 66 years) with AP admitted to Skåne University Hospital, Malmö, were consecutively enrolled. Blood samples were collected upon admission and clinical data were gathered both prospectively at inclusion and through review of medical notes. Cut-off levels were defined based on the reports of prior studies, and through their results eight biomarkers (IL-1 β , IL-6, IL-8, IL-10, TNF- α , MCP-1, procalcitonin and D-dimer) were selected for analysis. **Results:** Of the patients, 83.2% had mild AP and 16.8% had SAP. Levels of IL-1 β , IL-6 and IL-10 were significantly ($p < 0.05$) higher upon admission in the group with SAP. When applying the preset cut-off levels on our material, sensitivity and specificity for prediction of severity were low. Receiver operating characteristic curves showed that selected cut-off levels were acceptable, but areas under the curves were inferior compared to other studies. The results did not improve when using the revised Atlanta 2012 classification. **Conclusions:** Previous studies on severity prediction of AP are difficult to compare due to large variations in setups and outcomes. Calculated cut-offs in our cohort were in acceptable range from preset levels, however areas under the curves were low, indicating suboptimal biomarkers for the unselected population investigated. For comparable results and possible clinical implementations, future studies need large consecutive series with a reasonable percentage of severe cases. Additionally, novel biomarkers need to be explored.

© 2016 S. Karger AG, Basel

Sara Regnér, MD, PhD
Department of Surgery, Institution of Clinical Sciences Malmö
Skåne University Hospital, Lund University
Inga-Marie Nilssons Gata 47, SE-205 02 Malmö (Sweden)
E-Mail sara.regner@med.lu.se

Introduction

Acute pancreatitis (AP) is one of the most common gastroenterological disorders requiring hospitalization worldwide. Data indicate a rising incidence, at present approximately 50 cases/100,000 inhabitants [1–3]. From 1992 to 2012, patients with AP were subdivided into mild and severe disease according to the Atlanta 1992 classification [4]. Most cases of AP are classified as mild, but approximately 15–20% of the patients will develop severe AP (SAP), characterized by rapidly progressing organ failure and local complications [5, 6]. Mortality within this group is high, 20–30%, and the need for supportive treatment and resuscitation already in the emergency room is of significance [7, 8]. Early detection of SAP is thus crucial and numerous clinical scoring systems have been developed for this purpose [9–13]. However, these methods have proven either unpractical, too costly or insufficient in sensitivity and specificity for prediction of severe disease [14–16]. Additionally, it has been shown that in the early stage of AP, physicians are poor at identifying the patients that will develop SAP [8, 17].

With the aim of early prediction of SAP, multiorgan dysfunction syndrome and risk of death, numerous biomarkers have been iteratively studied [18]. The majority of these are inflammatory mediators reflecting the complex pathophysiological pathway of AP. Several promising results have been presented and a number of studies additionally report cut-off levels for prediction of severity for individual biomarkers in their specific cohort.

However, despite great efforts and numerous attempts, the biomarker that predicts SAP upon admission with high reliability is yet to be found. Additionally, for clinical applicability, a cut-off level with good predictive power needs to be identified. Previous studies used post hoc cut-offs, which implies a decline in sensitivity and specificity of severity prediction when applied in a prospective setting. However, such an approach does not mirror the ordinary situation with the AP patient in the emergency room. Consequently, results have been difficult to implement in clinical practice.

Among earlier studies none have, to our knowledge, used preset cut-off values applied on multiple biomarkers in a consecutive series of patients with AP. The aim of this study was to prospectively, in an unselected population, evaluate the most promising non-routine predictive biomarkers by using preset cut-off levels based on the results of earlier works.

Materials and Methods

Patients and Study Design

Patients >18 years with AP admitted to the Department of Surgery, Skåne University Hospital, Malmö, Sweden from January 2010 to September 2013 were consecutively enrolled. For the diagnose of AP two out of three criteria needed to be fulfilled: (1) acute characteristic upper abdominal pain, (2) serum amylase ≥ 3 times the upper limit or (3) characteristic findings of AP on CT scan, abdominal ultrasound or MRI. Only patients admitted within 72 h from disease onset were included. To enable comparison with previous studies, AP was classified as mild or severe according to the Atlanta 1992 classification [4]. The patients were additionally classified according to the revised Atlanta 2012 classification [19]. Clinical data were obtained from the patients at inclusion and retrospectively from review of medical notes.

Cut-Off Levels

PubMed was searched for human studies on predictive biomarkers in AP with SAP as outcome where cut-off levels for predicted severe disease were reported. Additionally, levels of sensitivity, specificity, positive and negative predicted values for each cut-off level had to be presented. Solely studies utilizing the Atlanta 1992 classification were considered [4]. In total, 16 studies fulfilled these criteria and were selected for the predetermination of cut-off levels [15, 20–34]. The biomarkers analyzed in these publications were interleukin-1 β (IL-1 β), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), tumor necrosis

Table 1. Patient characteristics of all patients and groups with mild and severe disease

	All patients 232	MAP 193 (83.2%)	SAP 39 (16.8%)
Gender			
Male	121 (52.2%)	101 (52.3%)	20 (51.3%)
Female	111 (47.8%)	92 (47.7%)	19 (48.3%)
Age, years	66 (19–97) [51–77]	66 (19–97) [51–77]	63 (29–90) [52–80]
Body mass index	26.3 (13.6–47.0) [23.7–30.4]	26.0 (15.2–45.4) [23.6–30.2]	26.4 (13.6–47.0) [24.2–31.9]
Etiology			
Biliary	131 (56.5%)	114 (59.1%)	17 (43.6%)
Alcohol	39 (16.8%)	30 (15.5%)	9 (23.1%)
Idiopathic	26 (11.2%)	18 (9.3%)	8 (20.5%)
Other	36 (15.5%)	31 (16.1%)	5 (12.8%)
Onset to admission, h	9 (0–72) [3–23]	10 (0–72) [3–24]	5 (0–72) [2–18]
Highest CRP, mg/l	150 (1–553) [45–250]	111 (1–397) [39–221]	330 (111–553) [206–440]
Mortality	5 (2.2%)	0	5 (12.8%)
Intensive care unit	19 (8.2%)	0	19 (48.7%)
Organ failure	33 (14.2%)	0	33 (84.6%)
MODS	15 (6.5%)	0	15 (38.5%)

Values are n (%) or median (range); figures in brackets are interquartile range.

Highest CRP = Highest level of CRP within the first 72 h; MODS = multiorgan dysfunction syndrome.

factor- α (TNF- α), monocyte chemoattractant protein-1 (MCP-1), procalcitonin and D-dimer. A majority of studies presented various cut-off levels for identical biomarkers, most frequently regarding IL-6. In those cases cohort characteristics (i.e. gender, etiology, incidence of severity) were considered when predetermining the cut-off for an unselected AP population.

Blood Samples and Measurement

Serum samples were collected upon admission, i.e. in the emergency room, centrifuged (2,000 rounds, 25°C, 10 min) and stored at –80°C until analyzed. For analysis of IL-1 β , IL-6, IL-8, IL-10 and TNF- α the human proinflammatory 7-plex ultrasensitive kit K15008C (Meso Scale Diagnostics LLC, Rockville, Md., USA) was used. MCP-1 was assessed through human CCL2 (MCP-1) ELISA Ready-set-go kit 88-7399-88 (aBioscience, San Diego, Calif., USA) and D-dimer by using Human D-Dimer (D2D) ELISA kit 20870 (Bmassay, Beijing, China). All analyses were assessed according to the manufacturer's instructions. Procalcitonin was determined with an accredited ELISA method based on monoclonal anti-procalcitonin antibodies in accordance with routine methods at the Department of Clinical Chemistry, Skåne University Hospital, Malmö.

Statistical Analysis

Sample size calculations were based on results from an earlier study on AP within the same population, i.e. patients with AP admitted to the University Hospital in Malmö [29]. In that study 11.5% of the cohort developed SAP. To reach a power of 80% with an α value of 0.05 and a sensitivity and specificity >85% for MCP-1, 37 patients (4 with SAP and 33 with mild AP [MAP]) were required. With 150 enrolled patients significant results would be reached for the most investigated markers. For more unusual biomarkers at least 200 patients were considered necessary for an adequate level of sensitivity and specificity.

For comparison of continuous data between the two groups, the Mann-Whitney U test was used and $p < 0.05$ was considered statistically significant. For determination of the optimal cut-off value for each specific biomarker in our cohort, receiver operating characteristic (ROC) curves were performed and areas under the curves (AUCs) were calculated. All statistical analyses were performed using IBM SPSS Statistics for Windows, version 21 and 22 (IBM Corp., Armonk, N.Y., USA).

Table 2. Result of the application of preset cut-off levels on severe cases

Biomarker	Preset cut-off	SAP	SAP below cut-off	SAP above cut-off	Sensitivity	Specificity	PPV	NPV	PPV Mors
IL-1 β , pg/ml	1	36 (16.0%)	14 (38.9%)	22 (61.1%)	61%	49%	0.19	0.87	0.04
IL-6, pg/ml	100	35 (15.6%)	24 (68.6%)	11 (31.4%)	31%	82%	0.24	0.87	0.04
IL-8, pg/ml	40	34 (15.1%)	8 (23.6%)	28 (82.4%)	78%	35%	0.19	0.89	0.03
IL-10, pg/ml	7.5	36 (16.0%)	5 (13.9%)	31 (86.1%)	86%	29%	0.19	0.92	0.02
TNF- α , pg/ml	10	35 (15.6%)	29 (82.9%)	6 (17.1%)	17%	78%	0.125	0.84	0.04
MCP-1, μ g/l	500	32 (14.2%)	23 (71.9%)	9 (28.1%)	28%	86%	0.26	0.87	0.03
PCT, ng/ml	0.5	33 (14.7%)	27 (81.8%)	6 (18.2%)	18%	82%	0.15	0.85	0.05
D-dimer, μ g/l	0.5	28 (12.4%)	7 (25.0%)	21 (75.0%)	75%	12%	0.12	0.74	0.02

NPV = Negative predictive value; PCT = procalcitonin; PPV = positive predictive value; PPV Mors = positive predictive value mortality.

Results

Patients

During a 3.5-year period, 233 patients were included. On retrospective review one patient was excluded for not meeting the criteria of AP. The baseline characteristics of the 232 patients are as shown in table 1. Gender distribution was almost equal with 52.2% men and 47.8% women. Etiology was divided into biliary (56.5%), alcohol (16.8%), other (i.e. post-endoscopic retrograde cholangiopancreatography pancreatitis, tumors, other strictures) (15.5%) and idiopathic (11.2%). According to the Atlanta 1992 classification, 83.2% had MAP and 16.8% had SAP. Mortality was 2.2% overall and 12.8% within the severe group. Of the patients with SAP, 84.6% were considered to have organ failure and 48.7% were admitted to the intensive care unit. A significant difference between the parameters of the mild and severe groups in table 1 was exclusively found for the highest level of C-reactive protein (CRP) within the first 72 h ($p < 0.001$). For baseline characteristics according to the revised Atlanta classification see the online supplementary file (www.karger.com/doi/10.1159/000444141).

Biomarkers and Cut-Off Levels

Upon admission significant differences between median values of the groups with MAP and SAP were found for IL-1 β ($p = 0.008$), IL-6 ($p = 0.013$) and IL-10 ($p = 0.009$). IL-8 ($p = 0.056$) and MCP-1 ($p = 0.062$) were close to significant. The results of the application of the preselected cut-off levels on the cohort are shown in table 2. ROC curves were performed to obtain the optimal cut-off level for each biomarker of this population; the results are presented in table 3 and figure 1. The ROC curve of CRP (upon admission) was added to the results since it has been repeatedly proven to be the best predictive marker for severe disease. For most parameters the preset cut-off values were within an acceptable range of those inferred from the ROC curves of the present study cohort. For IL-6, sensitivity and specificity of the preset cut-off value of 100 pg/ml were 31 and 81%, respectively. The optimal cut-off in the study population, 72 pg/ml, would have given a sensitivity of 40% and a specificity of 78%. Similarly, for procalcitonin there would have been a change in sensitivity from 18 to 52% and in specificity from 82 to 66% if the optimal cut-off, 0.35 ng/ml, had been used instead of the preset value of 0.5 ng/ml. Additionally, the AUCs of the biomarkers were inferior to those of previous studies, which might indicate that their prognostic ability is not sufficient in such a consecutive series of patients. None of the biomarkers were able to predict mortality in this cohort (see positive predictive value, table 2).




Fig. 1. ROC curves of investigated biomarkers using the Atlanta 1992 classification.

Since 2013 the revised Atlanta 2012 classification is considered the international standard for severity classification in AP [19]. Thus we performed a post hoc analysis using this trisected classification. Significant differences were found for IL-1 β ($p = 0.022$) and IL-10 ($p = 0.006$) when comparing the group with SAP versus those with mild and moderately severe disease together. Optimal cut-off levels and AUCs of the investigated biomarkers are presented in table 4 and pertaining ROC curves in figure 2. The results did, in general, not improve when applying the new classification.

Table 3. Optimal cut-off and AUC for each biomarker using the Atlanta 1992 classification

Biomarker	Optimal cut-off	ROC AUC
IL-1 β , pg/ml	0.9	0.640
IL-6, pg/ml	72	0.632
IL-8, pg/ml	49	0.601
IL-10, pg/ml	12	0.638
TNF- α , pg/ml	n.a.	0.459
MCP-1, μ g/l	399	0.604
PCT, ng/ml	0.35	0.552
D-dimer, μ g/l	n.a.	0.516
CRP, mg/l	59.5	0.720

n.a. = Not applicable.

Table 4. Optimal cut-off and AUC for each biomarker using the revised Atlanta classification

Biomarker	Optimal cut-off	ROC AUC
IL-1 β , pg/ml	0.99	0.689
IL-6, pg/ml	90.8	0.620
IL-8, pg/ml	135.1	0.612
IL-10, pg/ml	15.5	0.725
TNF- α , pg/ml	n.a.	0.497
MCP-1, μ g/l	425	0.519
PCT, ng/ml	0.35	0.517
D-dimer, μ g/l	n.a.	0.422
CRP, mg/l	113	0.802

n.a. = Not applicable.

Discussion

The hunt for a prognostic biomarker in AP has been ongoing for decades. A multitude of studies have emerged for this reason and several have presented promising results. Nevertheless the conclusions are still far from attaining clinical practice.

The aim of this study was to use cut-off levels for severity prediction reported in earlier works and to apply them in a prospective study on an unselected population with AP. The vast majority of earlier studies have been exploratory with retrospective analysis of cut-off levels for each specific cohort. However, this is not applicable on the routine situation for the physician. Investigation of predictive biomarkers with preset cut-off levels would more accurately resemble clinical reality. Given the large amount of studies conducted on promising biomarkers, a consensus on cut-off levels for these markers ought to be conceivable. Our study does, however, indicate that considerable efforts still remain to be made in order to reach adequate results in this respect.

Most studies on biomarkers for prediction of SAP only report median values of the cytokines examined. Comparatively few, for some biomarkers limited to one single study, present ROC curves, AUCs, cut-off levels and concordant levels of sensitivity, specificity, positive predictive value, negative predictive value and accuracy. For this reason the selection of biomarkers remaining to be investigated with our aim is limited. Additionally, in cases where cut-off levels are reported, sample sizes are small, study settings are dissimilar or not accurately presented and various outcomes are used. Together this makes comparison and general




Fig. 2. ROC curves of investigated biomarkers using the revised Atlanta classification.

conclusions complicated and imprecise. The weaknesses of this study are thus the lack of flexibility in the selection of prognostic biomarkers, in particular those of recent interest, and the risk of predetermined cut-off values being indistinct.

However, our analysis showed that cut-off levels of earlier studies were reasonably well in concordance with those found in our cohort (table 2). Dissimilarities are expected since the cut-off levels are specific for a particular cohort, while applied on a different population their predictive ability will be impaired. The total predictive capacity of the biomarkers, measured as the AUC, was generally inferior to those of previous studies. There are probably numerous reasons for these results. SAP is reported to develop in 15–20% of patients, which is comparable to the 16.8% found in our cohort [5, 6]. However, in the studies used for predetermi-

nation of cut-off levels these figures were in general much higher (median 39.5%, range 11.4–53.0%). Such a difference naturally influences the results – the greater the numbers of SAP, the more likely the finding of significant differences between the mild and severe group. A high amount of cases with SAP indicates cohort selection biases, for example referral centers or non-consecutive enrollment of patients. Another reason might be differing interpretations of the Atlanta 1992 classification. Bollen et al. [35, 36] showed extensive inappropriate use of this classification and frequent application of alternative definitions of severe disease. A clear shortcoming of our study is the utilization of this now outdated classification. We did, however, consider it necessary in this work to enable comparison with previous studies for the determination of cut-off levels. Future application of the revised Atlanta 2012 classification will hopefully make the division of patients more stringent and uniform, thus facilitating comparison of reports regarding cases of SAP [19]. Post hoc analyses of investigated biomarkers using current international standards are presented as ROC curves, AUCs and optimal cut-off levels in figure 2 and table 4. The results indicate that CRP remains the best prognostic marker and additionally demonstrate a stronger predictive ability of IL-1 β and IL-10.

In our material only 45.2% of the patients with SAP were admitted to the intensive care unit, indicating less severe disease of this group than in comparative studies. However, these low numbers are due to the existence of an intermediate ward at the University Hospital in Malmö with the capacity to handle transient organ failures and local complications as well as elderly severely ill patients where intervention or admittance to the intensive care unit is not considered. Nevertheless these patients all have SAP according to the Atlanta 1992 classification.

An important, but previously not particularly investigated, factor is the time aspect. In this material we present a median time from disease onset to hospital admission of only 9 h (table 1). All blood samples were taken immediately upon arrival at the emergency room. Earlier studies have not specified this exact time interval and the time lapse from disease onset is in most cases unknown. The importance of exact information in this matter is not sufficiently studied and thus not yet clarified. Still the rather short time found in our material might be an explanation for some biomarkers not yet showing significant difference between the mild and severe group. Similarly the time frame could play a role for the outcome of cut-off levels. Blood samples in our material were probably taken rather early compared to the studies selected for predetermination of cut-off levels.

Previous studies have presented significant differences between MAP and SAP concerning clinical characteristics such as age, body mass index and etiology. No such difference was found in our cohort. The main explanation for these discrepancies is the application of an unselected population of patients with AP containing a low proportion of SAP compared to other works.

The strengths of this prospective study are its large scale of consecutively enrolled patients with AP from an unselected population, showing the whole spectrum of the disease without referral cases or selection bias. We also report detailed information on exact numbers of hours from disease onset to collection of blood samples. Analysis of biomarkers with preset cut-off levels and no post hoc assumptions make this work to a large extent resemble the difficulties of routine clinical work.

We have investigated the predictive capacity of biomarkers in AP. Despite many years of research physicians still lack instruments to anticipate the significant share of patients who will develop severe disease. Several biomarkers have been investigated and evaluated for more than two decades but are yet to be adopted into routine clinical use. To reach general conclusions the possibility of comparing study results is a necessity. Our findings indicate, as has been alluded in previous reports, a need for a higher degree of standardization and

uniformity in the design and execution of future studies [18, 37]. Implementation of research findings into routine clinical application requires results from consecutive studies on unselected populations of patients. Additionally, this work illuminates the need for continuous exploration of novel prognostic biomarkers in AP.

Acknowledgements

The authors wish to thank Anne-Marie Rohrstock for valuable support in sample analysis and Ingrid Palmquist for assistance in the handling of samples. This research was supported by Einar och Inga Nilsson, Magnus Bergvall, Lundgren, Schyberg and Mossfelt Foundation, Malmö Hospital Foundation, Skåne University Hospital and Lund University.

Statement of Ethics

This study was approved by the regional ethics committee at Lund University (2009/415). Oral and written consent was provided by all included patients.

Disclosure Statement

The authors declare that they have no conflicts of interest.

References


- 1 Yadav D, Lowenfels AB: The epidemiology of pancreatitis and pancreatic cancer. *Gastroenterology* 2013;144:1252–1261.
- 2 Frey CF, Zhou H, Harvey DJ, White RH: The incidence and case-fatality rates of acute biliary, alcoholic, and idiopathic pancreatitis in California, 1994–2001. *Pancreas* 2006;33:336–344.
- 3 Peery AF, Dellon ES, Lund J, Crockett SD, McGowan CE, Bulsiewicz WJ, Gangarosa LM, Thiny MT, Stizenberg K, Morgan DR, Ringel Y, Kim HP, Dibonaventura MD, Carroll CF, Allen JK, Cook SF, Sandler RS, Kappelman MD, Shaheen NJ: Burden of gastrointestinal disease in the United States: 2012 update. *Gastroenterology* 2012;143:1179–1187.e1–3.
- 4 Bradley EL 3rd: A clinically based classification system for acute pancreatitis. Summary of the International Symposium on Acute Pancreatitis, Atlanta, Ga, September 11 through 13, 1992. *Arch Surg* 1993;128:586–590.
- 5 Frossard JL, Steer ML, Pastor CM: Acute pancreatitis. *Lancet* 2008;371:143–152.
- 6 Vege SS, Gardner TB, Chari ST, Munukuti P, Pearson RK, Clain JE, Petersen BT, Baron TH, Farnell MB, Sarr MG: Low mortality and high morbidity in severe acute pancreatitis without organ failure: a case for revising the Atlanta classification to include ‘moderately severe acute pancreatitis’. *Am J Gastroenterol* 2009;104:710–715.
- 7 Working Group IAP/APA Acute Pancreatitis Guidelines: IAP/APA evidence-based guidelines for the management of acute pancreatitis. *Pancreatol* 2013;13(4 suppl 2):e1–e15.
- 8 Tenner S, Baillie J, DeWitt J, Vege SS; American College of Gastroenterology: American College of Gastroenterology guideline: management of acute pancreatitis. *Am J Gastroenterol* 2013;108:1400–1415, 1416.
- 9 Knaus WA, Draper EA, Wagner DP, Zimmerman JE: Apache II: a severity of disease classification system. *Crit Care Med* 1985;13:818–829.
- 10 Balthazar EJ, Robinson DL, Megibow AJ, Ranson JH: Acute pancreatitis: value of CT in establishing prognosis. *Radiology* 1990;174:331–336.
- 11 Ranson JH, Rifkind KM, Roses DF, Fink SD, Eng K, Localio SA: Objective early identification of severe acute pancreatitis. *Am J Gastroenterol* 1974;61:443–451.
- 12 Ranson JH: Etiological and prognostic factors in human acute pancreatitis: a review. *Am J Gastroenterol* 1982;77:633–638.
- 13 Blamey SL, Imrie CW, O'Neill J, Gilmour WH, Carter DC: Prognostic factors in acute pancreatitis. *Gut* 1984;25:1340–1346.
- 14 Lankisch PG: Natural course of acute pancreatitis: what we know today and what we ought to know for tomorrow. *Pancreas* 2009;38:494–498.

- 15 Khanna AK, Meher S, Prakash S, Tiwary SK, Singh U, Srivastava A, Dixit VK: Comparison of Ranson, Glasgow, MOSS, SIRS, BISAP, Apache-II, CTSI scores, IL-6, CRP, and procalcitonin in predicting severity, organ failure, pancreatic necrosis, and mortality in acute pancreatitis. *HPB Surg* 2013;2013:367581.
- 16 Papachristou GI, Muddana V, Yadav D, O'Connell M, Sanders MK, Slivka A, Whitcomb DC: Comparison of BISAP, Ranson's, Apache-II, and CTSI scores in predicting organ failure, complications, and mortality in acute pancreatitis. *Am J Gastroenterol* 2010;105:435–441; quiz 442.
- 17 Larvin M, McMahon MJ: Apache-II score for assessment and monitoring of acute pancreatitis. *Lancet* 1989;2:201–205.
- 18 Sigounas DE, Tatsioni A, Christodoulou DK, Tsianos EV, Ioannidis JP: New prognostic markers for outcome of acute pancreatitis: Overview of reporting in 184 studies. *Pancreas* 2011;40:522–532.
- 19 Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, Tsiotis GG, Vege SS; Acute Pancreatitis Classification Working Group: Classification of acute pancreatitis – 2012: Revision of the Atlanta classification and definitions by international consensus. *Gut* 2013;62:102–111.
- 20 Heath DI, Cruickshank A, Gudgeon M, Jehanli A, Shenkin A, Imrie CW: Role of interleukin-6 in mediating the acute phase protein response and potential as an early means of severity assessment in acute pancreatitis. *Gut* 1993;34:41–45.
- 21 Pezzilli R, Billi P, Miniero R, Fiocchi M, Cappelletti O, Morselli-Labate AM, Barakat B, Sprovieri G, Miglioli M: Serum interleukin-6, interleukin-8, and beta 2-microglobulin in early assessment of severity of acute pancreatitis. Comparison with serum C-reactive protein. *Dig Dis Sci* 1995;40:2341–2348.
- 22 Chen CC, Wang SS, Lee FY, Chang FY, Lee SD: Proinflammatory cytokines in early assessment of the prognosis of acute pancreatitis. *Am J Gastroenterol* 1999;94:213–218.
- 23 Berney T, Gasche Y, Robert J, Jenny A, Mensi N, Grau G, Vermeulen B, Morel P: Serum profiles of interleukin-6, interleukin-8, and interleukin-10 in patients with severe and mild acute pancreatitis. *Pancreas* 1999;18:371–377.
- 24 Pezzilli R, Morselli-Labate AM, Miniero R, Barakat B, Fiocchi M, Cappelletti O: Simultaneous serum assays of lipase and interleukin-6 for early diagnosis and prognosis of acute pancreatitis. *Clin Chem* 1999;45:1762–1767.
- 25 Stimac D, Fistic E, Milic S, Bilic-Zulle L, Peric R: Prognostic values of IL-6, IL-8, and IL-10 in acute pancreatitis. *J Clin Gastroenterol* 2006;40:209–212.
- 26 Dambraskas Z, Gulbinas A, Pundzius J, Barauskas G: Value of the different prognostic systems and biological markers for predicting severity and progression of acute pancreatitis. *Scand J Gastroenterol* 2010;45:959–970.
- 27 Fistic E, Poropat G, Bilic-Zulle L, Licul V, Milic S, Stimac D: The role of IL-6, 8, and 10, sTNF α , CRP, and pancreatic elastase in the prediction of systemic complications in patients with acute pancreatitis. *Gastroenterol Res Pract* 2013;2013:282645.
- 28 Shokuhi S, Bhatia M, Christmas S, Sutton R, Neoptolemos JP, Slavin J: Levels of the chemokines growth-related oncogene alpha and epithelial neutrophil-activating protein 78 are raised in patients with severe acute pancreatitis. *Br J Surg* 2002;89:566–572.
- 29 Regner S, Appelros S, Hjalmarsson C, Manjer J, Sadic J, Borgstrom A: Monocyte chemoattractant protein 1, active carboxypeptidase B and CAPAP at hospital admission are predictive markers for severe acute pancreatitis. *Pancreatol* 2008;8:42–49.
- 30 Pindak D, Parrak V, Pechan J, Vavrecka A, Kuzela L, Fuchs D, Irsakova J: The clinical value of the procalcitonin in prediction of severity and outcome in acute pancreatitis. *Hepatogastroenterology* 2003;50(suppl 2):ccviii–ccix.
- 31 Gurda-Duda A, Kusnierz-Cabala B, Nowak W, Naskalski JW, Kulig J: Assessment of the prognostic value of certain acute-phase proteins and procalcitonin in the prognosis of acute pancreatitis. *Pancreas* 2008;37:449–453.
- 32 Woo SM, Noh MH, Kim BG, Hsing CT, Han JS, Ryu SH, Seo JM, Yoon HA, Jang JS, Choi SR, Cho JH: Comparison of serum procalcitonin with Ranson, Apache-II, Glasgow and Balthazar CT severity index scores in predicting severity of acute pancreatitis. *Korean J Gastroenterol* 2011;58:31–37.
- 33 Kim BG, Noh MH, Ryu CH, Nam HS, Woo SM, Ryu SH, Jang JS, Lee JH, Choi SR, Park BH: A comparison of the BISAP score and serum procalcitonin for predicting the severity of acute pancreatitis. *Korean J Intern Med* 2013;28:322–329.
- 34 Radenkovic D, Bajec D, Ivancevic N, Milic N, Bumbasirevic V, Jeremic V, Djukic V, Stefanovic B, Stefanovic B, Milosevic-Zbutega G, Gregoric P: D-dimer in acute pancreatitis: a new approach for an early assessment of organ failure. *Pancreas* 2009;38:655–660.
- 35 Bollen TL, Besselink MG, van Santvoort HC, Gooszen HG, van Leeuwen MS: Toward an update of the Atlanta classification on acute pancreatitis: review of new and abandoned terms. *Pancreas* 2007;35:107–113.
- 36 Bollen TL, van Santvoort HC, Besselink MG, van Leeuwen MS, Horvath KD, Freeny PC, Gooszen HG; Dutch Acute Pancreatitis Study Group: The Atlanta classification of acute pancreatitis revisited. *Br J Surg* 2008;95:6–21.
- 37 Windsor JA: Assessment of the severity of acute pancreatitis: no room for complacency. *Pancreatol* 2008;8:105–109.



Contents lists available at ScienceDirect

Pancreatology

journal homepage: www.elsevier.com/locate/pan

IL-6 and CRP are superior in early differentiation between mild and non-mild acute pancreatitis

Hanna Sternby^a, Hannes Hartman^b, Dorthe Johansen^a, Henrik Thorlacius^a, Sara Regnér^{a,*}

^a Department of Surgery, Institution of Clinical Sciences, Malmö, Skåne University Hospital, Lund University, Sweden

^b Department of Gastroenterology, Institution of Clinical Sciences, Malmö, Skåne University Hospital, Lund University, Sweden

ARTICLE INFO

Article history:

Received 17 February 2017

Received in revised form

3 May 2017

Accepted 29 May 2017

Available online xxx

Keywords:

Acute pancreatitis

Biomarkers

Classification

Stratification

ABSTRACT

Background: The revised Atlanta classification on acute pancreatitis (AP) presents distinct criteria for severity categorization. Due to the lack of reliable prognostic markers, a majority of patients with AP are currently hospitalized and initially managed identically. As incidence and financial costs are rising the need for early severity differentiation will increase.

This study aimed to investigate the capacity of biomarkers to stratify AP patients during the initial course of the disease.

Methods: Patients with AP were prospectively enrolled and dichotomized into mild or non-mild (moderately severe and severe AP) according to the revised Atlanta classification. Serum samples taken within 13–36 h after onset of disease were analyzed for 20 biomarkers. Through receiver operating curves cut-off levels were set for 5 biomarkers whose stratifying ability was further analyzed. Additionally, the patients were classified according to the harmless acute pancreatitis score (HAPS).

Results: Among the 175 patients, 70.9% had mild and 29.1% non-mild AP. CRP and IL-6 combined, with cut-off levels 57.0 and 23.6 respectively, demonstrated superior discriminative capacity with an area under the curve of 0.803, sensitivity 98%, specificity 54% and a positive and negative likelihood ratio of 2.1 and 0.06 for the non-mild group. Regarding the mild group likelihood ratios were positive 26.5 and negative 0.48. The identification potential of the HAPS was generally inferior when compared to CRP plus IL-6.

Conclusions: In this study CRP and IL-6 demonstrate a clinically relevant capacity to differentiate mild from non-mild AP early in the course of AP.

© 2017 IAP and EPC. Published by Elsevier B.V. All rights reserved.

Introduction

At a cost of several billion dollars per year, acute pancreatitis (AP) is reported to be the leading cause of hospital admission among gastrointestinal diseases in the United States [1,2]. Globally, the incidence of the disease is rising with the most frequent etiologies being gallstones and alcohol [1,3].

The revised Atlanta classification of 2012 categorizes AP into mild, moderately severe and severe disease [4]. The main focus in research has been on the severely ill group due to the associated

organ failure and high mortality rate. The majority of patients will, however, develop a self-limiting mild form of the disease. Mild AP is acknowledged to have no complications and mortality is extremely rare [4–6]. Nevertheless all patients with AP are hospitalized with supportive care and various interventions. Early severity stratification would reduce overtreatment of the mild group but also give legitimate attention to those in risk of developing non-mild (moderately severe and severe) AP. When the incidence rises, identification of both groups will be necessary for accurate medical surveillance and treatment as well as to reduce health care costs.

Clinical judgment in early severity assessment has been demonstrated to be poor [7,8]. Hence multiple studies have investigated the role of biomarkers in risk stratification of AP [9,10]. Previous works are mainly based on the Atlanta classification of 1992, and no biomarker has demonstrated sufficient prognostic

* Corresponding author. Department of Surgery, Institution of Clinical Sciences Malmö, Skåne University Hospital, Lund University, Inga-Marie Nilssons gata 47 205 02 Malmö, Sweden.

E-mail address: Sara.Regner@med.lu.se (S. Regnér).

capacity early in the course of the disease [9–11]. In 2009 Lankisch et al. introduced the Harmless Acute Pancreatitis Score (HAPS) to enable prompt identification of patients with mild AP [12]. Although simple and validated, this scoring system has not been embraced by general clinical practice.

To our knowledge, no study has yet examined the prognostic capacity of biomarkers based on the revised Atlanta classification. In this work we aimed to explore the potential in using biomarkers to separate mild AP from non-mild during the initial phase of the disease.

Methods

Patients and study design

Patients >18 years with AP admitted to the Department of Surgery, Skåne University Hospital, Malmö, Sweden, from January 2010 to September 2013 were prospectively and consecutively included. For the diagnose of AP two out of three criteria needed to be fulfilled; 1) acute characteristic upper abdominal pain, 2) serum amylase ≥ 3 times the upper limit or 3) characteristic findings of AP on CT scan, abdominal ultrasound or MRI. The patients were retrospectively classified as having mild, moderately severe or severe AP according to the revised Atlanta classification of 2012 [4]. Clinical data, including exact time for onset of disease (*equivalent to onset of pain*) and validated questions on etiology, were obtained from the patients upon inclusion and retrospectively through review of medical notes as described previously [13]. HAPS was analyzed for all patients [12].

The study was approved by the regional ethics committee at Lund University (2009/415). Informed consent (oral and written) was obtained from all participants included in the study.

Blood samples and biomarkers

Serum samples were collected upon admission to the emergency room. As the aim was to analyze the initial course of the disease, only specimens obtained between 13 and 36 h after onset of disease were included in analysis. The time interval was chosen based on a large review by Staubli et al. on laboratory biomarkers in AP [10]. Albumin (g/L), calcium (mmol/L), c-reactive protein (CRP, mg/L), glucose (mmol/L), hematocrit, hemoglobin (g/L), lactate (mmol/L), thrombocytes ($\times 10^9$ /L) and white blood cells ($\times 10^9$ /L) were analyzed in accordance with certified standard analysis at the department of Clinical Chemistry, Skåne University Hospital Malmö (ISO 15189:2012, accreditation number 1309). Blood samples for analysis of interferon gamma (IFN- γ), interleukin-1beta (IL-1 β), interleukin-6 (IL-6), interleukin-6 receptor (IL-6R), interleukin-8 (IL-8), interleukin-10 (IL-10), interleukin-12 (IL-12), tumor necrosis factor-alpha (TNF- α), monocyte chemoattractant protein-1 (MCP-1), procalcitonin and D-dimer were collected in plasma separator tubes, centrifuged (2000 rounds, 25 °C, 10 min) and stored at –80 °C until analyzed. IFN- γ , IL-1 β , IL-6, IL-8, IL-10, IL-12 and TNF- α were analyzed with human proinflammatory 7-plex ultrasensitive kit and IL-6R with 1-plex human IL-6R ultrasensitive kit (K15008C, K151ALC, Meso Scale Diagnostics LLC, Rockville, MD, USA). MCP-1 was assessed through human CCL2 (MCP-1) Elisa Ready-set-go kit (88-7399-88, aBioscience, San Diego, CA, USA) and D-dimer with human D-Dimer Elisa kit (D2D, 20870, Bm assay, Beijing, China). All analyses were assessed according to the manufacturer's instructions. Procalcitonin was determined with an accredited Elisa method based on monoclonal anti-procalcitonin antibodies in accordance with routine methods at the department of Clinical Chemistry, Skåne University Hospital Malmö. Unit of all interleukins, IFN- γ and TNF- α is pg/ml whereas MCP-1, d-

dimer and procalcitonin are in ng/ml.

Statistical analysis

All patients were dichotomized into mild and non-mild (moderately severe and severe) AP according to the revised Atlanta classification [4]. For continuous data, comparison between two groups, Mann-Whitney *U* test was used and $p < 0.05$ was considered statistically significant. The predictive performance of individual biomarkers were assessed through Receiver Operating Characteristic curves (ROC-curves), Areas Under Curves (AUCs) and cut-off levels with corresponding sensitivity, specificity, positive and negative likelihood ratio as well as positive and negative predictive value.

All statistical analysis was performed using IBM SPSS Statistics for Windows, version 21 and 22, Armonk, NY:IBM corp.

Results

During the inclusion period in total 245 patients with AP were admitted to the department of surgery. Among the 70 patients not enrolled 57 had samples taken before 13 h or after 36 h into the course of the disease, 5 patients refused to participate and 8 patients had insufficient level of language comprehension. Thus, 175 patients with samples taken within 13–36 h after onset of disease were included. Basal cohort characteristics are presented in Table 1. Median age was 66 years (range 19–97) and just over half were women. Most frequent etiology (54.8%) was biliary whereas a fifth was alcohol-induced. Remaining etiologies were idiopathic and other (post-ERCP, tumors, strictures etc). According to the revised Atlanta classification 70.9% had mild, 23.4% (41 patients) moderately severe and 5.7% (10 patients) severe AP. The non-mild group thus amounted to 29.1% of the patients. One patient with mild AP was admitted to the intensive care unit (ICU) due to delirium tremens. Among the 25 patients with organ failure, 12 were admitted to the ICU and 13 were managed at an interment ward. Significant difference ($p = 0.0001$) between the mild and non-mild groups was solely found for length of hospital stay.

Of the 20 biomarkers investigated, significant difference between the mild and non-mild groups was found for seven biomarkers: IL-1 β , IL-6, IL-6R, IL-10, MCP-1, calcium and CRP, see Table 2. ROC-curve analysis demonstrated AUCs below 0.5 for calcium and IL-6R, results for the remaining biomarkers are presented in Table 3. For graphical description of ROC-curves see Figs. 1–5 in supplementary material. CRP and IL-6 demonstrated superior results with AUCs of 0.808 and 0.749 respectively. Optimal cut-off levels, considering the risk of morbidity and mortality in AP, were identified from ROC-curves (Table 4). For each biomarker corresponding positive and negative likelihood ratios as well as positive and negative predictive values were calculated.

As CRP and IL-6 demonstrated superior predictive capacity in ROC-analysis a combination of these biomarkers was further investigated and the results are presented in Table 4. Only one non-mild patient with deterioration of co-morbidity (without need for admission to the ICU) was identified below the cut-off levels of both CRP (57.0) and IL-6 (23.6). Overall, severity stratification was improved when the combination of CRP and IL-6 was applied compared with individual biomarkers.

Analysis of the cohort according to the HAPS and corresponding figures using CRP plus IL-6 are presented in Table 5. The single non-mild patient classified as harmless developed moderately severe AP with multiple transient organ failure and needed management in the ICU. The HAPS demonstrated high specificity but low sensitivity for the mild AP patients. Application of selected cut-off levels for CRP and IL-6 combined resulted in equally high specificity as for the

Table 1

Baseline characteristics of all patients and mild and non-mild groups of AP.

	All	Mild	Non-mild
n (%)	175	124 (70.9)	51 (29.1)
Gender, n (%)			
Male	85 (48.6)	60 (48.3)	25 (49.0)
Female	90 (51.4)	64 (51.6)	26 (51.0)
Age, years	*66 (19–97)	*65 (19–97)	*66 (29–92)
BMI	*25.7 (13.6–47)	*25.1 (15.2–45.4)	*26.6 (13.6–47)
Hours from onset to admission	*24 (13–36)	*24 (13–36)	*23 (13–36)
^a Length of hospital stay	*8 (1–156)	*7 (1–39)	*12 (3–156)
Etiology, n (%)			
Biliary	96 (54.8)	70 (56.5)	26 (51.0)
Alcohol	36 (20.6)	24 (19.4)	12 (23.5)
Other	23 (13.1)	18 (14.5)	5 (9.8)
Idiopathic	20 (11.4)	12 (9.7)	8 (15.7)
Organ failure, n (%)	25 (14.3)	0	25 (49.0)
ICU, n (%)	13 (7.4)	1 (0.8)	12 (23.5)
Mortality, n (%)	7 (4.0)	0	7 (13.7)

*Values are in median (range).

BMI, body mass index; ICU, intensive care unit.

^a Significant difference ($p = 0.0001$) was found for length of hospital stay.**Table 2**

Comparison of biomarker levels between mild and non-mild groups.

Biomarkers	P	Mild		Non-mild	
		Median	range	Median	range
IFN- γ ¹	ns	2.6	0.4–282.8	2.6	0.1–94.5
IL-1 β ¹	0.0001	1.2	0.0–32.7	2.5	0.0–61.0
IL-6 ¹	0.0001	21.9	0.6–3776.0	120.5	12.0–3662.0
IL-6R ¹	0.006	37994	13125–84080	32169	9300–61028
IL-8 ¹	ns	55.0	5.2–3498.2	65.8	20.8–3339.1
IL-10 ¹	0.002	11.9	0.9–4429.7	23.4	3.3–3579.0
IL-12 ¹	ns	1.3	0.0–4761.5	0.8	0.0–411.5
TNF- α ¹	ns	6.0	2.3–916.7	5.2	1.9–103.0
MCP-1 ²	0.044	188.0	0.0–7299.0	236.5	54.0–7080.0
D-dimer ²	ns	797.5	333.0–3448.0	1013	329–2270
Procalcitonin ²	ns	1.6	0.0–48.0	0.8	0.0–60.0
Albumin ³	ns	31.4	20–43	31.4	21–41
Calcium ⁴	0.013	2.1	2.0–2.4	2.4	2.0–2.6
CRP ⁵	0.0001	58	1–385	211	7–489
p-glucose ⁴	ns	7.8	4.2–16.4	8.1	4.7–17.3
Hemoglobin ³	ns	140	102–18	145	115–171
Hematocrit	ns	0.44	0.32–0.56	0.44	0.36–0.54
Lactate ⁴	ns	1.9	0.5–4.0	1.7	0.8–7.0
Thrombocytes ⁶	ns	233	107–416	233	88–550
White blood cells ⁶	ns	11.4	3.8–29.1	12.7	1.0–24.8

Biomarker units: ¹pg/ml, ²ng/ml, ³g/L, ⁴mmol/L, ⁵mg/L and ⁶ $\times 10^9$ /L.**Table 3**

Results of ROC-curve analysis.

	AUC	p-value	95% CI
IL-1 β	0.677	0.0001	0.583–0.770
IL-6	0.749	0.0001	0.674–0.825
IL-10	0.654	0.002	0.568–0.739
MCP-1	0.609	0.044	0.509–0.710
CRP	0.808	0.0001	0.730–0.886

AUC, area under curve; CI, confidence interval.

HAPS but with increased sensitivity and superior stratification ability regarding predictive values and likelihood ratios.

Discussion

With the introduction of the revised Atlanta classification in 2012, the severity groups of AP are more explicitly defined than

Table 4

Results of cut-off level analysis.

	Cut-off	Sensitivity	Specificity	LR+	LR–	PPV	NPV
IL-1 β	0.89	0.85	0.42	1.47	0.36	0.37	0.88
IL-6	23.6	0.89	0.54	1.87	0.20	0.39	0.93
IL-10	10.9	0.81	0.46	1.5	0.41	0.37	0.85
MCP-1	118.5	0.92	0.26	1.24	0.31	0.31	0.86
CRP	57.0	0.88	0.5	1.76	0.24	0.42	0.87
CRP +	57.0	0.98	0.53	2.1	0.06	0.49	0.98
IL-6	23.6						

LR+, positive likelihood ratio; LR–, negative likelihood ratio; PPV, positive predictive value; NPV, negative predictive value.

previously [4,11]. Historically, focus has been on the severely ill patients. The search for prognostic biomarkers in AP is since decades an ongoing process. Several studies have presented promising results, however still none have reached clinical practice [14].

The mild group is not extensively investigated, despite containing the vast majority of cases. By providing a trisected severity distribution, the revised Atlanta classification enables more detailed comparison between AP patients. The objective of this study was to examine the capacity of biomarkers in differentiating mild from non-mild AP during the initial phase of the disease.

Within the interval 13–36 h after onset of disease, levels of 7 out of 20 investigated biomarkers differed significantly between the mild and non-mild groups. Predictive accuracy of non-mild disease was superior for CRP (AUC 0.808) and IL-6 (AUC 0.749) in ROC-curve analysis. Due to the potentially devastating consequences of severe AP, cut-off levels were selected to obtain high sensitivity. With 57 mg/L for CRP and 23.6 pg/mL for IL-6 sensitivities of almost 90% were derived with corresponding specificities of 50% and 54% (Table 4). When combining CRP and IL-6 severity stratification was strengthened, as presented in Table 4, with a sensitivity and specificity of 98% and 53% respectively. Additionally improved likelihood ratios as well as predictive values were obtained.

Currently all patients with AP are hospitalized with supportive care and various interventions [14]. Data show a 100% rise in the overall admissions for AP in the US during the last 2 decades with a subsequent augmentation in hospital expenses [2]. The increasing incidence of AP emphasizes the need for early identification of not only severe but also mild cases. Moreover, studies have demonstrated significant increases in hospital-acquired infections, length of hospital stay and even mortality also for cases of mild AP [15,16].

Table 5

Analysis of mild AP according to HAPS and CRP + IL-6.

	^a Outcome		Sensitivity	Specificity	PPV	NPV	LR+	LR–
	Mild	Non-mild						
HAPS								
Harmless	10	1	0.08	0.98	0.91	0.30	4	0.94
Not Harmless	114	50						
^bCRP + IL-6								
Mild	71	1	0.53	0.98	0.99	0.48	26.5	0.48
Non-mild	53	50						

LR+, positive likelihood ratio; LR–, negative likelihood ratio; PPV, positive predictive value; NPV, negative predictive value.

^a Outcome according to the revised Atlanta classification.^b Categories mild and non-mild based on cut-off levels 57.0 for CRP and 23.6 for IL-6.

If identified upon admission, early discharge or adequate treatment as outpatients with standardized follow-up plans is a possibility for this group of patients [17]. Additionally major medical attention would be directed towards those at risk of developing more severe disease. Such a strategy is, however, currently generally inapplicable as most centers do not have sufficient logistic structure to care for the mild AP patients as outpatients.

Herein is demonstrated good capacity of CRP and IL-6 in identifying mainly mild but also non-mild cases in AP. Our findings are in line with previous efforts to differentiate patients with AP, although the aim of most prior studies have been prediction of severe disease according to the Atlanta classification of 1993 [10,11,18]. Biomarkers analyzed in this study have earlier demonstrated acceptable performance in early assessment of AP [19–23].

The single scoring system developed for prediction of mild AP is the HAPS. Several studies have reported high specificity for the identification of mild cases when validating this algorithm [12,24]. When applied on our cohort high specificity but very low sensitivity was found. 92% of the patients with mild AP were classified as not harmless (Table 5). As the HAPS is developed for the Atlanta classification of 1993 comparison with the mild group in this work is not fully feasible. Investigation of mild cases using CRP plus IL-6 resulted in an equally high specificity as when applying the HAPS. However, clinically much more relevant figures were obtained regarding sensitivity, positive predictive value and positive likelihood ratio.

The major limitation of this study is its exploratory nature, as the aim was not to establish a new score for the identification of non-mild or mild AP. We have examined the capacity of biomarkers in separating mild from moderately severe and severe AP early in the course of the disease. Our results, with high discriminative ability for CRP and IL-6, indicate clinical applicability of these biomarkers in determining accurate level of care for the patients during the initial phase of the disease. Additionally, our findings regarding mild AP were superior to what was obtained from the HAPS.

Although being a common disease the research on AP is declining [25]. As the incidence is rising new efforts are needed for medically correct but also economically efficient managing of the patients. This study is, to our knowledge, the first study investigating biomarkers in severity stratification of mild and non-mild AP according to the revised Atlanta classification. According to our results two generally available and inexpensive markers obtained from regular blood samples can be of relevance when differing mild from non-mild disease. Further international multicenter studies, preferably investigating not only the combination of biomarkers but also the clinical outcome of an early discharge for mild AP patients, are needed to confirm our findings.

Funding

This work was supported by grants from the Swedish Medical Research Council (2012-3685), Bergwalls-, Ihre-, Lundgrens-, Einar och Inga Nilssons-, Stewens-, Schyberg- and SUS foundations.

Disclosure statement

The authors declare to have no conflicts of interest.

Acknowledgements

The authors wish to thank Anne-Marie Rohrstöck for valuable support in sample analysis and Ingrid Palmquist for assistance in the handling of samples.

Appendix A. Supplementary data

Supplementary data related to this article can be found at <http://dx.doi.org/10.1016/j.pan.2017.05.392>.

References

- [1] Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. *Gastroenterology* 2013;144:1252–61.
- [2] Peery AF, Crockett SD, Barritt AS, Dellon ES, Eluri S, Gangarosa LM, et al. Burden of gastrointestinal, liver, and pancreatic diseases in the United States. *Gastroenterology* 2015;149:1731–41.
- [3] Lowenfels AB, Maisonneuve P, Sullivan T. The changing character of acute pancreatitis: epidemiology, etiology, and prognosis. *Curr Gastroenterol Rep* 2009;11:97–103.
- [4] Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, et al. Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus. *Gut* 2013;62:102–11.
- [5] Working Group IAP/APA Acute Pancreatitis Guidelines. IAP/APA evidence-based guidelines for the management of acute pancreatitis. *Pancreatology* 2013;13:e1–15.
- [6] Lankisch PG, Apte M, Banks PA. Acute pancreatitis. *Lancet* 2015;386:85–96.
- [7] McMahon MJ, Playforth MJ, Pickford IR. A comparative study of methods for the prediction of severity of attacks of acute pancreatitis. *Br J Surg* 1980;67:22–5.
- [8] Wilson C, Heath DI, Imrie CW. Prediction of outcome in acute pancreatitis: a comparative study of APACHE II, clinical assessment and multiple factor scoring systems. *Br J Surg* 1990;77:1260–4.
- [9] Sigounas DE, Tatsioni A, Christodoulou DK, Tsianos EV, Ioannidis JP. New prognostic markers for outcome of acute pancreatitis: overview of reporting in 184 studies. *Pancreas* 2011;40:522–32.
- [10] Staubli SM, Oertli D, Nebiker CA. Laboratory markers predicting severity of acute pancreatitis. *Crit Rev Clin Lab Sci* 2015;52:273–83.
- [11] Bradley 3rd EL. A clinically based classification system for acute pancreatitis. Summary of the International Symposium on Acute Pancreatitis, Atlanta, Ga, September 11 through 13, 1992. *Arch Surg* 1993;128:586–90.
- [12] Lankisch PG, Weber-Dany B, Hebel K, Maisonneuve P, Lowenfels AB. The harmless acute pancreatitis score: a clinical algorithm for rapid initial stratification of nonsevere disease. *Clin Gastroenterol Hepatol* 2009;7:702–5.
- [13] Sternby H, Hartman H, Johansen D, Thorlacius H, Regner S. Predictive capacity of biomarkers for severe acute pancreatitis. *Eur Surg Res* 2016;56:154–63.

- [14] Chauhan S, Forsmark CE. The difficulty in predicting outcome in acute pancreatitis. *Am J Gastroenterol* 2010;105:443–5.
- [15] Wu BU, Johannes RS, Kurtz S, Banks PA. The impact of hospital-acquired infection on outcome in acute pancreatitis. *Gastroenterology* 2008;135: 816–20.
- [16] Moraes JM, Felga GE, Chebli LA, Franco MB, Gomes CA, Gaburri PD, et al. A full solid diet as the initial meal in mild acute pancreatitis is safe and result in a shorter length of hospitalization: results from a prospective, randomized, controlled, double-blind clinical trial. *J Clin Gastroenterol* 2010;44:517–22.
- [17] da Costa DW, Bouwense SA, Schepers NJ, Besselink MG, van Santvoort HC, van Brunschot S, et al. Same-admission versus interval cholecystectomy for mild gallstone pancreatitis (PONCHO): a multicentre randomised controlled trial. *Lancet* 2015;386:1261–8.
- [18] Gornatowski IP, Xiaodong X, Ghaneh P, Halloran C, Raraty M, Lane B, et al. Prognostic markers in acute pancreatitis. *Expert Rev Mol Diagn* 2014;14: 333–46.
- [19] Chen CC, Wang SS, Lee FY, Chang FY, Lee SD. Proinflammatory cytokines in early assessment of the prognosis of acute pancreatitis. *Am J Gastroenterol* 1999;94:213–8.
- [20] Chen CC, Wang SS, Lu RH, Chang FY, Lee SD. Serum interleukin 10 and interleukin 11 in patients with acute pancreatitis. *Gut* 1999;45:895–9.
- [21] Regner S, Appelros S, Hjalmarsson C, Manjer J, Sadic J, Borgstrom A. Monocyte chemoattractant protein 1, active carboxypeptidase B and CAPAP at hospital admission are predictive markers for severe acute pancreatitis. *Pancreatol* 2008;8:42–9.
- [22] Aoun E, Chen J, Reighard D, Gleeson FC, Whitcomb DC, Papachristou GI. Diagnostic accuracy of interleukin-6 and interleukin-8 in predicting severe acute pancreatitis: a meta-analysis. *Pancreatol* 2009;9:777–85.
- [23] Mofidi R, Suttie SA, Patil PV, Ogston S, Parks RW. The value of procalcitonin at predicting the severity of acute pancreatitis and development of infected pancreatic necrosis: systematic review. *Surgery* 2009;146:72–81.
- [24] Oskarsson V, Mehrabi M, Orsini N, Hammarqvist F, Segersvard R, Andren-Sandberg A, et al. Validation of the harmless acute pancreatitis score in predicting nonsevere course of acute pancreatitis. *Pancreatol* 2011;11:464–8.
- [25] Szentesi A, Toth E, Balint E, Fanczal J, Madacsy T, Laczko D, et al. Analysis of research activity in gastroenterology: pancreatitis is in real danger. *PLoS One* 2016;11. e0165244.